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Introduction and aims of the study
Chapter 1
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The inherited cerebellar syndromes show a striking genetic variability. With an estimated prevalence of
1/50,000, Friedreich’s ataxia (FRDA) is the most common inherited degenerative ataxia and accounts for
three-quarters of those with an onset before the age of 25. Of the autosomal dominant cerebellar ataxias
(ADCAs), about two-thirds of the prevalence seems to be explained by five mutations only: spinocerebellar
ataxia (SCA) type 1, 2, 3, 6 and 7. The prevalence of these mutations in the Netherlands is estimated to be
3/100.000. 
This thesis starts with a brief historical overview of the clinical nosology of the inherited cerebellar syndromes
(chapter 1). This historical overview is followed by an outline of the aims of the study, which is essentially
to expand the knowledge regarding the pheno- and genotype of these disorders. Before tackling the issue
of ‘expanding the knowledge’ an overview concerning the current state is provided. The current state of the
autosomal dominant cerebellar syndromes is addressed in chapter 2, and the current state of the auto-
somal recessive cerebellar syndromes in chapter 3. 
Historical overview
Nicolaus Friedreich was the first author who systematically described patients with a hereditary form of
ataxia (Table 1.1). In five different papers, published between 1863 and 1877, he described a distinctive clinical
syndrome in nine patients belonging to five sibships (Friedreich 1877; Friedreich 1876; Friedreich 1863a;
Friedreich 1863b; Friedreich 1863c). The clinical features were dominated by an early onset (first or second
decade), progressive cerebellar dysarthria and ataxia, sensory loss, muscle weakness, and in some, scoliosis,
diabetes, and cardiomyopathy. Autopsy, in four patients, showed a uniform picture of degeneration of the
funiculus dorsalis, posterior spinal roots, nuclei thoracicus, and spinal lateral funiculus. 
In 1893, Pierre Marie drew attention to four families with a clinical picture different from that of FRDA
(Marie 1893). The age at onset was later, the tendon reflexes were increased, and neither scoliosis nor foot
deformity was observed. Although Marie’s ‘heredo-ataxia cérébelleuse’ is now known to be a hetero-
geneous group of disorders, his observation led to the important distinction between juvenile, and adult-
onset, hereditary cerebellar ataxia. However, the significance of this distinction between early and late onset
with respect to the Mendelian concept of autosomal recessive (usually early onset) and autosomal dominant
inheritance (usually late onset) remained unrecognized until the beginning of the 20th century.
In 1900, Dejerine and Thomas described the clinical and post-mortem features of a sporadic case with
symptoms that were characterized by progressive ataxic gait, dysarthria, hypotonia, and hyporeflexia
(Dejerine-Thomas 1900). The symptoms started at the age of 30. Post-mortem examination revealed degene-
ration of the basis pontis, inferior olivary nuclei, and middle and inferior cerebellar peduncles. The post-
mortem features they found were summarized in the descriptive term olivopontocerebellar atrophy
(OPCA). 
Holmes presented the first classification of the hereditary cerebellar syndrome in 1907 (Holmes 1907). He
stated that the disease should be classified on the basis of morbid anatomy and pathogenesis. This approach
was also taken by Greenfield (Greenfield 1954) and by Koningsmark and Weiner (Koningsmark and Weiner
1970) (for review see Pulst 2000). 
However, several problems limited the usefulness of the clinicopathological classification systems. Because
of pathological heterogeneity within families, patients in the same family were sometimes classified into
different categories. Furthermore, the pathological classification system was not very helpful in everyday
clinical practice - there was a need for a ‘clinical’ type of classification. In 1983, Harding achieved this task
(Harding 1983). She proposed a classification based on clinical, genetic, and pathological features.
Harding’s classification soon became universally accepted. The subclassification of the ADCAs (a term
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introduced by Harding) into type I, type II, and type III proved to be extremely useful for both clinical
practice and research. In this classification, ADCA I was associated with additional features related to the
optic nerve, (extra)pyramidal system, cerebral cortex, and peripheral nerves. ADCA II was associated with
pigmentary macular dystrophy, and ADCA III was a relatively pure late-onset cerebellar syndrome.
While Harding’s monograph remains a landmark in the history of hereditary cerebellar ataxia research, her
classification has now been replaced by a new classification based on molecular genetic data. This new
genetic classification system is known as ‘SCA’ classification. 
Concerning the genetic SCA classification, linkage and assignment of the SCA1 locus, centromeric to the HLA
region on the short arm of chromosome 6, was achieved in 1989 (Zoghbi et al. 1989). The mutation for SCA1
was defined at the end of 1993 (Orr et al. 1993). They confirmed the earlier observation that SCA1 mapped to
6p22-p23 and found a highly polymorphic CAG repeat in this region. This CAG repeat was found to be
unstable and expanded in individuals with SCA1. Moreover, the size of the CAG repeat expansion was corre-
lated with the age of disease onset. Larger alleles occurred in those patients with a juvenile disease onset,
and anticipation was present in subsequent generations. A similar pathological mechanism had previous
been described in Huntington and Kennedy disease and was later also reported for SCA2, 3, and 7
(Huntington research group 1993; La Spada et al. 1992; Pulst et al. 1996; Kawaguchi et al. 1994; David et al.
1997). 
The number of a particular SCA is based on the sequence of finding the new locus. Currently, 25 different
types of SCA have been identified (see chapter 2; table 2.1). Not all of these SCAs are CAG repeat disorders. 
The identification of genetic abnormalities might be considered as the first step in the elucidation of the
processes of neurodegeneration. For the SCAs, a major second step forward came with the identification
of the neuronal intranuclear inclusions (NII), pathological structures found in Huntington disease, SCA1,
2, 3, 7 and 17 (for review see Davies et al. 1998). These two steps are essential to elucidate the biochemical
alterations that are induced by DNA mutation, followed by altered transcription and protein translation,
worsened by abnormal protein folding and protein segregation (NII) and ultimately leading to selective cell
degeneration. 
But what about Friedreich? In 1996, Campuzano et al. reported the molecular basis of FRDA (Campuzano
et al. 1996). Most patients with FRDA are homozygous for a new GAA triplet repeat expansion, but some
patients show an expansion in one allele and a point mutation in the other. With the discovery of the frataxin
gene, it was recognized that the clinical spectrum of FRDA was broader than previously thought. Even so,
the clinical features of most of our patients with ‘DNA-confirmed’ FRDA are similar to those described by
Friedreich in 1863.
Table 1.1 Historical overview of the hereditary cerebellar ataxias.
1863: Friedreich Concept of hereditary ataxia
1893: Marie Late, versus early onset hereditary ataxia
1900: Dejerine and Thomas Concept of ‘Olivopontocerebellar ataxia’
1907: Holmes First description of a classification system
1954: Greenfield ‘Classical’ pathological classification
1970: Koningsmark and Weiner Heterogeneity in OPCA
1983: Harding Classic ‘ADCA classification’
1993: Orr and Zoghbi CAG expansion in the SCA1 gene
1996: Campuzano GAA repeat expansion in the frataxin gene
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Aims of the thesis
Hereditary cerebellar ataxia is a complex neurological syndrome. At present, age at onset and mode of
transmission are key elements in the differential diagnosis. However, in order to develop a clinical algorithm
further, more needs to be known about the phenotype at a clinical, pathophysiological, and pathological
level, and about the different genotypes. 
The aims of the study are:
With respect to the autosomal dominant spinocerebellar ataxias:
• to identify a new SCA locus that might help to explain those families that cannot be assigned to
any of the known loci.
• to unravel the relevance of neuronal intranuclear inclusions (NII) to the pathophysiology of the
CAG trinucleotide repeat disorders.
• to determine whether there is peripheral nervous system involvement in SCA6, in order to introduce
a new element that might be useful for phenotype recognition and pathophysiological research.
With respect to the autosomal recessive cerebellar ataxias:
• to contribute to phenotype recognition, in particular with respect to the peripheral aspects of these
disorders. 
• to establish a clinical classification system for early-onset cerebellar ataxia (EOCA) that is based
on clear clinical features and nerve conduction studies, and which can be used for counseling and
DNA research.
Outline of the thesis 
After the introduction (Section I), the different aspects are covered in three sections. 
Section II covers the study of the phenotype and genotype of a large Dutch ADCA family that could not be
linked to any of the known loci. 
Section III describes an important aspect of the pathophysiology of CAG trinucleotide repeat disorders,
focusing on the pattern of neurodegeneration in relation to the presence of NII in the brains of five patients
with SCA3. The clinical relevance of CACNA1A (the SCA6 gene), which is expressed in both the central
nervous system (CNS) and the peripheral nervous system (PNS), is also addressed. 
Section IV describes studies performed with the aim of expanding the phenotype and genotype (including
clinical work-up and clinical classification) of the autosomal recessive cerebellar syndromes. 
Ultimately, in the discussion we will propose an expanded clinical algorithm generated on the basis of the
literature, our experience, and our findings.
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Similarities and differences in the phenotype,
genotype and pathogenesis of different spinocerebellar 
ataxias; a review
H.J. Schelhaas, P.F. Ippel, F.A. Beemer and G. Hageman
Chapter 2 
Adapted from: European Journal of Neurology 2000; 7:309-314.
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Introduction
The autosomal dominant cerebellar ataxias are a heterogeneous group of neurodegenerative disorders
characterized by progressive cerebellar dysfunction in combination with various associated features. Since
1993 these disorders have been increasingly characterized in terms of their genetic mutation and are referred
to as SCA. These mutations have been identified for SCA1, 2, 3, 6, 7, 8, 10, 12, 14, 17 and fibroblast grow
factor type 14 (FGF14) whereas the genes for SCA4, 5, 11, 13, 15, 16, 18, 19, 20, 21, 22, 23 and 25 remain to
be isolated (Table 2.1) (http://www.gene.ucl.ac.uk/cgi-bin/nomenclature). The status of SCA8 is still being
discussed (Schols et al. 2003). Some families with autosomal dominant cerebellar syndromes cannot be
assigned to any of the known loci, implying further genetic heterogeneity.
Despite of the genetic heterogeneity, the clinical syndromes are similar to each other. This clinical overlap
is possibly caused by similar mutations in different genes (Hardy and Gwinn-Hardy 1998). For example
SCA1, 2, 3 and 7 involve an unstable CAG repeat, which codes for glutamine (Orr et al. 1993; Pulst et al.
1996; Kawaguchi et al. 1994; David et al. 1997; Zhuchenko et al. 1997). In this review we focus on the clinical
presentation of the different SCAs and discuss the pathway from genetic mutation, abnormal protein to
common neuropathology in these disorders.
ADCA and SCA: progress in the understanding of autosomal dominant ataxias
In 1983, Harding proposed a clinical classification for ‘late onset’ ADCA (Harding 1983). In ADCA I, cere-
bellar ataxia was associated with additional features related to the optic nerve, (extra)pyramidal system,
cerebral cortex and peripheral nerves. ADCA II was associated with pigmentary macular dystrophy. ADCA
III was a pure late onset cerebellar syndrome while ADCA IV was associated with myoclonus and deafness.
In 1993 Harding adapted this classification, the main difference being that ADCA IV was no longer seen as
a distinct entity (Harding 1993). Nowadays, ADCAs are characterized in terms of their genetic locus and are
referred to as SCA. The ‘SCA-classification’ and the ‘ADCA-classification’ are not congruous. Since the
ADCA-classification was purely clinical, it could be applied to individuals only. For example, in a family with
the SCA6 mutation, there could be some family members with ADCA I and some with ADCA III. For this,
at least for those patient in which the mutation is known, the term ADCA should be considered obsolete. 
Genotype/phenotype relation
The overlap between the SCA phenotypes and the high variability within SCA subgroups mean that the
underlying mutation cannot be predicted reliably for individual patients. Therefore, diagnosis has to be
made on the genotype. Still, experienced neurologists may appreciate some fairly characteristic symptoms
and signs and may try to deduce the underlying mutation on the basis of the clinical, electrophysiological,
and magnetic resonance imaging (MRI) results (Schols 1997b). SCA4, 5, 11, 13, 15, 16, 18, 19, 21, 22, 23, 25
are acquired on the study of one or two families, can only be analyzed in a research setting, are probably
extremely rare, and, except for SCA19 (Verbeek et al. 2002), and SCA23 (Verbeek et al. 2004), have never
been found in the Netherlands. SCA9 is reserved but has, until now, not been claimed and SCA24 is a SCA
with autosomal recessive inheritance (Swartz et al. 2002). The pheno- and genotype of SCA8 is not fully
established and current evidence suggests that SCA8 merely reflects a risk factor for ataxia (Zeman et al.
2004). For SCA8, diagnostic tests should not be performed until its etiologic role is fully clarified (Schols et
al. 2003). The occurrence of SCA10, relatively pure cerebellar ataxia with epilepsy, and SCA12, cerebellar
ataxia with an intention tremor, seems to be confined to specific populations (Matsuura et al. 2002;
Fujigasaki et al. 2001b).
Therefore, in most Western European countries, DNA analysis is available (and useful) for SCA1, 2, 3, 6, 7,
14 and 17 only. For the clinical approach of these SCAs an algorithm can be helpful (Figure 2.1; Table 2.2). 
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Table 2.2 Clinical features, MRI morphology, and nerve conduction studies of the autosomal dominant spinocerebellar
ataxias that are most frequently encountered in Western Europe.
Disease Associated clinical features MRI studies Nerve conduction studies
SCA1 Ophthalmoplegia, pyramidal Atrophy of cerebellum Reduced MCV of tibial
and extrapyramidal signs, and pons and peroneal nerve
dementia, neuropathy, 
dysphagia, optic atrophy
SCA2 As in SCA1 but more frequent Like SCA1 but more Reduction of SNAP
reduction in saccade velocity, pronounced mainly affecting
hyporeflexia the upper limbs
SCA3 As in SCA1 but hardly ever Mild atrophy of cerebellum Reduction of SNAP
/MJD saccade velocity reduction. and brainstem and CMAP in both upper
More often extrapyramidal signs and lower limbs
SCA6 None Pure cerebellar atrophy Normal
SCA7 Retinal degeneration Atrophy of the pons as an Conflicting results (see text)
early sign. Cerebellar and
brainstem atrophy
SCA14 Pure cerebellar syndrome Marked atrophy of Not reported
with extrapyramidal features cerebellar vermis and
in patients with an early onset hemispheres
SCA17 Psychiatric symptoms and Most pronounced in cerebellum Not reported
dementia and occipital lobe. Atrophy of 
the caudate nucleus has been 
described
MJD, Machado Joseph disease (SCA3); MCV, motor nerve conduction velocity; SNAP, sensory nerve action poten-
tial. CMAP, compound motor action potential.
If retinal degeneration is present in a patient presenting with a late onset, autosomal dominant cerebellar
syndrome, then SCA7 is probable. At the beginning of disease most patients suffer from a predominantly
cerebellar syndrome with less prominent involvement of non-cerebellar systems. However, if this is still the
clinical picture many years after onset of symptoms and signs then SCA6 and SCA14 are most likely.
Whereas in SCA6 clinical features frequently starts after the age of 50 (Sinke et al. 2001), the mean age at
onset in SCA14 is around 40 (range 10-59). In SCA17, psychiatric symptoms and dementia are a hallmark
of disease and might even be a presenting symptom. The distinction between SCA1, 2 and 3 can be very dif-
ficult. SCA3 is the SCA with the highest worldwide prevalence and its phenotype is extremely pleiomorphic.
For this, SCA3 should always be considered. SCA2 is characterized by an extreme slowing of saccadic velo-
city (Wadia et al. 1998a). Furthermore, pyramidal features, usually present in SCA1 and SCA3, are usually
absent in SCA2 (Ramesar et al. 1997; Schols et al. 1997a; Wadia et al. 1998). The presence (SCA1) or absen-
ce (SCA3) of tendon reflexes might help to distinguish between SCA1 and SCA3.
MRI of the brain in different SCAs is generally in accordance with the clinical findings (Table 2.2). Although
it is known in clinical practice that the degree of atrophy is largely correlated to the age at onset and dura-
tion of disease, some generalizations might be considered. In SCA1 MRI usually shows mild olivopontoce-
rebellar atrophy (OPCA), whereas in SCA2 there is severe OPCA. The involvement of the efferent dentato-
rubral system, with atrophy of the frontal and temporal lobes and globus pallidus distinct from OPCA, is
characteristic of SCA3 (Murata et al. 1998). In SCA6 there is pure cerebellar atrophy with no evidence of
brainstem involvement.
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Figure 2.1 Algorithm for the work up of the spinocerebellar ataxias that are probably most frequently encountered
in Western Europe. The algorithm should be dealt with restrain but can be used for executing DNA analysis in
order of clinical likelihood.
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SCA7
SCA6
SCA14
SCA17 (particularly in com-
bination with dementia)
SCA3 
(highly pleiomorphic)
SCA1
SCA2 (particularly if
combined with severe
saccadic slowing)
yes
yes
yes
yes
no
no
no
no
yes
yes
Age at 
onset > 50
no
Depressed 
tendon reflexes
no
Retinal
degeneration
Relatively pure
cerebellar syndrome
Prominent 
psychiatric symptoms
Pyramidal signs
In SCA7 pontine atrophy is a prominent and consistent finding regardless of the degree of cerebellar atrophy
or duration of disease. Cerebellar atrophy is not found in those SCA7 patients with a short duration of disease
or mild ataxia, but becomes prominent as the severity and duration of illness progresses (Jobsis et al. 1997;
Bang et al. 2004). MRI studies of patients with SCA14 show marked atrophy of cerebellar vermis and
hemispheres with no cortical atrophy, no basal ganglia abnormalities, and no white matter changes (van de
Warrenburg et al. 2003). In SCA17, the atrophy is usually most pronounced in the cerebellum and occipital
lobe (Rolfs et al. 2003), but subcortical atrophy of the caudate nucleus has also been described.
Nerve conduction studies support and extend the clinical findings of peripheral nerve involvement (Table
2.1). Both Schöls et al. (Schols et al. 1997a) and van de Warrenburg et al. (van de Warrenburg et al. 2002),
found that in SCA1, the motor nerve conduction velocities of tibial and peroneal nerve, are significantly slower
compared to SCA2, 3 and 6. Nerve conduction studies in SCA2 usually reveal a sensory neuronopathy,
mainly affecting the upper limbs. In SCA3, nerve conduction studies are compatible with an axonal type of
neuropathy, or neuronopathy. Until now, there is no evidence of peripheral nerve involvement in SCA6.
There is some controversy concerning nerve conduction studies in SCA7. One study showed normal nerve
conductions studies in five SCA7 patients. In contrast, another study found peripheral nerve involvement
in all four SCA7 patients examined (van de Warrenburg et al. 2004; Kubis et al. 1999). Finally, nerve con-
duction studies of SCA14 and 17 have not been reported.
Trinucleotide repeats and neurodegenerative disorders 
DNA is a long, threadlike, macromolecule made up of a large number of deoxyribronucleotides, each com-
posed of a nitrogenous base, a sugar, and a phosphate group. The bases of DNA molecules carry genetic
information, whereas their sugar and phosphate groups perform a structural role. The nitrogenous base is
a derivate of purine or pyrimidine. The purines in DNA are adenine (A) and guanine (G), and the pyrimidines
are thymine (T) and cytosine (C). Single copy DNA occur only once in the genome and make up approxi-
mately 75 percent of the genome. Repetitve DNA is primarily found in the non-coding regions of the genome
and of the noncoding DNA, as many as 20 to 30 percent consist of repetitive DNA sequences. Trinucleotide
repeats consist of a sequence of three base pairs repeated several times in the DNA. Trinucleotide repeats
are polymorphic, which means that the number of repeats at one locus is variable in the population. In
several neurodegenerative disorders there is difference between ‘normal’ and ‘pathologically expanded’
repeats. Normal repeats are stable; that is, the length of the repeat does not change from generation to
generation. Pathological repeats are unstable and tend to expand during vertical transmission as well as in
mitotic divisioning. To date, variable types of unstable trinucleotide repeat expansions have been identified
(Figure 2.2, Table 2.3). The first type is represented by the fragile X syndrome. In these disorders CGG repeats
are present in the 5’ untranslated region (5’ UTR; that part of DNA that is located before the start codon)
of the gene. The CGG repeats are transcribed but not translated and current concepts suggest that the
pathogenesis of these disorders is consistent with a loss-of-function mechanism in which the non-coding
repeat expansion interfere with gene expression and cause a loss of protein production. 
A second type, of which myotonic dystrophy, and SCA8 (although still questioned) are representatives, is
caused by an expanded CTG repeat in the 3’ untranslated region (3’ UTR; that part of DNA that is located
after the stop codon). Again, these CTG repeats are transcribed but not translated. Current evidence sug-
gest that these mutations exert there deleterious effect at the RNA level (Ranum and Day 2004). 
The third type, discovered in 1996, is caused by an intronic expanded GAA trinucleotide repeat expansion
in intron 1 of the frataxin gene (Campuzano et al. 1996). In most control alleles the repeat length ranges
from 6 to 9, while a small subset of so-called large-normal alleles (14-34 repeats) has been identified that
may be the unique source of further expansions into an intermediate range of allele lengths (up to 90 repeats)
or clearly disease causing (90 to 1700 repeats) alleles (Durr et al. 1996; Cossee et al. 1997). The pathoge-
nesis of FRDA is consistent with the paradigma that recessive disorders are most often caused by a loss of
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protein function as the intron expansion prevents the normal protein production. The fourth type, expan-
ded GCG repeats in the polyadenylate binding protein nuclear 1 gene (PAPBN1), encoding a polyalanine tract,
is responsible for a late onset autosomal dominant muscle disorder called oculopharyngeal muscle dystro-
phy (OPMD). In this disorder, the accumulation of undegradable polyalanine rich molecules leads to the
formation of nuclear filaments. How this accumulation leads to the symptoms of OPMD is still subject of
research (Brais et al. 1998), but the pathophysiological concept of this disorder fits the classic concept that
dominant disorders are caused by a gain or change of function of the mutant protein. 
The fifth type, encoding expanded CAG repeat disorders, is responsible for SCA1, 2, 3, 6, 7 and 17. Other
disorders caused by expansion of this triplet are Huntington disease and spinal and bulbar muscular atro-
phy (SBMA). Again, pathogenesis seems compatible with a change of function model.
Table 2.3 Disease-causing repeats differ in nucleotide sequence, length of the expansion, location within the res-
pective disease gene and size of the repeated element (in this table only various types of trinucleotide repeat dis-
orders are covered; see also figure 2.2).
Trinucleotide Disease Inheritance Repeat size Reference
repeat
expansions Normal Disease
CGG Fragile X  X-linked 6-54 >200 (Verkerk et al. 1991)
syndrome (55-200)*
CTG Myotonic Autosomal dominant 5-37 52->1000 (Buxton et al. 1992; 
dystrophy Harley et al. 1992)
SCA8 Autosomal dominant 25-44 107-127 (Koob et al. 1999)
Huntington disease Autosomal dominant 10-27 51-57 (Koide et al.
like-phenotype-2 1999; Bauer et al. 2002)
(JPH3)
GCG Oculopharyngeal Autosomal dominant 6 9 (Brais et al. 1998)
muscle dystrophy
GAA Friedreich’s ataxia Autosomal recessive < 90 100-1700 (Campuzano et al.
1996)
CAG Huntington disease Autosomal dominant 9-35 39-121 (Read 1993; Rubinsz-
(36-39†) tein et al. 1996)
Spinal and bulbar X-linked 17-26 40-55 (La Spada et al. 1992)
muscular atrophy
SCA1, 2, 3, 6, 7, Autosomal dominant See 
12, 17 table 2.1
DRPLA Autosomal dominant 7-23 49-88 (Nagafuchi et al. 1994)
* ‘Premutation’, in this range the repeat expansion is mitotically unstable and responsible for the neurodegene-
rative disorder called fragile X associated tremor/ataxia syndrome (FXTAS) (Hagerman and Hagerman 2004). 
† intermediate range: the mutation is not fully penetrant in individuals with a borderline number of CAG repeats. 
DRPLA, dentatorubropallidolusian atrophy.
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CAG repeats in SCA: medical genetics
SCA’s are usually characterized by a ‘late onset’, a unique pattern of neurodegeneration, a dominant inhe-
ritance and anticipation. However, there are juvenile forms of SCA, which are accompanied by a much more
extensive neuropathology than the adult onset forms. These juvenile forms are genetically characterized by
long CAG-repeats. CAG repeat expansion is observed particularly in paternal transmission and it is the
genetic basis of anticipation. 
SCA1, 2, 3, 6, 7, 12 and 17 are caused by an expanded CAG repeat (Table 2.3) (Banfi et al. 1994; Gispert et
al. 1993; Kawaguchi et al. 1994; Zhuchenko et al. 1997; David et al. 1997; Nakamura et al. 2001). Unlike the
other CAG repeat expansion syndromes, the CAG repeat expansions causing SCA6, and SCA17, are consi-
dered stable. However, certainly with respect to SCA17 the issue has not been completely settled (Fujigasaki
et al. 2001a; Nakamura et al. 2001). 
‘Ataxins’, the gene products in SCA
The gene products of SCA1, 2, 3, 6, 7, 8, 10, 12, 14, 17 and FGF14 have been identified (Table 2.1). Ataxin-1
(ATX1), a protein of 792-829 amino acids, has a nuclear localization in most neurons but in cerebellar
Purkinje cells it is found in both the nucleus and the cytoplasm (Servadio et al. 1995). Current evidence sug-
gests that it might be involved in RNA-processing pathways (Yue et al. 2001) Ataxin-2 (ATX2) is the gene
product of SCA2. This 1313 amino acid protein is a basic protein with two domains implicated in RNA
splicing and protein interaction. The ‘wild type ataxin-2’, is found in the cytoplasm (Huynh et al. 1999;
Trottier et al. 1998). 
Ataxin-3 (ATXN3), a nuclear and cytoplasmatic protein of 359 amino acids, is not only expressed in the brain
but also in most, if not all, non-neuronal tissues. Recent evidence suggests that ataxin-3 is an ubiquitin-
binding protein that functions in the ubiquitin-proteasome protein degradation pathway (Chai et al. 2004). 
The gene product of SCA6 is the α1A-subunit of a P/Q voltage gated calcium channel (P/Q-VGCC). The poly-
glutamine stretch is located within the intracellular carboxyl terminal of this PQ-VGCC (Zhuchenko et al. 1997).
Ataxin-7 is a subunit of the TATA-binding protein-free TAF-containing complex (TFTC) (Helmlinger et al.
2004). Although the normal function of this complex has, until now, not been completely elucidated, it
certainly seemed to be involved in transcriptional regulation. 
The gene product of SCA14, protein kinase Cgamma (PKCgamma), is a member of a family of protein kinases
that plays an important role in fundamental neurobiological processes including neuronal development,
plasticity, excitability, and survival. PKCgamma is highly expressed in Purkinje cells. Current evidence con-
nect PKCgamma to ataxin-1 (Chen et al 2004) and this observation might suggest that a change of
PKCgamma activity may be part of a common pathway in autosomal dominant spinocerebellar ataxia (for
review see Pandolfo and van de Warrenburg 2005).
The gene product of SCA17, the TATA binding protein (TBP), is definitely a transcription factor (Nakamura
et al. 2001).
Apart from the polyglutamine stretch, and in some, the involvement in transcriptional regulation and RNA
metabolism, these proteins are completely dissimilar. As disease severity increases with the expansion of
the polyglutamine stretch, it is likely that the polyglutamine expansion itself plays a crucial role in the
mechanism of neurodegeneration.
From polyglutamine stretch to neurodegeneration: the missing link
Now that the initiating trigger, CAG repeats encoding polyglutamine, the gene product ataxin, and the clinical
outcome are known research has focused on a common neuropathology. The wild type ataxins appear to be
natively unfolded (Uversky 2003). However, when expanded, the ataxins are transported into the nucleus of
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neurons where they aggregate as insoluble, amyloid-like fibrils to form a neuropathological structure called
‘neuronal intranuclear inclusions (NII)’ (Davies et al. 1998). These NII have now been found in transgenic
models, both mammalian (mice) and invertebrate (Drosophila) of SCA1, and in patients with SCA2, 3, 7,
and 17 (Table 2.1) (Hardy and Gwinn-Hardy 1998; Davies et al. 1998). Aggregation of these ataxins can be
increased by various mechanisms like increased concentration of the protein, proteolytic cleavage of the
protein, phosphorylation of the ataxin, and oxidative protein modification (for review see Ross and Poirier
2004). However, although an increased propensity to form aggregates is a common feature of all polyglu-
tamin disease proteins, the role of these NII is still far from clear. Current evidence suggests that for the
pathogenesis the recruitment of other proteins into these polyglutamine aggregates might be essential. For
example, for SCA1 the recruitment of the 14-3-3 protein seems crucial (Chen et al. 2003). This 14-3-3 protein,
an important multifunctional regulatory molecule, mediates the neurotoxictiy of ataxin-1, by binding to and
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Figure 2.2 Disease-causing repeats differ in nucleotide sequence, size of the repeated element (not shown in this
figure), length of the expansion, and location within the respective disease gene (here all placed in one schema-
tic scheme). Some repeats reside within introns, others within exons containing untranslated regions, and still
others within protein coding exons. 
5’ UTR, 5’ untranslanted region (that part of DNA that is located before the start codon);
3’ UTR, 3’ untranslated region (that part of DNA that is located after the stop codon); mRNA,
messenger RNA; FRAXA, fragile X syndrome; FRDA, Friedreich’s ataxia; SCA, spinocerebellar
ataxia; DRPLA, dentatorubropallidolusian atrophy; SBMA, spinobulbar muscular atrophy;
JPH3, junctophilin-3 (mutated in Huntington disease like-phenotype 2).
3’ UTR:
SCA8, MD1 (CTG)
5’ UTR: SCA12 (CAG),
FRAXA (CGG)
SBMA
HD
SCA1
OPMD (GCG)
SCA17
(CAG/CAA)
JPH3 (CAG/CTG)
SCA3
SCA2
SCA7
DRPLA (CAG)
SCA6 (CAG)
(intronic GAA
repeat: FRDA)
M-RNA
mRNA
DNA
stabilizing the protein, thereby slowing its normal degradation. The binding of ataxin-1 with 14-3-3 is regu-
lated by Akt phosphorylation and is polyglutamine dependant. Current evidence suggests that a similar
mechanism might also hold true for ataxin-2, 3, and 7 (personal communications).
The mechanism of neurodegeneration in SCA6 is probably of a different kind. Stable expanded CAG repe-
at and point mutation in the CACNA1A gene on chromosome 19p13 are translated in a mutant α1A-subunit
of the PQ-VGCC, lead to a loss of function of the channel resulting in an influx of calcium in the cell. The
increase of intracellular calcium ultimately leads, by a cascade of deleterious events, to cell death and
neurodegeneration (Zoghbi 1997).
Concluding remarks
The differential diagnostic problems of the autosomal dominant spinocerebellar ataxias are partly resolved
with the use of a current available genetically based classification system. The ‘completion’ of this classifi-
cation, is an important step in elucidating the process of neurodegeneration in these CAG/polyglutamine
expansion disorders. A second step forward came with recognition of the NII, the pathological structures
found in SCA1, 2, 3, 7 and 17. These two steps are essential for creating transgenic animal models that will
enable research groups to study and ‘plot’ the pathway from genetic mutation to abnormal protein and cell
death. Because expanding CAG triplet repeat disorders are known to be responsible for at least ten neuro-
degenerative diseases, a breakthrough in one of these diseases might mean a breakthrough for all of them.
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The autosomal recessive cerebellar ataxias
Chapter 3
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In contrast to the well-defined clinicogenetic classification of the autosomal dominant cerebellar disorders,
much less is known about the autosomal recessive ataxias. Currently different forms have been identified.
FRDA seems to be the most common form, with a prevalence of about 2 per 100,000 (Cossee et al. 1997).
For a few other recessive Friedreich-like ataxias, such as ataxia with isolated vitamin E deficiency (AVED),
autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) and ataxia with oculomotor apraxia
type 1 and type 2, the molecular basis has also been elucidated (Table 3.1) (Ouahchi et al. 1995; Ben Hamida
et al. 1993; Engert et al. 2000; Moreira et al. 2001b; Moreira et al. 2004). Still, these mutations explain only
relatively few cases, and often occur in isolated populations only. 
In the absence of such a commonly accepted clinicogenetic classification system, the overview presented
in Table 3.1 might help investigators to categorize these patients. It is adapted from Harding’s classification
and has the advantage that it illuminates the progress that has been achieved in the unraveling of these dis-
orders. The classification shows some inconsistencies (‘secondary mitochondrial disorders’ like FRDA and
AVED, are not classified under the heading of metabolic disorders) and is certainly not very practical from
a clinical perspective. A major challenge is to develop a classification that is based on relatively unmistak-
able clinical features and at the same time provide an optimal strategy for molecular diagnosis. However,
the ‘current state’ is that such a classification is not available. In this chapter we will not address the meta-
bolic disorders but instead, will refer the reader to chapter 13 of the excellent textbook edited by Klockgether
(Bolthauser 2000). We will also not address Xeroderma pigmentosa and Cockayne’s syndrome as these
disorders usually manifest themselves not by cerebellar ataxia but by respectively, skin disease, and grow
retardation with severe dementia (Harding 1984a). 
Disorders characterized by secondary mitochondrial dysfunction
At least four different types of recessive ataxias are recognized as nuclear encoded disorders with secon-
dary mitochondrial dysfunction. 
Friedreich’s ataxia
The most common and currently best know recessive ataxia is FRDA. Its estimated prevalence in the
western world is about 2 in 100,000 individuals while the estimated gene carrier frequency is about 1:100
(Leone et al. 1990; Cossee et al. 1997; Durr 2002). In contrast, FRDA seems rare to absent in other ethnic
groups, like black Africans and Japanese (Labuda et al. 2000). The causative mutation affects the frataxin
gene on 9q13 and most commonly consists of an expanded GAA trinucleotide repeat expansion in intron 1
of the gene (Campuzano et al. 1996). 
Initial clinical criteria as proposed by Geoffroy and Barbeau in 1976 were designed for research purposes
and so strict that a diagnosis could not be made in many instances (Geoffroy et al. 1976). In 1981, Harding
therefore, proposed less stringent clinical criteria (Harding 1981a). These included age at onset before 25
years, progressive ataxia of limbs and gait, absent knee and ankle jerks, and extensor plantar responses.
The discovery of the pathogenic mutation has clearly shown that the clinical spectrum of FRDA is even
wider than initially defined and currently includes onset ages over 30 years, a much milder disease course,
spastic ataxia, and even extrapyramidal movement disorders such as myoclonus or chorea (Hanna et al.
1998; Klockgether et al. 1991). Cardiomyopathy is now known to be present in most cases, although its
manifestations are variable and may often remain undetected (Dutka et al. 1999; Isnard et al. 1997).
Friedreich’s ataxia is primarily a disease of dorsal root sensory neurons. The loss of these sensory neurons
and the associated posterior column degeneration may in fact constitute the main cause of the initial ataxia.
Nerve conduction studies reveal an early loss of sensory nerve action potentials. Those fibers that originate
more caudally are more severely affected. In addition to degeneration of the sensory posterior columns, the
spinocerebellar tracts and the corticospinal motor tracts degenerate as well. The cerebellar cortex shows
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Table 3.1 Current state: the autosomal recessive spinocerebellar disorders.
I Ataxic disorders with known metabolic or other cause
A. Metabolic disorders
1. Progressive, unremitting ataxia:
Lysosomal disorders: 
Hexosaminidase deficiency
pingolipidaemia
M. Refsum
Globoid cell leukodystrophy
Metachromatic leukodystrophy
Adrenoleukodystrophy
Lipid storage disorders
Cerebrotindinous xanthomatosis
Niemann-Pick type C
Copper-metabolic disorders
Wilson’s disease
Ceruloplasmin deficiency hemosiderosis
Neuronal ceroid lipofuscinosis
Sialidosis
2. Intermittent ataxia:
Amino acid disorders
Organic aciduria 
Pyruvate dehydrogenase deficiency
Urea cycle defects
B. Disorders characterized by (secondary) mitochondrial dysfunction 
Friedreich ataxia type 1              
Ataxia with isolated vitamin E deficiency (AVED)
Abetalipoproteinemia
X-linked sideroblastic anemia with ataxia
C. Disorders characterized by defective DNA repair 
Ataxia teleangiectasia (Louis Bar syndrome)
Ataxia-teleangiectasia-like disorder (ATLD)
Ataxia with oculomotor apraxia type I 
Ataxia with oculomotor apraxia type 2
Spinocerebellar Ataxia with Axonal neuropathy (SCAN1)
Xeroderma pigmentosum
Cockayne syndrome
D. Disorders caused by a dysfunction in chaperone mediated protein folding
Autosomal recessive spastic ataxia of Charlevoix-Saguenay      
II Disorders for which the locus is well established but the mutation still unknown
Friedreich ataxia type 2 
Infantile onset spinocerebellar ataxia and sensory neuropathy (IOSCA) 
Autosomal recessive ataxia with hearing impairment and optic 
atrophy (locus 6p21- 23)
Autosomal recessive non-progressive infantile ataxia (locus 20q11-q13)
III Disorders of unknown metabolic or other cause
‘EOCA’
only mild loss of Purkinje cells late in the disease course (Lamarche et al. 1984). Thus, cerebellar atrophy
on MRI scanning is mild at most, and virtually absent in patients that have not yet progressed well into the
disease (Klockgether et al. 1991).
FRDA is the sole example of an intronic expanded trinucleotide (GAA) repeat (Campuzano et al. 1996). In
most control alleles the repeat length ranges from 6 to 9, while a small subset of so-called large-normal
alleles (14-34 repeats) has been identified that may be the unique source of further expansions into an inter-
mediate range of allele lengths (up to 90 repeats) or clearly disease causing (90 to 1700 repeats) alleles
(Campuzano et al. 1996; Durr et al. 1996; Cossee et al. 1997; Epplen et al. 1997). Frataxin gene point
mutations have been described, but such alleles may only be pathogenic in conjunction with an allele
that carries a GAA expansion (Cossee et al. 1999).
The large expansions suppress frataxin gene expression, thus causing a classical recessive genotype with
loss of function of the frataxin protein, a mitochondrial matrix protein (Campuzano et al. 1997; Koutnikova
et al. 1997). In vitro, deletion of a yeast frataxin homologue (YFH1) resulted in a decrease in mitochondrial
respiration; an increase in mitochondrial iron accumulation and oxidative stress; mitochondrial and nuclear
DNA damage; and a strong reduction in the assembly of Fe/S protein dependent mitochondrial complex I,
II and III subunits, as well as aconitase (Babcock et al. 1997; Wilson and Roof 1997; Adamec et al. 2000;
Karthikeyan et al. 2002; Muhlenhoff et al. 2002). Results from these mechanistic studies in unicellular
model systems have to a large extent been confirmed in fibroblasts, cardiomyocytes, cerebellar MRI and
skeletal magnetic resonance spectroscopy studies of FRDA patients (for review see: Durr 2002). Therefore,
an old hypothesis that was published in the eighties (Dijkstra et al. 1984) is currently mainstream: FRDA is
a nuclear encoded mitochondrial disorder.
Hereditary ataxia with vitamin E deficiency (AVED)
This is a rare condition that clinically resembles Friedreich’s ataxia; autosomal recessive early onset
progressive spinocerebellar ataxia with marked proprioceptive loss and areflexia (Burck et al. 1981). Again,
peripheral nerve pathology is prominent (Zouari et al. 1998). The crucial lab finding in this condition is the
very low serum concentration of vitamin E/tocopherol. The underlying molecular defects in the various
families described turned out to be mutations in the alpha-tocopherol transfer protein gene (alpha-TTP),
which is localized on chromosome 8q13 (Ouahchi et al. 1995). Most known patients come from Tunisia.
Separate mutations have been described in Europe, North America and Japan.
Alpha-TTP is responsible for selective retention of alpha-tocopherol from dietary vitamin E, which is a mix-
ture of alpha, beta, gamma, and delta-tocopherols and the corresponding tocotrienols. The alpha-TTP-
mediated transfer of alpha-tocopherol into nascent VLDL constitutes the major determinant of plasma
alpha-tocopherol levels in humans. AVED patients, therefore, have an impaired ability to incorporate alpha-
tocopherol into lipoproteins secreted by the liver. The resulting loss of free radical scavenging capabilities
and anti-oxidant capabilities may lead to mitochondrial dysfunction - similar to the situation in FRDA.
In these patients vitamin E should be supplemented, since trials have suggested a stabilization of neuro-
logical decline after the start of treatment (Gabsi et al. 2001).
Apart from AVED, other causes of low serum vitamin E concentration may lead to cerebellar ataxia, spinal
cord degeneration and neuropathy. These causes include both hereditary diseases such as abetalipoprotei-
nemia (Bassen-Kornzweig disease) and acquired disorders such as cystic fibrosis, chronic cholestatic liver
disease, short bowel syndrome and celiac disease (Sitrin and Bengoa 1987; Harding et al. 1982b).
X-linked sideroblastic anemia with ataxia
This very rare disorder, described in a few families worldwide, consists phenotypically of juvenile onset non-
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progressive ataxia, pyramidal tract signs and a siderblastic anemia in affected males. Allikmets et al.
demonstrated a missense mutation in the ABC7 gene, a nuclear encoded mitochondrial ATP-binding cas-
sette (ABC) transporter that localizes to the mitochondrial inner membrane and is involved in iron homeo-
stasis (Allikmets et al. 1999). Thus, like in Friedreich’s disease, mitochondrial iron homeostatic impairment
may lead to cerebellar dysfunction.
Disorders characterized by defective DNA repair
Another group of ataxias is pathophysiologically characterized by defective DNA repair and clinically by early
onset cerebellar ataxia, muscle wasting and prominent extrapyramidal features with a rather specific eye
movement abnormality called oculomotor apraxia. This consists of initial saccadic slowing, head thrust on
fast lateral gaze with gaze lag, difficulties in saccade initiation, and ultimately gaze paralysis. Ataxia telan-
giectasia (AT) is the best known of these disorders, but at least two novel forms have recently been identified.
Ataxia telangiectasia
The first clinical and pathological outline of AT was presented by Boder and Segwick in 1958 (Boder and
Sedwick 1958). However, their description was preceded by reports from the Czechs Syllaba and Henner in
1926 (Syllaba and Henner 1926) and from the Belgian Denise Louis-Bar in 1941 (Louis-Bar 1941), whose
name has become eponymic to the disease until recently. Although well known to many neurologists and
pediatricians, this recessive disorder is in fact so rare that many may never have seen a case personally. Its
incidence has been estimated at about 0.3-1.0 per 100.000 live births (Swift et al. 1986). The ATM mutated
gene carrier frequencies have been estimated for western populations to be 0,5 - 1.0 percent, but percen-
tages as high as 3,5 have been suggested (Swift et al. 1986).
The disease typically starts in early childhood with progressive cerebellar ataxia. Truncal ataxia precedes
appendicular ataxia. Progressive oculomotor apraxia with absent optokinetic nystagmus is quite characte-
ristic. Chorea, dystonia and related extrapyramidal features occur in the vast majority of patients. Deep ten-
don reflexes become diminished or absent by age eight and patients later develop diminished large-fiber
sensation (Woods and Taylor 1992). Progressive spinal muscular atrophy that affects mostly hands and feet
debuts at an older age. In combination with early-onset dystonic posturing this leads to striking combined
flexion-extension contractures of the fingers. Memory problems may occur in elder patients but in general
cognition is spared.
The gene responsible for AT is called ATM (AT mutated). ATM is a protein kinase that belongs to a highly
conserved family of ‘phosphatidyl-inositol 3-kinase (PI3K)-like protein kinases’ (PIKKs) with serine/threonine-
kinase activity (Savitsky et al. 1995). ATM may be functionally located at the apex of a response cascade that
senses and responds to DNA damage and repair. Its role has been particularly well described in the very
rapid response to double strand DNA breaks where it initiates a large number of various protein phosphory-
lation pathways (Shiloh 2000). 
Apart from ataxia, the clinical manifestations in homozygotes consist of conjunctival telangiectasias, which
typically become apparent between age three and five. Respiratory tract infections occur very frequently, but
other infections have an increased incidence as well. Radiosensitivity and a predisposition to various forms
of cancer complement the clinical problems of these patients. The most common malignancies associated
with homozygous AT are T-CLL leukemia and B-cell lymphomas. Other malignancies include gastric ade-
nocarcinoma, hepatocellular carcinoma, ovarian tumors, renal cell carcinoma and cerebellar glioma,
medulloblastoma and breast cancer. Diagnostic laboratory features are an elevation of serum alpha-feto-
protein and carcinoembryonic antigen concentrations, dysgammaglobulinemias, and impairment of cellular
immunity. Mutation detection at the ATM locus is difficult because of the large size of the gene (66 exons),
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the fact that mutations are located throughout the gene with no hotspots, and the difficulty of distinguishing
mutations from polymorphisms.
The neuropathology of AT seems not very specific. In advanced cases the cerebellum is severely atrophic,
due to thinning of the molecular layer, granule cell depletion and Purkinje cell loss. Additional affected
structures include the spinal cord, where dorsal column demyelination with neuroaxonal dystrophy, astro-
cytic proliferation, dorsal root ganglion and anterior horn cell degeneration may be observed. 
Ataxia-telangiectasia like disorder (ATLD)
ATLD is a very rare disorder. The clinical features are similar to those of ataxia teleangiectasia with cerebel-
lar ataxia and oculomotor apraxia. Some patients may present with chorea. Still, ATLD is characterized by
a later onset and a slower progression. Affected patients do not show teleangiectasia. The disorder is the
result of a deficiency of the human Mre 11 protein that is caused by a mutation in the hMRE11 gene (Meiotic
Recombination). At the cellular level, the disorder exhibit hypersensitivity to ionizing radiation, radiore-
sistant DNA synthesis and failure to induce stress activated protein kinases following exposure to ionizing
radiation. For this, current evidence suggests that AT and ATLD act in the same DNA response pathway.
Ataxia with Oculomotor Apraxia type 1 (AOA1)
Since the early seventies many patients have been reported with an AT-like phenotype that could neverthe-
less be distinguished from true AT on clinical and biological grounds. The syndrome was recognized by its
oculomotor apraxia, with added features of early onset cerebellar ataxia, choreo-athetosis, peripheral nerve
involvement and, in a subset of patients, mental retardation (Barbot et al. 2001). However, telangiectasias
or frequent infections were specifically absent, while hypoalbuminemia and hyperlipidemia were present in
many patients, particularly those from Japan. In addition, normal immunoglobulin composition, and nor-
mal alpha-fetoprotein levels further contrasted these patients with classical AT.
The first mapping results, from five Portuguese families and two Japanese families, showed homozygosity
and haplosharing over a region on 9p13 (Moreira et al. 2001a). The causative gene turned out to be a mem-
ber of the histidine triad (HIT) superfamily and was named aprataxin (APTX) (Shimazaki et al. 2002). This
allows the correct molecular classification of many patients with recessive cerebellar ataxia and has esta-
blished the connection of hypoalbuminemia with the diseases. A long-form splice variant aprataxin has
been found to interact with XRCC1 (x-ray repair cross-complementing group 1), and aprataxin and XRCC1
may constitute a multiprotein complex that is involved in single-strand DNA break repair (Sano et al. 2004).
Thus, like AT, AOA1 seems primarily a DNA repair disorder.
Ataxia with Oculomotor Apraxia type 2 (AOA2)
A second locus on 9q34 was identified in two non-related families with five and four affected sibs, respec-
tively (Bomont et al. 2000; Nemeth et al. 2000). Clinically these patients had late childhood or adolescent
onset ataxia, inconsistent oculomotor apraxia and elevated levels of serum creatine kinase, gamma-globulin
and alpha-fetoprotein (Nemeth et al. 2000; Watanabe et al. 1998b). The gene associated with this disorder
has been designated senataxin and shares extensive homology to fungal Sen1p proteins that are involved in
splicing and termination of tRNA, small nuclear RNA, and small nucleolar RNA. Senataxin may have RNA
and DNA helicase activity and it may act in the DNA repair pathway, thus, again, linking AOA2 to a DNA
repair defect (Moreira et al. 2004). 
Spinocerebellar Ataxia with Axonal neuropathy (SCAN1)
This recessive ataxia has recently been described in a Saudi Arabian family and is clinically characterized by
a mild cerebellar ataxia with mild cerebellar atrophy, and peripheral axonal motor and sensory neuropathy
(Takashima et al. 2002). A homozygous A1478G transition mutation in the Tyrosyl-DNA phosphodiesterase 1
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gene (TDP1), encoding a DNA repair enzyme was identified as the cause of this form of ataxia (Takashima
et al. 2002).
Disorders caused by a dysfunction in chaperone mediated protein folding
Autosomal recessive ataxia of Charlevoix-Saguenay (ARSACS)
This disorder was first described in 1978 as a form of spastic ataxia in a group of families from the two epo-
nymic Quebec regions (Bouchard et al. 1978). All related to a common founder who lived in Quebec around
1650. Clinical features of the original families included, apart from core ataxic features such as truncal and
limb ataxia, dysarthria and oculomotor abnormalities, also lower limb spasticity, distal muscle wasting and
foot deformities. Specific features appeared to include retinal striation reminiscent of early Leber’s atrophy,
mild mental retardation and the frequent presence of mitral valve prolapse. Disease onset was early: none
of the patients ever walked normally. But after the age of 20, little disease progression was noted. Shared
homozygosity analysis identified a locus on 13q11 and two distinct ancestral haplotypes were revealed
(Engert et al. 2000). Based on these data the first families originating from outside Quebec could be iden-
tified in Turkey and Tunisia, while the cloning of the gene, called SACs, allowed additional families from Italy
and Japan to be unambiguously diagnosed (Grieco et al. 2004; Mrissa et al. 2000; Criscuolo et al. 2004;
Ogawa et al. 2004). Thus, the disease appears to occur in many more parts of the world than originally anti-
cipated and concurrent with this notion, new mutations were found. It also appeared that neither retinal
striation nor mitral valve prolapse were as specific as initially reported.
The mutated gene, SACs, encodes a novel protein, called sacsin. SACs is expressed in various tissues, inclu-
ding the central nervous system. The presence of heat-shock domains suggests a function for sacsin in cha-
perone-mediated protein folding.
Disorders for which the locus is well established but the mutation still unknown
FRDA2
A second locus, on 9p23-p11, was found to co segregate with a disorder that was phenotypically described
as classic Friedreich’s disease (Christodoulou et al. 2001). No progress has been reported on this entity.
Infantile onset spinocerebellar ataxia (IOSCA)
IOSCA is extremely rare, having been described exclusively in a small founder group of Finnish patients.
Slowly progressive clinical symptoms manifested between one and two years of age in previously healthy
infants, with as the first manifestation clumsiness and gait problems. Ataxia, athetosis and muscle hypo-
tonia with loss of deep tendon reflexes could already be observed at that age. By school age ophthalmo-
plegia and hearing loss manifested while sensory neuropathy developed by adolescence. Female hypogo-
nadism and epilepsy were late manifestations. Ancillary examinations showed marked decrease in sensory
nerve condition velocities and a progressive loss of myelinated fibers in sural nerve specimen.
Neuroradiological investigations revealed cerebellar atrophy (Koskinen et al. 1994). The IOSCA locus was
mapped to 10q24 (Varilo et al. 1996). A gene has not been found yet.
Disorders of unknown metabolic or other cause
Early Onset Cerebellar Ataxia (with retained Tendon Reflexes)
The term EOCA with retained tendon reflexes was, again, introduced by Anita Harding in 1981, as a den-
ominator for patients with a phenotype that is distinct from classical FRDA (Harding 1981a). This and later
descriptions emphasized features that distinguish this entity from FRDA, such as a slower rate of progres-
sion, no cardiac abnormalities, the absence of scoliosis, and prominent cerebellar atrophy on MRI
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(Klockgether et al. 1991; Filla et al. 1990). Although retained (lower limb) tendon reflexes have been consi-
dered part of the clinical definition, many patients appear to have lost them during the course of the disease.
The prevalence of EOCA is unknown; estimates yielded about half of the prevalence of FRDA. But, as most
of the publications date from prior to the discovery of the FRDA gene, and given the clinical phenotypic
heterogeneity associated with the FRDA mutation, inclusion of FRDA cases in these series must be sus-
pected and prevalence data are not more than educated guesses. The current position of EOCA is that these
cases represent a clinically and genetically heterogeneous group of recessive ataxias in which a definite
genetic or biochemical diagnosis cannot be established, and with a slower disease course and a better prog-
nosis than classical FRDA (Klockgether et al. 1998).
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Part II
The pheno and genotype of a new dominant 
spinocerebellar syndrome (SCA19)
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Clinical and genetic analysis of a four-generation family with 
a distinct autosomal dominant cerebellar ataxia
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E.N. van der Laan and F.A. Beemer
Chapter 4 
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Abstract
The autosomal dominant cerebellar ataxias (ADCAs) are a heterogeneous group of neurodegenerative dis-
orders characterized by progressive cerebellar dysfunction in combination with a variety of other associati-
ve features. Since 1993, ADCAs have been increasingly characterized in terms of their genetic mutation and
are now referred to as spinocerebellar ataxias (SCAs). Some families with an autosomal dominant spino-
cerebellar syndrome cannot be assigned to any of the known genotypes, which imply further genetic hetero-
geneity. We investigated the clinical symptoms of 12 patients of a four-generation family with an autosomal
dominant cerebellar syndrome and carried out mutation and genetic linkage studies. The family showed a
relatively mild cerebellar ataxic syndrome with cognitive impairment, poor performance on the Wisconsin
Card Sorting Test (WCST), myoclonus, and a postural irregular tremor of slow frequency. Age at disease
onset and severity of cerebellar signs and symptoms suggest anticipation. The genetic loci implicated in
these disorders were excluded by mutation analyses (SCA1, 2, 3, 6, 7, 8, 12) and genetic linkage (SCA4, 5,
6, 10, 11). We conclude that this family represents a clinically and genetically distinct form of SCA.
Introduction
The autosomal dominant spinocerebellar ataxias are a heterogeneous group of neurodegenerative disor-
ders characterized by progressive cerebellar dysfunction in combination with a variety of other associated
features (Harding 1983). The genetic loci implicated in these disorders have been labeled and numbered
(1-8, 10-25) as SCA. Mutations have been identified for SCA1, 2, 3, 6, 7, 8 and 12 while the genes for SCA4,
5, 10 and 11, which have been linked to chromosomes 16, 11, 22 and 15, respectively, are yet to be isolated
(http://www.gene.ucl.ac.uk/cgi-bin/nomenclature). Since not all families with an autosomal dominant
spinocerebellar ataxia can be linked to one of the known loci, additional SCA loci are expected to be identi-
fied in the future. Here we describe a four-generation family with a genetically distinct form of SCA and a
phenotype characterized by mild cerebellar ataxia, cognitive impairment, poor performance on the WCST,
myoclonus, and a postural irregular tremor of slow frequency. Moreover, molecular analysis allowed classi-
fication of the disease in this family as a new type of SCA.
Patients and methods
Patients
The index patient (Fig. 1,V-31), a 56-year-old man of Dutch descent, presented with complaints of speech
disturbance, walking difficulty and head tremor. The symptoms had started approximately at the age of 31
years, with the head tremor. There was no medical history of note. He had been unemployed for 10 years
as a result of his poor coordination. The findings of the general physical examination were unremarkable.
Upon neurological examination he showed a postural irregular tremor of slow frequency of his head, neck,
and upper extremities that increased with changes in posture or standing in an upright position. Eye move-
ments were intact in all directions, but there were fine saccadic movements and a first-grade nystagmus.
Sensory examination showed impaired joint position and reduced vibration sense in both feet.
Coordination was severely disturbed in all limbs, showing dysmetria and dysdiadochokinesis. His gait was
ataxic. Case 2 was the mother of the index patient (IV-11), who had experience speech disturbance, jerky
movements and poor coordination since the age of 45 years. On examination there was an evident cere-
bellar syndrome and some cognitive inconsistencies (Table 4.1). There were also intermittent, irregular brief
muscle jerks in the neck. Twenty years previously electroencephalography (EEG) had shown paroxysmal
rhythmic theta activity over the temporal and parietal lobes followed by intermittent brief muscle jerks in
the neck. Case 3 was the eldest son of the index patient (VI-31), who had had mild dysarthria, fine sac-
cadic eye movements and an intention tremor with hypermetric movements upon heel-shin test since
the age of 10 years. He also had severe learning difficulty, because of which he had attended a special
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school. His brother (VI-32) did not show any ataxic features or learning difficulty. After identification of the
index patient, his mother and his children, additional members of the family were invited to participate in
the study. After they gave their informed consent, they were examined. Some information on patient III-8
was available because he and his eldest daughter IV-4 had attended a university clinic 40 years previously.
The only information on patient IV-5, obtained by history from members of the family, was that he had
suffered severe coordination problems and learning difficulty and had died at the age of 51 years. Patients
IV-4, IV-9, IV-11, V-24, V-28, V-31 and V-34 had been investigated several times over a period of 20 years,
which allowed us to assess the progression of the disorder. We used the international ataxia cooperative
rating scale to quantify the severity of cerebellar symptoms (Trouillas et al. 1997). This scale involves a com-
partmentalized quantification of postural and stance disorders, limb ataxia, dysarthria and oculomotor
abnormalities. Sub-scores for these symptoms can be studied separately. The total ataxia score ranges from
0 (no ataxic features) to 100 (complete cerebellar syndrome).
Neuropsychological methodology
Two patients of the fourth generation (IV-4 and IV-11), and three of the fifth generation (V-1, V-28, V-34)
underwent neuropsychological testing. Global cognitive functions were assessed by the Mini Mental State
Examination (MMSE). Premorbid IQ was estimated on the basis of socio-economic background and edu-
cation (Luteyn 1983). Verbal and non-verbal intelligence was assessed with the Wechsler Adult Intelligence
Scale-Revised (WAIS-R) and Raven Standard Progressive Matrices (RSPM) (Wechsler 1974; Raven 1960).
Memory performance was tested with the WAIS digit span for immediate memory, with the 15-Words Test
(a Dutch version of the Ray Auditory Verbal Learning Test) for immediate recall, delayed recall and recog-
nition in the auditory domain, and with the Recognition Memory Test for Faces for memory in the visual
domain (Heslinga et al. 1983; Warrington 1984). The tests for measuring executive function were the WCST
and the Bobertag (Grant and Berg 1948) Cortical language functions were assessed with the SAN test
(Deelman BG et al. 1983) Depression was rated with the Beck Depression Inventory (BDI) and the Zung
Depression Scale (Beck et al. 1961; Zung 1965).
Electrophysiological studies
Nerve conduction studies were performed using the antidromic technique with surface electrodes for sen-
sory and motor nerve testing. Concentric needle electrodes were used for electromyography. In this way the
peroneal, sural, and median and/or ulnar nerves were investigated in six patients, with the H-reflex of the
tibial nerve in five. Transcranial magnetic stimulation (TMS) was performed with a Cadwell MES 10 stimu-
lator with a maximum magnetic field of 2T. Central conduction times were investigated in six patients with
magnetic stimulation of the motor cortex and cervical spine. Motor evoked potentials were recorded with
surface electrodes taped over the belly and tendon of the biceps and abductor digiti V muscles.
Cerebral magnetic resonance imaging
Seven patients were examined using 1.5-T magnetic resonance imaging (MRI). T1-weighted axial images
(repetition time 550ms, echo time 20ms) and T2-weighted axial images (repetition time 4000ms, echo time
100ms) were recorded. Atrophy was qualitatively graded on a four-point scale (0=no atrophy, 1=mild,
2=moderate, 3=severe) by two experienced neuroradiologists who reported by consensus.
Molecular analysis
DNA was isolated from blood of 17 family members. Two of these samples were analyzed for CAG trinucleo-
tide repeat expansions in the SCA1, 2, 3, 6, 7 and 12 genes and the CTG trinucleotide repeat expansion,
associated with SCA8, by polymerase chain reaction amplification and polyacrylamide gel electrophoresis.
Furthermore, to exclude linkage to SCA4, 5 and 10 loci we performed linkage analysis with markers specific for
these loci, i. e. D16S3396 for the SCA4 locus, D11S1911, D11S1993 and D11S1978 for the SCA5 locus D22S274,
D22S928 for the SCA10 locus and D15S659 for the SCA11 locus. LOD scores for the markers are shown in
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Table 4.2 (selected from the Marshfield database; http://www.marshmed.org/genetics/ Map_Markers).
Table 4.2 LOD scores for various markers
Locus Marker θ=0 θ=0.1 θ=0.2 θ=0.3 θ=0.4 θ=0.5
SCA4 D16S3396 -7.23 -0.82 -0.32 -0.10 -0.02 0
SCA5 <?2> D11S1911 -5.20 -0.86 -0.37 -0.14 -0.03 0
D11S1993 -8.32 -1.56 -0.70 -0.27 -0.06 0
D11S1978 -3.35 0.60 0.59 0.34 0.10 0
SCA6 D19S1150 -7.27 -1.65 -0.83 -0.39 0.13 0
SCA10 <?1> D22S274 -5.40 -0.34 -0.05 0.03 0.02 0
D22S928 -10.41 -1.06 -0.31 -0.03 0.04 0
SCA11 D15S659 -5.98 -0.39 0.02 0.12 0.08 0
Results
Clinical findings
Of the 12 affected members of the family 10 were available for neurological examination (Table 4.1). The
mean age at onset in the fourth generation was 40 years (IV; n=3), in the fifth generation it was 30 years
(V; n=5). In the sixth generation, patient VI-31 showed mild dysarthria, jerkiness of smooth pursuit eye
movements and intention tremor before the age of 10 years. In contrast, patient VI-28 only showed ocular
dysmetria at the age of 28. Cerebellar dysarthria was an early feature in all individuals. Patients V-24 and V-
31 both presented with a postural and irregular tremor of slow frequency, which was consistent with Holmes
tremor (Deuschl et al. 1998). Patient V-24 also had a segmental myoclonus (frequency 3 Hz) of the abdo-
minal muscles, which in the absence of additional extrapyramidal symptoms and normal EEG findings
(registered concurrently with electromyography at the time of the muscle jerks), was suggestive of spinal
myoclonus. The irregular brief muscle jerks in patient IV-11 preceded by paroxysmal theta activity over the
temporal and parietal lobes on EEG were considered indicative of cortical myoclonus. Walking difficulty
with frequent falling was also an early symptom. Ataxia of the upper extremities was a relatively late symp-
tom. All subjects showed fine saccadic eye movements, and in all but one a first-grade horizontal nystag-
mus was present. Only one patient complained of cognitive impairment (V-34).
Electrophysiological studies
Nerve conduction studies showed normal velocities in four patients but slightly decreased velocities in two
(IV-4 and V-1). These two patients also had increased H-M intervals (35ms). Electromyography recorded
fibrillation potentials in the leg muscles of patient IV-4. These findings were consistent with a mild axonal
neuropathy. TMS showed slightly increased central conduction times in four patients (IV-11, V-1, V-28, V-31)
with values of 9.1, 9.5, 9.6 and 10.2ms (normal values 7-8.5ms).
Neuropsychological test
Table 4.3 summarizes the test performance of the individuals investigated. Three patients showed eviden-
ce of severe or moderate depression and their estimated premorbid IQ was below 105 (education not com-
pleted). Despite this, the MMSE score was above the usual cut-off value of 24 in all five patients examined.
Four of these five patients had scores at least 2 SD below the norm on the WCST and one a score more
than 1SD below the norm.
Magnetic resonance imaging
Table 4.4 summarizes the results of the MRI studies. In six subjects there was mild to severe atrophy of the
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cerebellar hemispheres, with moderate or mild atrophy of the vermis in four of them. In two patients there
was mild cerebral atrophy.
Molecular analysis
Analysis of the CAG trinucleotide repeats in the SCA1, 2, 3, 6, 7 and 12 genes and the CTG trinucleotide repe-
at at the SCA8 locus did not reveal any abnormalities. Further linkage analysis also excluded the SCA4, 5
and 10 loci as candidate loci involved in the disease pathogenesis in this family. Since point mutations have
been reported in the SCA6 gene in families with ataxia (Ducros et al. 1999; Yue et al. 1997), linkage to the
SCA6 locus was formally excluded by using the CAG trinucleotide repeat as a polymorphic marker.
Table 4.3 Neuropsychological tests in 5 patients.
IV-4 IV-11 V-1 V-28 V-34
Age (years)a 87 80 55 57 51
Duration 57 35 10 30 26
MMSE 25/30 26/30 27/30 26/30 26/30
Estimated premorbid IQ < 105 < 105 < 105 < 105 < 105
Intelligence
Verbal IQ (WAIS) n.d. n.d. 103 83 80
Non-verbal (Raven SPM/CPM) 12/36 24/36 48/60 25/60 35/60
Memory
Memory (MQ) 89 100 101 73 84
WMS Digit span
(forward/backward) 4/2 5/4 5/3 4/2 4/3
15-Words/8-Words test (8 if > 70)
Learning curve 2-4-2-3-4 3-4-5-6-5 2-4-6-5-7 3-5-4-6-4 2-2-5-5-5
Delayed recall 0/8 3/8 4/15 2/15 3/15
Recognition 13/16 14/16 28/30 21/30 21/30
Visual (RMT faces) n.d. n.d. 38 38 39
‘Executive functioning’
Bobertag n.d. A A N N
WCST
Categories F 0 4 2 2
Correct F 16 73 52 30
Perseverative errors F 68 29 80 95
PE/TE 100 % F 98.5 22.7 62.5 74.2
Visual-spatial perception
Hooper VOT (impairment) Severe Moderate Mild Moderate Mild
Visual-spatial construction
WAIS-R (Block design) n.d. n.d. 6 5 7
Verbal fluency (SAN) n.d. 48 18 48 48
Mood
Zung (degree of depression) n.d. n.d. N Severe Severe
BDI (degree of depression) Moderate n.d. Mild Severe Moderate
a Age at 1 January 1999; Scores are raw scores, when not indicated otherwise; MMSE, Mini Mental State Examination;
WAIS, Wechsler Adult Intelligence Scale; Raven SPM, Raven standard progressive matrices; Raven CPM, colored pro-
gressive matrices; WMS, Wechsler Memory Scale; RMT faces, Recognition Memory Test for Faces; WCST, Wisconsin
Card Sorting Test; P/TE 100%, percentage of errors that are perseverative; SAN, cortical language test; BDI, Beck
Depression Inventory; N, normal performance; A, abnormal performance; n.d., no reliable data available.
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Table 4.4 MRI imaging features in 7 patients.
IV-11 V-1 V-28 V-31 V-34 VI-28 VI-31
Age (years)a 80 55 57 56 51 28 11
Duration (years) 45 45 27 31 27 n.d. n.d.
Atrophy
Cerebellar +++ + + + + + -
hemispheres
Vermis ++ - - + + + -
Medulla - - - - - - -
Pons - - - - - - -
Cerebrum + - - - - + -
White matter + - - - - - -
lesions
a Age at 1 January 1999. 
- = no atrophy; + = mild atrophy; (++) moderate atrophy; (+++) severe atrophy; n.d., no reliable data available.
Discussion
In 1983 Harding proposed a useful clinical classification for ‘late onset’ ADCA by division of the ADCAs into
type I (ophthalmoplegia, optic atrophy, dementia and pyramidal/extrapyramidal features), type II (pigmen-
tary retinopathy) and type III (‘pure’ cerebellar ataxia) (Harding 1983). Since 1993, ADCAs have been incre-
asingly characterized in terms of their genetic locus and are referred to as SCA. The mutations for SCA1, 2,
3, 6, 7 and 12 have been characterized as expansions of CAG trinucleotide repeats in the coding region of
the respective genes. The mutations for SCA4, 5, 11, 13 and 16, which have been linked to chromosomes 16,
11, 19 and 8, respectively, are yet to be isolated, but the underlying gene defects remain to be identified. The
relevance of the CTG trinucleotide repeat expansion, associated with SCA8, is not clear (Stevanin et al.
2000; Worth et al. 2000). In some families with ADCA, including the one reported here, there is no linka-
ge to any of these loci. For these families Harding’s classification could still be relevant. Given the eviden-
ce for cognitive impairment, pyramidal tract involvement, (Holmes) tremor, and peripheral neuropathy,
members of this family would fall into the category of ADCA I. Since our family showed rather poor results
on most neuropsychological tests and estimated premorbid IQ was below 105 in three of the five examin-
ed patients, careful follow-up should confirm whether the cognitive impairment is progressive.
Nevertheless, the poor performance on the WCST was striking. Poor performance on the WCST, suggesting
disturbance of abstract reasoning and the ability to shift cognitive sets to changing contingencies, is asso-
ciated with damage to the dorsolateral prefrontal cortex or its connection to (sub)cortical structures
(Nagahama et al. 1996). Poor performance on the WCST has been described in SCA1 and particularly SCA2
families (Kish et al. 1994; Burk et al. 1999; Gambardella et al. 1998; Storey et al. 1999). Similar cognitive
defects have also been described in SCA3 (Maruff et al. 1996). In families with SCA4, 5, 6, 10, 11 and 12 no
detailed neuropsychological studies have been performed (addendum 2004: for review see Schelhaas et al.
2003). One patient clinically presented with a spinal myoclonus and one patient with a cortical myoclonus.
Unfortunately, it was not possible in either patient to reanalyze the myoclonus according to modern stan-
dards. For this, and as myoclonus has been described in SCA1, 2, 3, 7, 14 and even SCA6 families (Pareyson
et al. 1999; Jobsis et al. 1997; Schols et al. 1997b; Watanabe et al. 1998a), we feel that the significance with
regard to myoclonus as being characteristic of this family, is limited. Although there were too few affected
individuals to be able to draw firm conclusions about anticipation, the available data on age at onset and the
severity of additional features raise the possibility of anticipation. Such a phenomenon may be explained
molecularly by expansion of unstable trinucleotide repeats during vertical transmission. Currently we are per-
forming a genome-wide scan to determine the chromosomal localization of the disease gene in this family. 
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Figure 4.1 Pedigree
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Identification of a novel SCA locus (SCA19) in 
a Dutch autosomal dominant cerebellar ataxia family 
on chromosome region 1p21-q21
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Abstract
We present a linkage study in a four-generation autosomal dominant cerebellar ataxia (ADCA) family of
Dutch ancestry. The family shows a clinically and genetically distinct form of ADCA. This neurodegenerative
disorder manifests in the family as a relatively mild ataxia syndrome with some additional characteristic
symptoms. We have identified a SCA19 locus, approved by the Human Genome Nomenclature Committee
that can be assigned to the chromosome region 1p21-q21. Our mutation analysis failed to identify any muta-
tions in the known spinocerebellar ataxia (SCA) genes and linkage analysis excluded the remaining SCA
loci. We therefore performed a genome-wide scan with 350 microsatellite markers to identify the location of
the disease-causing gene in this family. Multi-point analysis was performed and exclusion maps were gene-
rated. Linkage and haplotype analysis revealed linkage to an interval located on chromosome 1. The esti-
mated minimal prevalence of ADCA in the Netherlands is about 3:100,000. To date, sixteen different SCA
loci have been identified in ADCA (SCA1-8 and SCA10-17). However, mutation analysis has been commer-
cially available only for the SCA1, 2, 3, 6 and 7 genes. So far, a molecular analysis in these SCA genes can-
not be made in about one-third of the ADCA families. Thus, the identification of this new, additional SCA19
locus will contribute to expanding the DNA diagnostic possibilities. 
Introduction
ADCA is one of the most frequently occurring subgroups of hereditary progressive neurodegenerative
disorders. This serious and invalidating disorder is caused by a progressive neurodegeneration of the cere-
bellum, brain stem and spinal cord leading to a balance disturbance and loss of neurological functions. In
addition to ataxia, various other symptoms such as tremor, epilepsy, retinal degeneration and mental retar-
dation are seen. In general, the symptoms usually begin around the age of 40 years.
So far, a series of genes has been identified. Characterization of the first five spinocerebellar ataxia (SCA)
genes, SCA1, 2, 3, 6, 7 (Orr et al. 1993; Pulst et al. 1996; Kawaguchi et al. 1994; Zhuchenko et al. 1997; David
et al. 1997), and the more recently identified SCA17 gene (Koide et al. 1999; Nakamura et al. 2001), seem
to point to a common underlying molecular defect, namely the involvement of a CAG repeat expansion in
the coding region of the gene. However, these six genes do not show any homology in either structure or
function, and the only common feature is the CAG repeat expansion. The CAG repeat expansions are trans-
lated into polyglutamine tracts leading to a so-called ‘polyglutamine’ disease (Paulson et al. 1997a). The ini-
tial CAG repeat number and the composition of the repeat (perfect or interrupted) seem to be related to the
expanded CAG repeat numbers (Pearson et al. 1998). The repeat numbers of the expansion are generally asso-
ciated with the severity of the disease and the age at onset, often reported as intra-familiar anticipation.
Based on testing of the SCA1, 2, 3, 6 and 7 genes in all available Dutch ADCA families, we can conclude that
mutations in these genes account for about 70% of the Dutch ADCA families. For the Netherlands, this
indicates a minimal prevalence of the disorder of about 3:100,000, with the mutation in the SCA3 gene
being found most frequently (44.1%), and followed by the SCA6 gene (23.4%) (van de Warrenburg et al.
2002).
The idea that the only causative component in the pathogenesis of ADCA is expanded polyglutamine tracts
becomes more unlikely (Richards 2001). The analyses of SCA8, 10 and 12 genes, point to significant diffe-
rences from the ‘polyglutamine’ hypothesis (Holmes et al. 1999; Koob et al. 1999; Matsuura et al. 2000; Zu
et al. 1999). First, although the clinical characteristics between the different SCA genes show some overlap,
there are a variety of additional neurological symptoms (Schols et al. 1997b), including tremor and mental
retardation. Secondly, the mutations in these genes are also repeat expansions, but are non-coding CAG,
CTG, and ATTCT repeats instead of coding CAG repeats (Holmes et al. 1999; Koob et al. 1999; Matsuura
et al. 2000). How these non-coding repeat expansions contribute to the pathology of ADCA is not known.
Thirdly, these mutations seem to be rare and have been described in only one or a few families. Some muta-
tions seemed to be confined to specific populations (Fujigasaki et al. 2000; Fujigasaki et al. 2001a) and new
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SCA genes still have to be identified to account for the remaining 30% of the Dutch ADCA families in which
no mutation has been identified so far.
Here, we present a linkage analysis in a large Dutch ADCA family, in which no repeat expansion could be
detected in the SCA1, 2, 3, 6, 7, 8, 12 and 17 genes. The remaining SCA loci (SCA4, 5, 10, 11, 13-14 and 16), for
which mutations still have to be identified (Flanigan et al. 1996; Herman-Bert et al. 2000; Matsuura et al.
1999; Miyoshi et al. 2001; Ranum et al. 1994; Worth et al. 1999; Zu et al. 1999), were excluded by 2-point
linkage analysis (Schelhaas et al. 2001). We localized the disease gene involved in this family by performing
a genome-wide screen. Significant evidence for linkage was found on chromosome region 1p21-1q21. The
discovery of this novel locus, SCA19, adds to the extensive genetic heterogeneity exhibited by the ADCA
phenotype.
Materials and methods
The patients
The family used in this study was described by Schelhaas et al (Schelhaas et al. 2001). Briefly, clinical
investigation showed a relatively mild ataxic syndrome with some additional characteristic symptoms,
including cognitive impairment, bad performance in the Wisconsin Card Sorting Test, myoclonus and
postural irregular tremor of low frequency. Harding’s classification characterizes the phenotype in this family
as ADCA type I (Harding 1983). There were too few affected individuals in this family to draw firm conclu-
sions about anticipation. Although, a decrease in age at onset is seen, this is not accompanied by an increase
in severity of the disorder (Schelhaas et al. 2001). Sixteen family members were included in the clinical
investigation and 11 were diagnosed as affected. There were no asymptomatic obligate carriers. There was
also no indication for sex-limited transmission since both male-to-male and male-to-female transmissions
were observed.
Mutation analysis of known SCA genes 
High molecular weight genomic DNA was extracted from peripheral blood leukocytes using a routine sal-
ting-out method. Diagnostic analysis failed to identify any mutation in one of the known SCA genes (SCA1-
3, 6-8, 12 and 17) (data not shown). Subsequently, linkage analysis with specific markers excluded the remai-
ning known SCA loci (SCA4, 5, 10, 11, 13, 14 and 16) (Schelhaas et al. 2001). Since point mutations have been
described in the SCA6 gene (Yue et al. 1997), this locus was also excluded by linkage analysis using the
intragenic marker D19S1150. The markers used in this linkage study were selected from the Marshfield data-
base: http://www.marshmed.org/genetics_Markers. 
Genome-wide genotyping analysis
In an attempt to localize the disease-causing gene, a genome-wide genotyping analysis was performed after
excluding all the known SCA genes and loci. The linkage mapping set consisted of 350 microsatellite markers,
covering all autosomes, with an average spacing of 10-15 cM. Additional markers were selected to narrow down
possible candidate regions. All markers were 5 end-labeled with fluorescent-dyes: 6-FAM, TET or HEX. 
PCR reactions were performed in a total volume of 10 µl, containing 25 ng of genomic DNA, 1 µl PCR buf-
fer II (Applied Biosystems, Foster City, Calif., USA), 25 mM MgCl2, 2 mM dNTPs, 12.5 ng of each marker
and 0.4 U of AmpliTaq Gold (Applied Biosystems). The PCR reaction started with a 10 min denaturation
step at 94°C, followed by 33 cycles of 30 s denaturation (94°C), 30 s annealing (55°C) and 30 s extension
(72°C), ending with a final extension step of 30 min at 72°C. The PCR was carried out on a GeneAmp PCR
system 9600 or 9700 machine (Applied Biosystems). The PCR product (0.9 µl) was mixed with 1.6 µl loa-
ding buffer containing formamide, blue dextran, and GS500XL, the internal lane standard (Applied
Biosystems) and analyzed on a 6% polyacrylamide gel (Longranger Single Packs, BioWhittaker Molecular
Applications, Rockland, Me., USA) in an ABI 377 sequencer (Applied Biosystems). Fragment analysis was
performed using Genescan (v 3.1) and Genotyper (v 2.1) software. 
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Linkage and haplotype analysis
In the initial screen, two-point lod scores were calculated for each microsatellite marker using MLINK of
the FASTLINK (v 5.2) software package, assuming autosomal dominant inheritance, a disease frequency of
1:100,000, and 95% penetrance (Lathrop and Lalouel 1984). In the linkage analysis, equal allele frequencies
were used for all markers. All affected individuals (n=11) and the five unaffected individuals older than 50
years were included in the initial linkage analysis. Two-point lod scores of 1.0 and higher were considered
to indicate regions of interest. These candidate regions were tested by additional markers and haplotype
analysis for further fine mapping. Finally, a multipoint analysis was performed for all autosomes using
Genehunter v 2.0 (Kruglyak et al. 1996).
Results
Linkage analysis
Five potential candidate regions, with two-point lod scores of 1.0 or higher, were obtained after testing the
whole linkage screening set, involving loci on chromosomes 1, 7, 9, 10 and 12. Significant linkage of the
disease (lod score >3.0) was found only with the microsatellite marker D1S534 with a maximal two-point
lod score (Zmax) of 3.82 at a recombination fraction of 0.00 (Table 5.1). In addition, a multipoint analysis
was performed for each autosome. Figure 5.1 shows the multi-point analysis for chromosome 1. The other
possible candidate regions located on chromosomes 7, 9, 10 and 12 were excluded by both multipoint and
haplotype analysis (data not shown). 
Haplotype analysis of chromosome 1
Flanking markers of D1S534 were tested and although high positive lod scores were obtained, none exceeded
the Zmax of 3.82 (Table 5.1). The chromosome 1 candidate interval is defined by two recombination events
in one affected person (III: 10) (Fig. 5.2). These two recombination events, proximal at D1S1588 and distal
at marker D1S1595, occurred on opposite sides of the centromere. The marker order in this interval, based
on the Marshfield database (October 2001), is: D1S1588 - 0 cM - D1S435 - 3.86 cM - GATA124C08 - 1.97 cM
- GATA45B07 - 5.54 cM - D1S1631 - 12.32 cM - D1S1675 - 2.68 cM - D1S534 - 1.71 cM - D1S2696 - 1.15 cM -
D1S442 - 6.31 cM - D1S1595. All the affected individuals share the same haplotype for the candidate interval
flanked by D1S1588 and D1S1595, whereas none of the unaffected individuals showed this haplotype. The size
of the interval, which harbors the disease gene in this family, is approximately 35 cM (Fig. 5.2).
Table 5.1 Two-point lodscores between the disease locus and 13 chromosome 1 markers.
Lodscore at recombination rate (theta)
Markers 0.00 0.10 0.20 0.30 0.40 Zmax theta =
D1S551 -0.29 -0.10 0.07 0.09 0.04 0.09 0.28
D1S435 -6.04 -0.38 -0.01 0.11 0.11 0.13 0.35
D1S1588 -3.91 0.17 0.28 0.26 0.15 0.29 0.22
GATA124C08 2.34 1.89 1.39 0.84 0.31 2.34 0.00
GATA45B07 3.02 2.46 1.83 1.14 0.41 3.02 0.00
D1S1631 2.10 1.68 1.23 0.73 0.23 2.10 0.00
D1S1675 1.94 1.60 1.22 0.79 0.31 1.94 0.00
D1S534 3.83 3.15 2.40 1.55 0.63 3.83 0.00
D1S2696 3.23 2.94 1.99 1.26 0.49 3.23 0.00
D1S442 1.46 1.19 0.89 0.56 0.22 1.46 0.00
D1S1595 -3.43 1.16 1.02 0.67 0.24 1.16 0.11
D1S1679 0.60 0.69 0.54 0.32 0.10 0.71 0.06
D1S1677 -4.78 0.27 0.34 0.28 0.16 0.34 0.19
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Discussion
We performed a genome-wide screen in a four-generation Dutch ADCA family. The disease in this family
manifests as a relatively mild ataxia syndrome with some additional characteristic symptoms (Schelhaas et
al. 2001). Given the presence of the main clinical characteristics, including pyramidal signs, peripheral
neuropathy and cognitive impairment, the phenotype in this family is classified as ADCA type I (Harding
1983). Our marker analysis reveals significant linkage with marker D1S534 with a maximal two-point lod
score (Zmax) of 3.82 at recombination fraction 0.00. The candidate interval is defined at the proximal boun-
dary by marker D1S1588 and at the distal end by marker D1S1595. Multi-point and haplotype analysis of the
chromosome 1 markers revealed a candidate interval of approximately 35 cM. This SCA19 locus, approved
by the Human Genome Nomenclature Committee, can be assigned to the chromosome region 1p21-q21.
We used a haplotype sharing approach in an attempt to further narrow down the disease gene location of
the SCA19 locus, and we are currently searching for additional ADCA families exhibiting linkage with the
same region. However, at this moment, we only have two additional large Dutch ADCA families available
for linkage studies. In these families no linkage could be detected (data not shown), indicating the presen-
ce of at least one other SCA locus in the Dutch population. In addition, we are searching for possible can-
didate genes within the candidate interval, by first focusing on CAG repeat-containing genes. Mutation ana-
lysis has now (addendum 2003) excluded the CAG containing genes KCNN3, TNRC4 and KIAA0467 (data
not shown). Secondly, genes encoding ion channels may be of particular interest, because of the presence
of myoclonus and tremor in this family. Other genetic disorders exhibiting myoclonus and tremor also carry
mutations in ion channels, including epilepsy (Escayg et al. 2000), episodic ataxia 2 (EA2) and SCA6
(Jodice et al. 1997). The SCA6 gene, encoding the α1A-subunit of a voltage-dependent calcium channel,
CACNA1A, was originally identified as being involved in familial hemiplegic migraine (FHM) (Ophoff et al.
1994). Interestingly, distinct types of CACNA1A mutations have been identified in FHM and SCA6 (Denier
et al. 1999). A second familial hemiplegic migraine locus has been localized to chromosome 1q21-q23
(Ducros et al. 1997). In parallel with the CACNA1A gene, candidate genes for FHM located on the long arm
of chromosome 1 are also direct candidate genes for SCA19, although no migraine has been recorded in
the affected individuals of the current family. Such candidates include the KCNN3, KCNC4, KCNJ10, KCNA2
and KCNA3 genes but now (addendum 2003) these genes have also been excluded (data not shown).
Following identification of SCA7, four novel SCA genes were defined (SCA8, 10, 12 and 17). Approximately
200 individual Dutch ataxia patients have been tested but revealed no mutations (data not shown) in the
SCA10, 12 or 17 genes. An exception was the SCA8 gene in which a repeat expansion was detected in seve-
ral cases (data not shown). However, non-pathogenic polymorphisms in the SCA8 gene have also been
detected in normal controls, and secondly, additional SCA8 expansions have been identified in patients car-
rying mutations in one of the other SCA loci (Sobrido et al. 2001). The relation between SCA8 mutations
and the etiology of ADCA must still be established. The frequency of these novel identified genes seems to
be so rare that none can be the main causative mutation for the other 30% of Dutch ADCA families.
However, our identification of the mutation involved in the SCA19 locus will improve the diagnostic possi-
bilities and genetic counseling of some of the remaining ADCA families, and it will provide further insight
into the controversy of whether expanded polyglutamine tracts are the main causation in the pathology of
the ADCAs. 
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Figure 5.1 Multipoint linkage analyses for 21 chromosome 1 markers, covering the entire chromosome. Marker
D1S1588 and marker D1S1595 flank the candidate interval.
Figure 5.2  Haplotype analyses for 13 chromosome 1 markers. The putative disease haplotype is boxed. Arrows
indicate the informative recombination events.
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We read with interest the paper by Ming-Yi Chung and colleagues (Chung et al. 2003). In this paper, the
authors characterized a four-generation Chinese pedigree with an autosomal dominant phenotype for cere-
bellar ataxia (ADCA). Their genome-wide linkage study suggested linkage to a locus on chromosome 1p21-
q23. The authors stated that the form of ADCA found in this family is distinct from other spinocerebellar
ataxias (SCA) and designated this SCA as spinocerebellar ataxia type 22 (SCA22). However, this locus was
previously assigned to SCA19 by the HUGO Gene Nomenclature Committee (http://www. gene.ucl.ac.uk/
cgi-bin/nomenclature). Both the clinical features of the affected Dutch ADCA family and the identification
of this locus have been extensively described (Schelhaas et al. 2001; Verbeek et al. 2002). The four-genera-
tion Dutch ADCA family has a relatively mild ataxia syndrome with slow progression and additional clinical
features, including cognitive impairment, pyramidal signs and peripheral neuropathy (ADCA type I).
Genome-wide screening revealed significant linkage with marker D1S534 (maximum lod score 3.82 with
theta = 0,00). The candidate interval spans ~35 cM and is located between the markers D1S1588 and
D1S1595. The SCA19 locus has been assigned to the chromosomal region 1p21-q21. 
Chung and colleagues report that the candidate SCA22 gene is located between the markers D1S206 and
D1S2878. There is significant overlap between the two regions: ~26.9 cM between the markers D1S206 and
D1S1595. Although it cannot be excluded that the genes lie in close approximation at this locus, it is more
likely that the Dutch and Chinese families suffer from a mutation in the same gene, and that SCA19 and
SCA22 represent an identical condition, which should be designated SCA19 as this was the first linkage
assigned. By first focusing on CAG repeat-containing genes, both research groups indicated that KCNN3,
TNRC4 and KIAA0467 were the most likely candidate genes. However, CAG expansions in these genes were
not found in affected individuals of the Chinese family, and therefore KCNN3, TNRC4 and KIAA0467 can be
excluded as candidate genes. Potassium channel genes (e.g. KCNJ10, potassium channel, inwardly rectify-
ing, subfamily J, member ten) are also mapped to this region and were mentioned as serious candidate
genes for both SCA19 and SCA22. These genes are of particular interest, because of the presence of myo-
clonus and tremor in the Dutch SCA19 family. 
Unfortunately, Dr Chung and colleagues must have overlooked this earlier assignment. Their excellent work
has narrowed the genetic region of interest and suggests that SCA19 is an SCA with worldwide occurrence.
The correct assignment of these two families will help clarify the evolving chaos in the genetic classification
of these disorders. 
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Part III
Expanding the phenotype of SCA3 and SCA6
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Abstract
The clinical phenomenon of a split hand, dominant muscle atrophy in the thenar as compared to the hypo-
thenar complex, has been used to support the theory of primary cortical degeneration in ALS. However, the
same phenomenon, both clinically and electrophysiologically, was observed in three diseases with a second
but not first motor neuron affection: autosomal dominant spinal muscular atrophy, spinocerebellar ataxia
type 3, and juvenile muscular atrophy. Therefore, we conclude that neurogenic loss according to a split hand
distribution points to a spinal instead of cortical origin.
Introduction
The term ‘split hand’, first coined by Willbourn et al. refers to a type of hand muscle atrophy in which the
muscles of the lateral aspect of the hand (first dorsal interosseus and thenar) are more affected than those
of the medial aspect (hypothenar) (Wilbourn 1994). Willbourn described the split hand in the context of
amyotrophic lateral sclerosis (ALS) and stated that, although not limited to ALS, this phenomenon seems
to be specific for anterior horn disease (Wilbourn 2000). However, as the thenar and hypothenar complex
have the same segmental supply and a different cortical presentation, others suggested that this pattern of
muscle wasting is of cortical origin (Weber et al. 2000). As such, the dissociation of hand muscle wasting
is considered to confirm the theory of cortical dysfunction with anterograde degeneration as the initial step
in the pathogenesis of ALS. We wondered whether the split hand is also observed in disorders that are
known to be characterized by lower motor neuron degeneration in the absence of cortical degeneration.
Therefore we performed nerve conduction studies in patients with autosomal dominant distal spinal mus-
cular atrophy (DSMA), spinocerebellar ataxia type 3 (SCA3), and juvenile muscular atrophy (JMA). 
Patients and methods
Patients
All five affected members of a three-generation family with DSMA, five consecutive SCA3 patients, and three
patients with JMA participated in the study. Each patient was subjected to a thorough neurological and elec-
trophysiological examination. 
Nerve conduction studies
Nerve conduction studies were recorded with a Medelec Synergy EMG system (Oxford Medical
Instruments). Skin temperature was maintained at 34°C and limbs were warmed if necessary. CMAPs of the
thenar and hypothenar complexes were evoked by supramaximal peripheral stimulation of the median and
ulnar nerves, respectively. One SCA3 subject (data not shown) with neurophysiological evidence of a carpal
tunnel syndrome was excluded.
Statistics
Analysis was done using binomial distribution statistics.
Results
The five members of the DSMA family showed a mild disease severity, slow progression, with lower limb
predominance. Dissociated hand muscle wasting was evident in four of five member of the DSMA family. 
The phenotype of the five SCA3 patients was characterized by a late onset (40-60 years), slow progression,
cerebellar ataxia, cramps, fasciculations, and muscle atrophy. A split hand pattern of muscle atrophy was
present in four of five patients with SCA3.
The clinical course of the three (male) JMA patients was characterized by an insidious onset, slow pro-
gression and, ultimately, stabilization of disease. Dominant muscle atrophy in the thenar as compared to
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the hypothenar complex was present in two patients with JMA. One JMA patient showed a reverse pattern
of muscle wasting, with sparing of the thenar and prominent involvement of the hypothenar muscles.
Intriguingly, this patient showed lower focal cervical cord atrophy on cervical MRI.
In four of five subjects with DSMA, in all SCA3 patients, and in two patients with JMA, the electrically
evoked hypothenar CMAP was larger than the thenar CMAP (Table 6.1). 
Concerning a total population of 13 patients, a binomial distribution and an ‘a prior probability’ of 0.5
(no significant difference in the thenar as compared to the hypothenar CMAP in normal controls), with 13
trials and two failures: p = 0.0111 (one-tailed sign test). 
Table 6.1 Clinical features and nerve conduction studies in 5 patients of a three-generation family with autosomal
dominant DSMA, in 5 patients with SCA3, and in 3 patients with JMA.
Thenar Hypothenar
Diagnosis Age Muscle CMAP Muscle CMAP
y/sex weakness weakness 
(MRC) (mV) † (MRC) (mV)‡
DSMA 82/f 2 0 5 11.4     
DSMA 59/f 4 7.8 5 12.6     
DSMA 56/m 4- 0.5 5 13.4     
DSMA 50/m 4+ 11.7 4 9.8       
DSMA 27/m 4 5 4 9         
SCA3* 61/f 4 5.0 4 8.5       
SCA3 62/f 4 6.1 5 11.7      
SCA3 66/f 4- 2.0 4 10.4      
SCA3 51/m 4 6.1 5 18.3      
SCA3 52/m 4 6.7 5 12.3      
JMA 34/m 4- 2.0 4 10.8      
JMA 38/m 4- 4.9 4 9.5       
JMA 29/m 5 15.7 4- 3.1       
* Clinically this patient showed generalized, not dissociated, small hand muscle atrophy.
† thenar CMAP reference value (mean, SD): 13.4 ± 3.4
‡ hypothenar CMAP reference value (mean, SD) 12.3 ± 1.9
CMAP, compound muscle action potential; DSMA, distal spinal muscular atrophy; SCA3, spinocerebellar ataxia
type 3; JMA, juvenile muscular atrophy of distal upper extremity; MRC, Medical Research Counsel examination.
Discussion
Our results support the theory that a dissociation of hand muscle atrophy, in which the thenar muscles are
more affected than the hypothenar muscles, is an important clinical feature that localizes the lesion to the
anterior horn. Greater thenar than hypothenar involvement is also seen in patients with T1 root involvement
and in patients with lower trunk plexus involvement. However, the indefinite onset with slow progression
over years in the absence of pain or sensory symptoms makes the possibility of additional radicular or
plexus involvement unlikely.
DSMA, SCA3, and JMA are clinically and genetically very different disorders. Still, distal muscle atrophy and
motor neuron degeneration is a common feature in all. Autosomal dominant DSMA is a rare, genetically
heterogeneous, lower motor neuron disorder that may be difficult to distinguish clinically from type II
Charcot-Marie-Tooth disease (De Angelis et al. 2002). SCA3 or Machado-Joseph disease (MJD) is an auto-
somal dominant cerebellar ataxia caused by CAG trinucleotide repeat expansions in the MJD/SCA3 gene
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(Kawaguchi et al. 1994). The phenotype of the five SCA3 patients studied here is compatible with a SCA3
subtype (subtype III) (Lopes-Cendes et al. 1996), in which late onset, slow progression, cramps, fascicula-
tions, and muscle atrophy are typical features and degeneration of anterior horn cells a common neuro-
pathological finding (Kinoshita et al. 1995). JMA is a focal amyotrophy with unilateral or asymmetrical bila-
teral wasting of C7 - Th1 innervated muscles (Hirayama et al. 1963). Whereas some studies suggest that
JMA is an intrinsic motor neuron disease (Schroder et al. 1999), others favor the view that the disorder
result from mechanical distortion of the cervical spinal cord due to neck flexion during growth (Hirayama
and Tokumaru 2000). 
Since the pathophysiological mechanisms of DSMA, SCA3, and JMA are presumably very different, the
observation of a ‘split hand’ in these diseases weakens the theory of the cortical origin of degeneration in
ALS and supports the theory of an intrinsic vulnerability of spinal motor neurons subserving the thenar
complex. 
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Abstract
We previously identified the inflammatory mediators IL-1ß, IL-1ra, IL-6 and the transcription factors IRF-1
and C/EBPdelta in a cell model of spinocerebellar ataxia type 3 (SCA3) by gene expression profiling. Here,
we analyzed the expression of the respective proteins in the central nervous system of SCA3 patients in rela-
tion to neuronal cell loss and ataxin-3 positive macroscopic neuronal intranuclear inclusions (NII) using
light- and electron microscopy immunohistochemistry. NII were found almost exclusively in brain regions
that also showed neuronal cell loss, i.e. in pons and dentate nucleus neurons, rarely in putamen and tha-
lamus, but not in cerebral or cerebellar cortex. NII were more readily labeled with C-terminal than with N-
terminal antibodies, suggesting that C-terminal ataxin-3 fragments are the major components of NII.
Quantitative analysis of NII in the pons showed that more severe neuronal cell loss was accompanied by
reduced frequencies of NII. Only a higher probability of NII bearing pontine neurons to degenerate can
account for this phenomenon that renders a protective role for NII in SCA3 unlikely.
The expression of IL-1ß, IL-1ra, IL-6 and C/EBPdelta was altered only in pons and dentate nucleus neurons,
but was not restricted to neurons with NII, suggesting that although NII and transcriptional changes coin-
cide, macroscopic NII are not a prerequisite for transcriptional changes. No generalized upregulation of
cytokines or microglia reaction was observed in SCA3 brains, ruling out the possibility that enhanced cyto-
kine expression was an early and generalized event mediating neuronal dysfunction in SCA3. 
Introduction
Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease is the most common dominantly inheri-
ted ataxia. Clinically, SCA3 is characterized by progressive ataxia in combination with various non-cerebel-
lar symptoms including oculomotor abnormalities, spasticity, basal ganglia symptoms, peripheral neuro-
pathy and cognitive impairment (Burk et al. 1996; Durr et al. 1996). The SCA3 gene encodes ataxin-3, a pro-
tein of yet unknown functions (Albrecht et al. 2003; Scheel et al. 2003). Although ataxin-3 is ubiquitously
expressed, neuronal death preferentially occurs in distinct brain regions including the pontine nuclei and
the dentate nucleus (Paulson et al. 1997a; Schmidt et al. 1998). Like Huntington’s disease (HD), dentato-
rubropallidoluysian atrophy (DRPLA), spinobulbar muscular atrophy (SBMA) and other spinocerebellar
ataxias, SCA3 is caused by a translated unstable CAG trinucleotide repeat expansion, resulting in a poly-
glutamine expansion in the respective proteins (Cummings and Zoghbi 2000). The expansion of the poly-
glutamine stretch leads to conformational changes of the protein with subsequent oligomerisation and for-
mation of amyloid-like fibrils (Paulson et al. 1997b; Scherzinger et al. 1997). In SCA3 and many other poly-
glutamine disorders, neuronal intranuclear inclusions (NII) containing aggregated mutated polyglutamine,
ubiquitin and various other proteins have been found (Paulson et al. 1997b; Cummings et al. 1999). While
initially NII were believed to be a prerequisite of neurodegeneration in all polyglutamine disorders, recent
data suggest a more complex picture. In HD, NII were more frequent in the cortex than in the striatum,
although the striatum is the most severely affected brain region in HD (Gutekunst et al. 1999). Similarly in
SCA1 and SCA2, NII were absent from Purkinje cells despite prominent involvement of Purkinje cells in
these disorder (Koyano et al. 2002). Also, in a number of experimental studies in cellular and animal
models of HD, SCA1 and SCA3, a dissociation of polyglutamine toxicity from macroscopic aggregate for-
mation was found (Saudou et al. 1998; Cummings et al. 1999; Warrick et al. 1999). Thus although increa-
sed propensity to form aggregates represents a common feature of all polyglutamine disease proteins, the
role of NII is far from clear. A systematic study of the distribution of NII in relation to neuronal cell death
in SCA3 brains has not yet been performed.
In addition to a toxic gain of function, specific protein-protein interactions and possible impaired physio-
logical functions of the respective proteins appear to contribute to the pathogenesis of most polygluta-
mine disorders (Yue et al. 2001; Zuccato et al. 2003). In SCA3, sequestration of ataxin-3 and loss of the
physiological function as a potential transcriptional co-repressor may cause transcriptional dysregulation
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involving both up- and down regulation of a variety of genes (Li et al. 2002). We recently found increased
expression of the inflammatory cytokines IL-1ß, IL-1ra, IL-6 and the transcription factors IRF-1 and
C/EBPdelta together with several other genes involved in extracellular matrix remodeling and transcriptio-
nal regulation in a cell model of SCA3 (Evert et al. 2001; Evert et al. 2003). Irregular expression of these
genes could constitute an early event in the disease process and might contribute to neurological deficits
prior to actual cell death (Li et al. 2002; Luthi-Carter et al. 2000; Tait et al. 1998). Alternatively, transcrip-
tional dysregulation might be restricted to neurons committed to death. To clarify the functional signifi-
cance of these findings, we examined the expression of IL-1ß, IL-1ra, IL-6, IRF-1 and C/EBPdelta in relation
to cell loss, microglia infiltration and the occurrence of NII in SCA3. For our study we selected a number of
brain regions including pons, dentate nucleus and pallidum that are known to be severely involved in the
disease process and compared these regions with others such as the cerebellar cortex and the cerebral cor-
tex which are believed to be neuropathologically spared in SCA3. 
Materials and methods
SCA3 tissues were derived from five patients from unrelated families with genetically confirmed diagnosis
(m:f = 4:1, age 54±9 years, disease duration 19±5 years, p.m. delay 15±3 hours); CAG repeat lengths in SCA3
patients were very similar, ranging from 70 to 75 (Tab. 7.1). Six individuals without a history of neurological
or inflammatory disease served as control (m:f = 4:2; age 68±8 years, p.m. delay 31±14 hours). All brains
were sampled at autopsy by one of us (RdV). Tissue samples of the same patients had been thoroughly stu-
died previously (Rüb et al. 2002). For the present experiments, serial 6 µm sections were cut from forma-
lin fixed tissue blocks of cervical and thoracic spinal cord, upper pons, oculomotor nucleus, substantia
nigra, putamen, thalamus (ventral anterior, ventral posterolateral, parafascicular and mediodorsal nuclei),
cerebellar cortex, dentate nucleus, frontal, occipital and insular cortex. Regularly spaced consecutive secti-
ons were analyzed using standard neuropathological staining techniques and the antibodies indicated
below; in each case at least three sections per region per antigen were used for semi-quantitative densito-
metric and morphological measurements without counterstain using a Nikon Eclipse E800 microscope.
For the cell counts in the pons, we used sections at the level of the abducens nerve, which were available
from the four male cases, spaced by 30µm. At least 250 neurons were sampled for each case (290 ± 52).
Digitised images at 20x magnification were collected with a Sony 3CCD digital camera and the Nikon LUCIA
imaging software package was used to analyze the number, size (area) and staining intensity (mean
optical density) of cytoplasm and nucleus of all neurons per given section. 
Table 7.1 Patients characteristics.
Age at onset Time to wheel- Time to Repeat Accompanying symptoms: 
(yr.) / gender chair (yr.) death (yr.) length ataxia plus
30 / m 14 32 70 (23) Bradykinesia
35 / m 20 30 70 (23) -
35 / f 13 24 72 (20) Neuropathy, dystonia, amyotrophy
30 / m 12 21 72 (27) Spasticity, dystonia
23 / m 5 11 75 (20) Bradykinesia
Light microscopy
For immunohistochemistry formalin fixed and paraffin embedded tissue was used. Regularly spaced 6 µm
sections (Histobond) were hydrated in Xylol (10 min, 3x5 min), downgraded alcohols (100% 2x5 min, 96%
2x5 min, 70% 3 min) and aqua dest (2 min). For antigen retrieval sections were microwave-heated in citrate-
buffer (pH 6,2) for 3x5 min at 750 W and subsequently incubated in H2O2 (1,5 % in methanol) for 15 min
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to reduce peroxidase activity, in phosphate-buffered saline (PBS) containing 20% normal serum (species
dependent of origin of secondary antibody) and 0,4% Triton X for 60 min for 1H9, IRF-1, IL-1ra, IL-6 and
C/EBPdelta at room temperature; for IL-1ß and CD68 ‘DAKO Blocking Solution Serum Free’ (DAKO
Cytomation, Gastrup, Denmark) was used according to the instructions of the manufacturer. The following
primary antibodies and dilutions were used: 1H9 mouse monoclonal anti- ataxin-3 antibody (1:1500; detects
a 20 amino acid polypeptide at the C-terminus from E213 to L233 close to the glutamine tract (kindly pro-
vided by Y. Trottier (Trottier et al. 1998b)); mouse monoclonal anti-human CD68 (PG/M1) antibody (1:50;
Dako); rabbit polyclonal anti-human IRF-1(C20) antibody (1:250; Santa Cruz Biotechnology, CA); rabbit poly-
clonal anti-human IL-6 (H-183) antibody (1:50; Santa Cruz); goat polyclonal anti-human IL-1ra antibody
(1:15; R&D Systems, Minneapolis, MN); goat polyclonal anti-human IL-1ß antibody (1:10; R&D Systems);
rabbit polyclonal anti human C/CEBPdelta antibody (1:2000; Santa Cruz).
Secondary antibodies were biotinylated anti-mouse, -rabbit or -goat dependent of origin) made in rabbit or
goat (1:200; Linaris, Wertheim, Germany). Incubation with primary antibodies was performed overnight at
4°C in PBS containing 5% normal serum and 0,4% Triton X for 1H9, IRF-1, IL-1ra, IL-6 and C/EBPdelta; in
‘DAKO Antibody Dilutent with background reducing components’ for IL-1ß and CD68. After washing in PBS
and incubation with secondary antibodies for 40 min at room temperature containing 5% normal serum
and 0,4% Triton X for 1H9, IRF-1, IL-1ra, IL-6 and C/EBPdelta and in ‘DAKO Antibody Dilutent with back-
ground reducing components’ for IL-1ß and CD68, respectively, visualization was performed with Avidin-
Biotin-Complex (Vectastain Elite Standard ABC-Kit, Linaris) for 40 min at room temperature and DAB stai-
ning for 2 min (Sigma-Aldrich, St. Louis, MO, USA). 
Table 7.2 Cell loss, nuclear inclusions (NII) and staining intensity in SCA3 neurons.
Cell loss NII AT-3 CD68 IRF-1 IL-1ra Il-1ß Il-6 C/EBPdelta
Pons Moderate +++ n.c. ++ n.c. ++ ++ ++ ++
Oculomotor nuclei Severe + n.c. ++ n.c. (+) (+) n.c. (+)
Substantia nigra Moderate (+) # n.c. + n.c. n.c. n.c. n.c. n.c.
Dentate nucleus Severe ++ n.c. +++ n.c. + (+) n.c. +
Purkinje cells Mild 0 n.c. n.c. n.c. n.c. n.c. n.c. n.c.
Granule cells None 0 n.c. n.c. n.c. n.c. n.c. n.c. n.c.
Thalamus Mild + n.c. n.c. n.c. n.c. n.c. n.c. n.c.
Subthalamic nucl. Severe 0 n.c. n.c. n.c. n.c. n.c. n.c. n.c.
Putamen Moderate + n.c. n.c. n.c. n.c. n.c. n.c. *
Pallidum (internal) Severe + + + n.c. * n.c. n.c. n.c.
Pallidum (external) Mild 0 n.c. n.c. n.c. n.c. n.c. n.c. n.c.
Insular cortex None 0 n.c. n.c. n.c. * n.c. n.c. *
Cerebral cortex None 0 n.c. n.c. n.c. * n.c. n.c. n.c.
Basal nucl. (Meynert) None 0 n.c. n.c. n.c. n.c. n.c. n.c. n.c.
Spinal cord Moderate 0 n.c. n.c. n.c. n.c. n.c. n.c. n.c.
Nuclear inclusions (NII) in more than 20 % of neurons per investigated region (+++), approximately 5 % (++),
approximately 1 % (+); ataxin-3 positive Marinesco bodies were identified in the substantia nigra of SCA3 patients
and controls (#).
Ataxin-3 (AT-3, IRF-1, IL-1ra, Il-1ß, Il-6, C/EBPdelta) immunoreactivity not changed (n.c.), increased (+), stron-
gly increased (++) compared to control; (*) single strongly labeled neurons in the internal pallidum and layer V
of the insular (and occipital) cerebral cortex.
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Electron microscopy
For the EM studies SCA3 pontine tissue was available from two of the SCA3 patients. Pons sections of two
healthy individuals without a history of neurological illness served as control. In addition to the antibodies
described above, we used another C-terminal (CT1) and a N-terminal (NT1) antibody (both antibodies kind-
ly provided by E. Wanker). NT1 is directed against aminoacid 1 to 178; CT1 against aminoacid 179 and 360;
CT1 was used for double-immunogold labeling experiments with anti-ubiquitin (Tait et al. 1998b).
Secondary antibodies were goat anti-rabbit- (for CT1 and NT1) or goat anti-mouse (for 1H9) gold conjuga-
tes (10 nm, 1:20; British BioCell, Cardiff, UK).
For immunogold electron microscopy the tissue was fixed overnight in 4% paraformaldehyde and 0,1% glu-
taraldehyde in PBS, washed 3x10 min in PBS and dehydrated in graded alcohols for 15 min each. Tissues
were incubated in a 1:2 mixture of 90% alcohol and LR White acrylic (LRW) for 1 hour and embedded in
pure LRW for 1 hour at room temperature and in fresh LRW overnight at 4°C. Tissues were transferred into
gelatine-capsules filled with LRW for polymerization under UV-light at 4°C. Regularly spaced ultrathin sec-
tions (60 nm) were cut on a ZEISS Ultracut-Microtome and fixed on 300 mesh nickel grids. Consecutive
sections were stained with the C- and N-terminal antibodies (20 sections per antibody). Ultrathin sections
were rinsed on drops of 0,1% glycerine in aqua dest. for 15 min to block paraformaldehyde-structures.
Unspecific binding-sites were blocked with 5% bovine serum albumin, 0,1% cold water fish skin gelatine
washing buffer (CWFS) and 5% normal goat serum in PBS for 25 min. Sections were again washed in PBS
containing 0,5% BSA and 0,1% CWFS and incubated with the respective primary antibodies at 4°C in wet
chambers overnight. After 6x5 min washing in PBS, sections were incubated with the secondary antibody
for 2 hours at room temperature, washed 6x5 min with washing buffer and 3x5 min with PBS, postfixed with
2% glutaraldehyde for 10 min, washed in PBS for 5 min and contrasted with uranyl acetate for 1 min.
Examinations were performed with a Zeiss EM 900 electron microscope. 
Results
Neuronal cell loss and nuclear inclusions
A significant loss of neurons was evident in pons and dentate nucleus and also the pallidum, the anterior
horn of the spinal cord, the oculomotor nucleus and the substantia nigra of SCA3 patients (Tab. 7.2).
Compared to healthy controls, the number of pontine neurons was reduced to 38 ± 14 % in SCA3. Ataxin-
3-positive NII were present only in SCA3 brains and were confined to pons, dentate nucleus, putamen, tha-
lamus and the oculomotor nucleus (Tab. 7.2, Fig. 7.1). By far the most NII were found in the pons where 37
± 9 % of the neurons per field of view contained NII, approximately 5 % more than one. In contrast, only 4
± 2 % of the neurons in the dentate nucleus, and less than 1 % of the neurons in the oculomotor nucleus,
putamen and thalamus contained NII. In the pons, SCA3 patients with severe neuronal loss showed less
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Figure 7.1 Distribution of ataxin-3-immunoreactivity.
Ataxin-3-immunoreactivity in dentate nucleus (a,b) and pontine neurons (c,d) in SCA3 patients (b, d) and con-
trols (a, c); no significant differences were detected although we observed a tendency towards increased nuclear
and decreased cytoplasmic ataxin-3 staining intensity in SCA3 patients. Neurons with NII (arrowheads) displayed
both strong or weak nuclear staining intensities and similar strong or weak nuclear staining was also observed in
neurons without NII. Scale bar: 10 µm.
NII-positive neurons whereas patients with less severe cell loss displayed a higher frequency of NII-positi-
ve neurons (Fig. 7.2). Ataxin-3-positive NII were not detected in any other brain region, but both SCA3
patients and controls showed ataxin-3 positive structures, most likely Marinesco bodies, in many pigmen-
ted neurons of the substantia nigra. Glial inclusions positive for ataxin-3 or cytoplasmic aggregates were
not found. 
We detected no consistent morphological differences between ataxin-3 positive neurons in SCA3 and con-
trol except a tendency towards smaller neuron area, which reached significance only in dentate nucleus
neurons (data not shown). Similarly, we observed a tendency to increased nuclear and decreased cytoplas-
mic ataxin-3 staining intensity in SCA3 patients in dentate nucleus and to a lesser extent also in pontine
neurons (Fig. 7.1). Interestingly, the staining intensity in the neuropil of SCA3 patients appeared also to
express less ataxin-3. Analysis of the intracellular distribution of ataxin-3 in pontine neurons in SCA3 with
and without NII showed that within a given patient the average area of nuclei with NII was reduced to 83 ±
6 % and the mean nuclear ataxin-3 staining intensity was increased to 124 ± 6 % compared to nuclei wit-
hout NII. In the other regions however, cytoplasmic and nuclear staining intensity varied greatly, both in
SCA3 patients and controls suggesting that the intracellular localization of ataxin-3 might rather reflect the
functional state of individual cells but is not altered as a consequence of expression of the mutated protein. 
We further examined pontine sections of SCA3 and healthy controls using immunogold electron microsco-
py with antibodies directed against the N-terminal (NT1) or the C-terminal (CT1, 1H9) regions of ataxin-3.
With all antibodies, ataxin-3 was found at similar levels in the cytoplasm and nuclei of neurons and showed
no particular association with specific subcellular structures i.e. mitochondria, ER, lysosomes or the nucle-
ar membrane neither in control or SCA3 pons (Fig. 7.3a). However, in SCA3, only the C-terminal antibodies
strongly labeled NII in pontine neurons. In adjacent sections, containing essentially the same cellular struc-
tures, the C-terminal antibody CT1 detected 12 NII in 35 neuronal cell nuclei while the N-terminal antibody
NT1 labeled only 2 NII, suggesting that C-terminal fragments are the major component of NII. The fre-
quency of NII-bearing neurons corresponded well with the lightmicroscopic exams of the same patients.
Two inclusions within the same nucleus were found in 5-10 % of NII-bearing neurons. The NII displayed
two distinct morphologies: the majority showed an irregular surface and appeared to bind chromatin struc-
tures or were attached to the nucleolus (Fig 7.3e). Approximately 10 % of NII were clearly separated from
the nucleolus and were surrounded by a membrane- or ring like structure (Fig 7.3b,c,d). When we perfor-
med ubiquitin single- and double-labeling immunogold electron microscopy with anti-ataxin-3 antibodies
(Fig. 7.3e,f), all NII were double-labeled but no distinct regional pattern of ubiquitin within the NII became
evident. In contrast, promyelocytic leukemia protein (PML) was found exclusively in the outer perimeter of
the inclusion (Fig 7.3d). In addition to the preferential neuronal staining pattern, the C-terminal antibodies
also labeled astrocytic (GFAP-positive) fibers in SCA3 and control pons (Fig. 7.3g,h). 
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Figure 7.2 Correlation of nuclear inclusions and surviving neurons in SCA3 pons.
x-axis: percentage of surviving neurons with
NII; y-axis: percentage of surviving neurons
compared to control; (—-) polynomic trendline.
The percentage of NII bearing neurons was
higher in patients with less severe cell loss, a
finding that can be explained only if the pro-
bability of neurons with NII to die is higher. 
Expression of IL-1ß, IL-1ra, IL-6, IRF-1 and C/EBPdelta 
IL-1ß is one of the most prominent cytokines in the brain and is expressed in neurons, microglia and astro-
cytes (Boutin et al. 2003). Constitutive expression of IL-1ß in healthy neurons is extremely low and aberrant
synthesis of IL-1ß is thought to contribute to the development of acute and chronic CNS pathologies
(Rothwell 2003). In healthy human controls only very weak immunostaining for IL-1ß was detected in all
regions examined. In contrast, IL-1ß was strongly increased in the cytoplasm of pontine neurons in SCA3
(Fig. 7.4) while neurons of the dentate nucleus displayed a heterogeneous, less distinct staining pattern.
Similarly, in the oculomotor nucleus, substantia nigra, dentate nucleus, cerebellar and occipital cortex both
SCA3 patients and controls showed variable nuclear or cytoplasmic staining intensity. The known actions
of IL-1ß are blocked by the selective, competitive interleukin-1 receptor antagonist (IL-1ra). No agonist acti-
on has been described for IL-1ra so far and no information on the expression of IL-1ra in the human CNS
has yet been published. Complementary to IL-1ß, we found increased IL-1ra expression only in the cyto-
plasm of pontine and dentate nucleus neurons of SCA3 patients (Fig. 7.4). Double-labeling experiments
showed no differences of IL-1ß or IL-1ra staining between neurons with or without NII and IL-1ß and IL-1ra
were not sequestered into or co-localized to NII. Interestingly, we frequently found intensely IL-1ra positive
neurons also in the insular and deeper layers of the occipital cortex in SCA3 patients, which were only occa-
sionally observed in controls. 
Interleukin 6 (IL-6) is another member of the IL-family and may function as a mediator of IL-1ra producti-
on to induce both neuronal survival and differentiation (Taga and Kishimoto 1997), IL-6 is expressed in
neurons and increased levels of IL-6 are consistently detected in the brains of Alzheimer’s disease patients
(Hull et al. 1996). IL-6 was increased in the cytoplasm of pontine neurons in SCA3 (Fig. 7.4), but not in any
other brain region. Again, no differences between neurons with or without NII were detected. Interferon regu-
latory factors (IRF’s) are involved in immune regulation, cell growth and hematopoetic development; IRF-1
can contribute to induction of growth arrest and programmed cell death (Taniguchi et al. 2001). In our expe-
riments IRF-1 showed a heterogeneous staining pattern both in SCA3 and control tissues. In SCA3 pons many
neurons displayed decreased nuclear and increased cytoplasmic staining intensity; this trend, however, did
not reach statistical significance. No consistent difference in the glial expression pattern was observed.
CCAAT/enhancer-binding-proteins (C/EBPs) comprise a family of transcription factors that act as pivotal
regulators of cellular differentiation; in addition C/EBPs have been implicated in the regulation of IL-6-
expression (Vales and Friedl 2002). The predominantly cytoplasmic immunoreactivity of C/EBPdelta was
strongly increased in SCA3 pontine neurons and to a lesser extent also in the dentate nucleus (Fig.7.4).
Similar to IL-1ra, single strongly labeled cells where found in the deeper layers of the insular cortex, but no
such cells appeared in the occipital cortex. No sequestration into or co-localization to NII was observed.
Presence of CD68-positve microglia
Increased numbers of microglia cells were present in pons and dentate nucleus and also the pallidum, and
the oculomotor nucleus and the substantia nigra of SCA3 patients, i.e. in areas of moderate or severe cell
loss (Tab. 7.2). Compared to healthy controls, the number of microglia cells was not altered elsewhere.
Discussion
The principal findings of this study can be summarized as follows: (1) In SCA3 brains, NII were found
almost exclusively in brain regions that also showed neuronal cell loss; the by far greatest frequency of NII
was found in the pons. (2) In the pons, NII were less frequent in SCA3 brains with severe neuronal cell loss,
suggesting that NII-bearing neurons have a higher probability to die. (3) Ataxin-3 was found in the cyto-
plasm and nucleus of neurons without association with specific cellular organelles. NII were more readily
labeled with C-terminal than with N-terminal antibodies suggesting that C-terminal ataxin-3 fragments are
the major components of NII. (4) Increased expression of IL-1ß and related proteins was confined to the
pons and dentate nucleus, two brain regions heavily involved in neurodegeneration. Within the pons,
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Figure 7.3 Electronmicroscopy of SCA3 pons.
(a) pontine SCA3 neuronal nucleus with NII (arrow); bar: 3,75  µm. (b) NII from (a) at higher magnification,
labeled with anti-ataxin (CT1); no immunoreactivity is found at the surrounding membrane-like structure
(arrow); bar: 400 nm. (c) NII labeled with anti-ubiquitin; no immunoreactivity is found at the membrane-like
structure; bar: 400 nm. (d) NII labeled with anti-PML, immunoreactivity is found only at the membrane-like
structure (arrow-heads); bar: 400 nm. (e) NII with irregular surface, in contact with the nucleolus (N) and chro-
matin (C); double-labeling with ataxin and ubiquitin; bar: 900nm. (f ) higher magnification of (e): ataxin
(arrows), ubiquitin (arrowheads); bar: 200nm. (g) ataxin-labeled glial fiber in SCA3 pons, bar: 750 nm. (h)
GFAP-labeled glial fiber in SCA3 pons, scale bar: 750 nm.
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increased IL-1ß expression occurred both in neurons with and without NII. There was no generalized up
regulation of cytokines or increased microglia in SCA3 brains, and in some brain regions undergoing severe
neurodegeneration such as the pallidum, cytokine expression was not increased. These observations rule
out the possibility that enhanced cytokine expression is an early and generalized event mediating neuronal
dysfunction in SCA3.
NII in SCA3 brains are associated with neuronal cell death and neurodegeneration. 
The frequency of NII-bearing neurons found in the present study is in good agreement with previously
published data (Paulson et al. 1997b; Schmidt et al. 1998). Although the limited number of cases calls for
caution, our quantitative analysis indicates that the relative proportion of NII-positive neurons in the pons
decreases with progressing cell loss (Fig. 7.2). Assuming that more neurons develop NII during the disease
and that the equilibrium of newly formed and (possibly) dissolved NII results in a gain in NII, a decrease of
the relative proportion of NII-positive neurons with progressing cell loss fits only with a greater probability
of NII-positive neurons to degenerate, suggesting that in SCA3 neurons with NII indeed have a greater like-
lihood to degenerate. On the contrary, if NII were protective, the relative proportion of NII-positive neurons
would increase over time, the faster the higher the likelihood that neurons develop NII (a three state
Markov model is available at http://www.meb.uni-bonn.de/neurologie/SCA to illustrate the process). This
conclusion fits well with the observation that NII were present only in brain regions that also showed
neuronal cell death. A protective role of NII in SCA3, as suggested for HD, is thus unlikely. However, it can-
not be deduced from the present data whether NII in SCA3 only ‘indicate’ neurons that are more likely to
die or are somehow implicated in the pathogenesis itself. 
Ataxin-3 expression and NII
We initially hypothesized that altered localization of ataxin-3 might be responsible for the observed tran-
scriptional changes and therefore investigated whether altered subcellular distribution of ataxin-3 in SCA3
might correlate with the observed transcriptional changes. The intracellular localization of ataxin-3 initially
was reported with a predominant cytoplasmic ataxin-3 staining in various subsets of neurons and intense
nuclear staining only in Purkinje cells (Trottier et al. 1998). Subsequently, various investigators found both
cytoplasmic and nuclear staining of various cell types (Paulson et al. 1997a; Tait et al. 1998). Schmidt and
co-workers suggested that non-expanded ataxin-3 might be present preferentially in the cytoplasm whereas
expanded ataxin-3 or C-terminal fragments localized to the nucleus (Schmidt et al. 1998). Consistent with
this hypothesis, neurons with NII displayed increased nuclear staining intensity, which could point to a
nuclear sequestration of ataxin-3. However, using electron microscopy we found ataxin-3 in the nuclei and
cytoplasm of human pontine neurons with different C- and N-terminal antibodies. While both C- and N-ter-
minal antibodies were bound to structures in the nucleus and cytoplasm, only the C-terminal antibody con-
sistently labeled NII. Our finding that C-terminal ataxin-3 fragments are the major components of NII is in
good agreement with recent in vitro data showing that ataxin-3 fragments with an N-terminal deletion of 257
amino acids have the greatest tendency to aggregate (Kobayashi and Kakizuka 2003). No association of
expanded ataxin-3 with specific cellular organelles was found in SCA3 pontine neurons. While the majority
of NII displayed an irregular surface and appeared attached to the nucleolus, approximately 10 % were cle-
arly separated from the nucleolus and were surrounded by a membrane- or ring like structure. An associa-
tion with the nuclear matrix, as suggested earlier, was not found (Tait et al. 1998; Perez et al. 1999). Also,
we found no evidence for a particular pattern of ataxin-3 and ubiquitin at the ultrastructural level within NII
in SCA3. At the ultrastructural level all NII in pontine neurons appeared to include both ataxin-3 and ubi-
quitin (Hayashi et al. 2003). While Fujigasaki and co-workers postulated a ring-like structure of ubiquitin
surrounding the NII, double-labeling immunogold electron microscopy revealed no distinct pattern of ubi-
quitin within the two types of NII while PML-immunoreactivity was indeed concentrated in the outer mem-
brane-like structures as described earlier (Fujigasaki et al. 2000; Yamada et al. 2001). 
Increased expression of cytokines is a specific phenomenon in SCA3 pons and dentate nucleus neurons.
Upon identification of several differentially expressed genes related to inflammation in a cell model of SCA3,
we investigated whether the expression of the respective proteins might constitute a general mechanism in
SCA3. Enhanced expression of the cytokines IL-1ß, IL-1ra and IL-6 and the cytokine-inducible transcription fac-
tor C/EBPdelta could be functionally interconnected. IL-1ß, IL-1ra and IL-6, like many other genes, contain
CCAAT enhancer elements in the respective promoter regions and are transcriptionally regulated by C/EBPs
in response to inflammatory stimuli. Vice versa, the IL-1ß and other pro-inflammatory cytokines have been
shown to induce the synthesis of the transcription factors C/EBPdelta and C/EBPdelta in astrocytes (Cardinaux
et al. 2000). It was conceivable, that in vulnerable neuronal populations a vicious cycle was initiated early in
the disease process. Consistent with the hypothesis that transcriptional dysregulation is involved in the patho-
genesis of SCA3, we found increased cytoplasmic expression of Il-1ß, IL-1ra, IL-6 and C/EBPdelta - but confi-
ned to two brain regions severely affected by the disease process, pons and dentate nucleus and most pro-
nounced in the pons. No changes in the expression of Il-1ß, IL-1ra, IL-6 and C/EBPdelta were found in corti-
cal, putaminal, pallidal or nigral neurons, although the clinical presentation of the SCA3 patients examined
included dystonia and parkinsonian symptoms. The lack of expression changes in areas implicated in clinically
compromised functions argues against a hypothesis which implies transcriptional changes in the functional
neurological deficits of SCA3 patients but rather supports the notion that an inflammatory cascade is involved
in the cell death process in specific cells in SCA3. It is intriguing, that transcriptional changes and the occur-
rence of NII-bearing neurons was most pronounced in the pons, although comparable cell loss is also found
in the pallidum or the oculomotor nucleus. Within the surviving pontine nucleus neurons no difference was
detected between neurons with or without NII, suggesting that transcriptional dysregulation constitutes an
event that occurs in a specific vulnerable neuronal phenotype independent or even prior to macroscopic NII. 
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Taken together, the present study identified occurrence of NII and enhanced cytokine expression as cellu-
lar events associated with neurodegeneration in specific affected brain regions in SCA3. Neither of the two,
however, appeared to be a necessary or sufficient condition of neuronal cell death. The essential mecha-
nisms mediating neurodegeneration in SCA3 remain to be identified. 
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Figure 7.4 Expression of cytokines in SCA3.
Immunoreactivity of pontine (row 1,2; a-h), dentate nucleus (row 3,4; i-p) and spinal cord neurons (row 5,6; q-x)
for IL-1ß (column 1), IL-1ra (column 2), IL-6 (column 3) and C/EBPdelta (column 4); note the increased staining
intensity especially in pontine SCA3 neurons (top row) compared to control (second row). Bar: 10 µm.
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Spinocerebellar ataxia type 6 (SCA6) is caused by a small CAG expansion in the CACNA1A gene encoding
the α1A-subunit of the neuronal voltage-dependent P/Q-type Ca2+-channel (P/Q-VGCC) (Zhuchenko et al.
1997). P/Q-VGCCs are widely expressed, not only in the central nervous system (CNS), but also at the
neuromuscular junction (NMJ) (Uchitel et al. 1992). The presence of P/Q-VGCCs at motor nerve terminals,
together with the demonstration that SCA6 related polyglutamine expansions may influence channel func-
tion (Piedras-Renteria et al. 2001), suggests that neuromuscular transmission might be compromised in
SCA6. However, muscle weakness is not a clinical feature of SCA6. Therefore, a possible neuromuscular
defect is likely to be sub-clinical and might appear as an increased jitter without blockings in single fiber
electromyography (SFEMG). 
Ten SCA6 patients from eight different families participated in the study. In all patients, genetic analysis
revealed a CAG expansion in the SCA6 gene of 22 repeats. In order to study both proximal and distal mus-
cles, the variability in latency (jitter) of single-fiber action potentials was assessed in both the extensor digi-
torum communis muscle (4 patients) and in the orbicularis oculi muscle (6 patients). The data are shown
and the results were all normal (Table 8.1). Our results confirm a preliminary observation that neuromus-
cular dysfunction is not a feature of SCA6 (Jen et al. 2001). These findings appear to be inconsistent with
the results in patients with episodic ataxia type 2 (EA-2) (Jen et al. 2001), a disorder allelic with SCA6, but
usually caused by more damaging frameshift mutations or aberrant splicing that both result in truncated
proteins. Presently, the question whether SCA6 is a channelopathy due to an endogenous dysfunction of
the calcium channel involved or results from a toxic gain of function attributable to the expanded polyglu-
tamine tract, as seen in other CAG expansion disorders, remains unanswered. Either way, our study indi-
cates that SCA6 results from CNS-specific disease pathways. Two possible mechanisms might account for
the CNS-selectivity. First, the presence of pathogenic splice forms of the CACNA1A gene products may be
confined to the CNS compartment. Second, interaction with tissue-specific subunits of the channel seems
to be important, as a previous study suggested that interaction with the ß4-subunit, which is primarily
found in Purkinje cells and not in the NMJ, is crucial for the development of neuronal dysfunction
(Restituito et al. 2000).
Although some believe that SCA6, EA-2, and familial hemiplegic migraine are representatives of the same
disease with a large phenotypical variability, the nature of the mutation apparently results in a distinctive
phenotype at the level of neuromuscular transmission. 
Table 8.1 Single-fiber EMG in ten patients with spinocerebellar ataxia type 6.
M. Ext. Dig. Com. M. Orbicularis Oculi
Age(y)/sex Mean MCD MCD % of pulses Mean MCD MCD range % of pulses
(µs) range (µs) blocked (µs) (µs) blocked
(N < 25) (N < 40) (N = 0) (N < 20) (N < 31) (N = 0)
62/F 24 12-38 0
39/F 18 8-32 0
73/F 23 12-35 0
34/F 22 13-30 0
27/M 17 6-29 0
33/M 20 13-26 0
56/F 18 10-29 0
58/M 16 10-23 0
49/M 16 10-27 0
69/M 18 9-29 0
M. Ext. Dig. Com., musculus extensor digitorum communis; MCD, mean consecutive difference.
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Expanding the phenotype and classification system
of the early onset cerebellar syndromes
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Abstract
The discovery of the gene for Friedreich’s ataxia (FRDA) has not only broadened the FRDA phenotype, but
has also identified a group of patients with early onset cerebellar ataxia, who resemble FRDA clinically, but
who do not carry a mutation in the frataxin gene. In order to identify subgroups that may represent a uni-
form underlying disorder, we performed nerve conduction studies and electromyography (EMG) in 15
patients with an early-onset, slowly progressive, non-dominant, unexplained ataxia. Fifteen patients, classi-
fied as ‘non-Friedreich’ early-onset cerebellar ataxia (NF-EOCA), participated in the neurophysiological stu-
dies. In addition, transcranial magnetic stimulation (TMS) studies were conducted in nine of these patients
and sural nerve biopsy data were available in four patients. The neurophysiological data identified three
distinctive groups of NF-EOCA patients. Three patients with normal conduction studies (group 1); three
patients with a mild motor axonal neuropathy (group 2); and nine patients with a severe sensory and motor
axonal neuropathy (group 3). We conclude that neurophysiological studies are useful in splitting the hetero-
geneous group of NF-EOCA and that, based on these studies, at least three distinctive entities can be
delineated.
Introduction
Harding was the first to recognize a clinical syndrome characterized by progressive cerebellar ataxia, retai-
ned tendon reflexes, and onset before the age of 25 years (Harding 1981a). The syndrome was called early-
onset cerebellar ataxia (EOCA) and was distinguished from FRDA mainly by the preservation of tendon
reflexes and a much slower disease progression. Nowadays, EOCA is considered a heterogeneous syn-
drome that shares clinical features and, indeed, overlaps clinically with classic FRDA, atypical FRDA
and other slowly progressive, early-onset, non-dominant, cerebellar syndromes in which no definite
genetic or biochemical diagnosis can yet be established (Lynch et al. 2002). To prevent confusion with
the original description of EOCA we prefer to use the term non-Friedreich early-onset cerebellar ataxia
(NF-EOCA) to describe this heterogeneous group of patients. For FRDA, current data has shown that
peripheral nerves do express the underlying pathophysiological mechanisms (Santoro et al. 1999). We
hypothesized that the extent and nature of involvement of the peripheral nervous system might also allow
identification of specific NF-EOCA subtypes. To test this hypothesis we performed neurophysiological
studies in 15 patients with NF-EOCA. 
Material and methods
Patients
After approval of this study by the ethical committee of our hospital, the medical records of all patients
referred to our department and classified as ‘unexplained slowly progressive cerebellar ataxia’ were
reviewed and 109 patients were identified. In this study the diagnosis ‘NF-EOCA’ was based on the follo-
wing criteria: (1) progressive, unexplained cerebellar ataxia with a disease-onset before the age of 25 years,
(2) family history compatible with autosomal recessive inheritance, including sporadic patients, (3) absence
of mental retardation, pigmentary retinal degeneration, oculomotor apraxia, and myoclonus, (4) MRI evi-
dence of cerebellar atrophy, (5) absence of a GAA expansion in the frataxin gene. Of the 109 patients,
patients were excluded with an age at onset > 25 years, possibly indicating multi-system atrophy or spino-
cerebellar ataxia type 1, 2, 3, 6, 7, 14 (n = 72), mental retardation (n = 4), pigmentary retinal degeneration
(n =4), and myoclonus (n = 6). Of the remaining 23 patients fulfilling our criteria of NF-EOCA, 15 patients
were willing to participate in the neurophysiological studies. Nine of these patients also underwent tran-
scranial magnetic stimulation (TMS) studies. Sural nerve biopsy data were available of four patients plus
an affected brother of one patient. In all these patients, the various differential diagnostic conditions were
excluded by extensive ancillary tests (vitamin E, alpha-fetoprotein, hexosaminidase A, very long-chain fatty
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acids, serum albumin, ceruloplasmin, serum lactate and, on indication, muscle biopsy for histology and
mitochondrial DNA analysis). We used the international ataxia co-operative rating scale (ICARS) to quanti-
fy the severity of cerebellar symptoms. The scale (rating from 0 [normal] to 100 [severe]), involves a com-
partmentalized quantification of postural and stance disorders, limb ataxia, dysarthria, and oculomotor
abnormalities (Trouillas et al. 1997).
Nerve conduction studies and EMG recording
A Synergy EMG machine (Oxford Medical Instruments) was used to record nerve conduction and concen-
tric needle EMG studies and these studies were performed according to standard techniques (Dumitru et
al. 2002). Eleven patients underwent a predesigned protocol. In four other patients, recent previous EMG
studies were re-evaluated (patient 3, 4, 7 and 10). The predesigned protocol covered motor nerve conduc-
tion studies of the median, peroneal and tibial nerve, antidromic sensory nerve conduction studies of the
ulnar, radial, and sural nerve, H-reflexes and M-response recording the soleus-gastrocnemius muscle, and
needle EMG of one proximal (rectus femoris), and one distal lower limb muscle (tibialis anterior or exten-
sor hallucis). The amplitudes of the sensory nerve action potential (SNAP) and compound muscle action
potential (CMAP) were measured from peak to peak. 
Transcranial magnetic stimulation
In nine patients, motor evoked potentials (MEPs) were evoked by a Magstim 200 (2.0 Tesla) magnetic sti-
mulator and recorded from the abductor digiti minimi muscle (ADM) of the left hand and from the vastus
medialis muscle (VM) of the left leg. The stimulator was fitted by a circular 70mm coil and stimulation
intensity was set at 100%. Cervical and lumbar motor roots were stimulated over the seventh cervical spi-
nal level or lumbar region, respectively. Two subsequent stimuli were given at each stimulation site. During
cortex stimulation the target muscle was contracted slightly. The central motor conduction time (CMCT)
was calculated by subtracting the shortest latency of the MEP in response to root stimulation from the shor-
test latency of the MEP in response to cortical stimulation. Signals were amplified and filtered between 10
Hz and 1 KHz. Two pulses were delivered in order to check their reproducibility. Both the absence of a MEP
to cortical stimulation in one of more muscles and a CMCT 2 SD beyond the mean of our normal values
were considered abnormal.
Nerve Biopsy
Sural nerve biopsy had been performed in four patients, 19 to 29 years before the present electrophysiolo-
gical study, and in an affected brother of one patient. Midcalf sural nerve biopsy was prepared for light and
electron microscopic examination, including teased fiber studies, using standard techniques (Gabreëls-
Festen et al. 1992). The specimen for electron microscopy was fixed in buffered 2% glutaraldehyde at pH
7.4, postfixed in buffered 2% osmium tetroxide, dehydrated and embedded in epoxy resin. Semi-thin, 1 µm
sections were stained with 1% toluidin blue. Ultra thin sections were stained with uranyl acetate and lead
citrate. Eight to ten randomly chosen electron microscopical prints (x 1700) were used for morphometrical
analysis. Enlargements were checked with the aid of a rating grid. Density and diameter distribution of mye-
linated fibers were determined using a Zeiss TGZ particle size analyzer. 
Molecular analysis
DNA was isolated from peripheral blood using the high salt/ chloroform extraction method. Mutation ana-
lysis of the gene responsible for autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS or
SACs), covering mutations 6594delT and 5254C→T, was carried out as previously described by automated
direct sequencing (Richter et al. 1999). The APTX gene, encoding aprataxin and responsible for ataxia with
oculomotor apraxia type 1 (AOA1), was analyzed as described previously (Moreira et al. 2001b).
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Results
Patients
The clinical features are summarized in Table 9.1. Eight male and seven female patients participated in the
study (mean age 39.5, standard deviation 10.0, range 23-53). In seven subjects of five different families,
family history strongly suggested an autosomal recessive inheritance (consanguinity or two affected sibs
with unaffected parents). The other eight patients were the only affected members of their family. The age
at onset varied between 0 and 19 years (mean 10.1 ± 6.4 years) and the duration of symptoms varied bet-
ween 12 and 52 years (29.3 ± 10.5). Vibration sense at the ankles was impaired in 10 patients (patients 1, 4,
6, 8-11, 13-15). In three patients lower limb reflexes were absent while in 12 patients these were retained
(patients 1-10, 12 and 14). Foot deformity was present in seven (patients 1, 7-9, 12-14), sphincter dysfuncti-
on in five (patients 7, 9, 10, 14 and 15) and mitral valve prolapse in one (patient 11). Only one patient sho-
wed a clinically relevant spastic paraparesis. The ataxia severity varied between 24 and 74 (49.1 ±15.3).
Nerve conduction and EMG
The electrophysiological data are shown in Table 9.2. Abnormal motor or sensory conduction or both were
present in 12 of the 15 patients. In seven patients (7-9 and 11-14) both no CMAP’s and SNAP’s could be evo-
ked in the lower extremities. In seven patients (8-12 and 14, 15) no SNAP’s could be evoked in both lower
and upper extremities. If elicited, the conduction velocities were sometimes slowed but were compatible
with an axonal type of neuropathy. Abnormalities in both motor and sensory nerve conduction studies and
EMG showed a distal-to-proximal gradient. Nerve conduction studies and EMG clearly differentiated three
groups. Group one (patient 1-3) with normal conduction studies, group two (patients 4-6) consisted of
patients with a relatively mild motor axonal neuropathy and group three (patients 7-15) included those with
a severe sensory and motor axonal neuropathy.
Table 9.1 Clinical features in 15 patients with NF-EOCA.
Patient Sex Age,y Age at Ataxia Vibration Babinski Lower Lower Foot Sphincter
onset,y severity sense sign limb limb defor- dys-
(../100)* muscle tendon mity function
atrophy reflexes
1 M 23 3 57/100 - + - + + -
2 F 34 14 30/100 + - - + - -
3 M 44 14 49/100 + - - + - -
4 F 36 18 48/100 - + + + - -
5 M 53 17 31/100 + - + + - -
6 F 31 19 24/100 - + + + - -
7 F 26 3 48/100 + + + + + + 
8 M 42 12 54/100 - + - + + -
9 M 49 8 54/100 - + - + + +
10 F 32 3 56/100 - + + + - +
11 F 46 10 57/100 - + + - - -
12 F 30 3 26/100 + + - + + -
13 M 41 16 58/100 - + + - + -
14 M 53 12 71/100 - + + + + +
15 M 52 0 74/100 - + + - - + 
* Ataxia severity, as measured by the Ataxia Rating Scale. 
(+) = clinical feature present; (-) = clinical feature absent. 
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Transcranial magnetic stimulation
MEPs in response to cervical radicular stimulation in nine patients revealed abnormal latencies in eight
(Table 9.3) and MEPs in response to lumbar radicular stimulation (data not shown) were delayed in two.
MEPs elicited by cortical stimulation in both ADM and VM were abnormal in all patients examined. The
CMCT elicited from the ADM was abnormal in eight of nine patients examined (normal in patient 5) and
the CMCT elicited from the VM were abnormal in all.
Table 9.3 Transcranial magnetic stimulation.
Patient * Abductor digiti minimi Vastus medialis
latency (ms) latency (ms)
Root Cortical CMCT Root Cortical CMCT
Normal ** < 16 < 23.5 < 9 < 13.5 < 26 < 15.5
1 14.8 n.r n.r 8.7 n.r n.r
5 17.7 26.1 8.4 11.7 31.4 19.7
7 17.5 36.9 19.4 11.0 n.r n.r
8 22.8 37.1 14.3 14.2 n.r n.r
9 19.2 32.5 13.3 11.7 n.r n.r
11 22.3 34.1 11.9 13.5 32.8 20
12 17.2 38.5 21.3 8.7 n.r n.r
14 18.4 n.r n.r 12.4 n.r n.r
15 16.9 41.5 25.5 12.2 n.r n.r
*The number of patients from table 9.3 align with those of table 9.1. 
**mean + 2 SD 
CMCT, central motor conduction time; n.r, no response. 
Sural nerve biopsy
In four patients a sural nerve biopsy was performed 19 to 29 years before the present electrophysiological
study (Table 9.4). A fifth sample had been obtained in a five years younger brother of patient 11, who sho-
wed an identical clinical syndrome. Myelinated fiber density was in the normal range or slightly decreased,
except in patient 13, who showed a severe loss of myelinated fibers. The percentage of large diameter fibers
(< 8µm) was decreased, except in patient 14. In three patients some active axonal degeneration was obser-
ved, especially in the biopsy of patient 11. Few clusters of small regenerated fibers were present in patient 13.
Table 9.4 Sural nerve biopsy.
Patient * Age at biopsy MF % MF > 8µm Details
density/mm2
9 20 y 8800 2.4 -
11 19 y 8180 9.9 AxD ++
brother of pat. 11 14 y 12040 8.1 AxD +
13 20 y 2370 2.4 AxD ±, clusters ±
15 23 y 8740 24.1 -
*The number of patients from table 9.4 align with those of table 9.1.
MF density, myelinated fiber density, normal for age 11-31 year: 10060 fibers/mm2.
% myelinated fibers > 8µm, normal for age 11-31 year; 23.4 %. 
AxD, active axonal degeneration, ± incidental, + mild, ++ moderate.
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Molecular analysis
Molecular analysis excluded a 6594delT and 5254C→T mutation in the SACs gene in all patients.
Sequencing of exons 5, 6 and 7 of the APTX gene, responsible for AOA1, did not reveal a mutation in any
of the patients with abnormal nerve conduction studies.
Discussion 
In the present study we performed nerve conduction and EMG studies in 15 patients with NF-EOCA. The
clinical and neurophysiological data clearly differentiated three phenotypes. Group one, with retained ten-
don reflexes and normal conduction studies, group two, with an onset in the second decade, absence of
foot deformities, and a mild motor axonal neuropathy, and group three, with pyramidal features and a seve-
re sensory and motor axonal neuropathy. None of our patient displayed a pure sensory neuropathy as
encountered in classical FRDA, infantile-onset spinocerebellar ataxia, and ataxia with isolated vitamin E
deficiency. The patients in groups 1, 2 and 3 did not differ significantly in age, disease duration, or ICARS
score which suggests that the neurophysiological differences did not, purely, reflect differences in disease
progression. The presence and type of neuropathy has differential diagnostic consequences and, therefore,
might guide additional tests (see discussion and the end of this thesis). The nerve conduction studies of
the three patients from group two, that consist of a reduction of the CMAPs, with a distal to proximal gra-
dient, suggests motor neuropathy rather than involvement of spinal motor neurons. In these patients, the
differential diagnostic possibilities include ataxia teleangiectasia and hexosaminidase deficiency (Navon et
al. 1997; Larnaout et al. 1998), but additional studies ruled out these disorders. In nine patients (group
three), a severe sensory and motor axonal neuropathy was demonstrated. In four of the nine patients, sural
nerve biopsy was performed which showed a mild to marked loss of large myelinated fibers and several
fibers in a stage of active axonal degeneration. TMS, in seven of these nine patients, confirmed the clinical
suggestion of pyramidal involvement by showing a complete absence of motor evoked potentials to the
musculus vastus medianus in all. In patients with both an early onset cerebellar ataxia and a severe sen-
sory and motor axonal neuropathy, various diagnostic possibilities like, Bassen Kornzweig disease
(Wichman et al. 1985), congenital disorders of glycosylation (different types) (Marquardt and Denecke
2003), cerebellar ataxia with oculomotor apraxia type 1 (AOA1) (Le, Ber et al. 2003), and type 2 (AOA2) (Le,
Ber et al. 2004), should be considered. However, in our patients, clinical features, metabolic studies and
DNA analysis (AOA1) made these diagnoses extremely unlikely. The combination of early onset ataxia with
pyramidal features, MRI data (data not shown), nerve conduction studies and sural nerve findings (loss of
large myelinated fibers) in patients of group three were not incompatible with autosomal recessive spastic
ataxia of the Charlevoix-Saguenay type (ARSACS) (Peyronnaud JM et al. 1979; Bouchard et al. 1978). Unlike
ARSACS however, none of our patients showed a clinical relevant spastic syndrome and non showed pro-
minent myelinated fibers in the fundus. Although current evidence suggests that ARSACS might be much
more common than originally anticipated (Gomez 2004; Criscuolo et al. 2004; Grieco et al. 2004), these
data, in combination with an absence of mutations in the first two described SACs‘hotspots’, suggests that
our patients do not suffer from ARSACS. Therefore, these patients might be classified as spinocerebellar
ataxia with axonal neuropathy (SCAN). SCAN1, recently described, shares some of the clinical features of
our patients, but is distinguished by the presence of pyramidal features and the absence of hypoalbumine-
mia-, and hypercholesterolemia (Takashima et al. 2002). Apparently, SCAN is a heterogeneous group of dis-
orders, which might be split by the presence, or absence of pyramidal tract involvement. For now, we con-
clude that, on the basis of nerve conduction studies and EMG, at least three distinctive groups of patients
with NF-EOCA can be delineated and that differentiation between these groups can be useful for differen-
tial diagnostic consideration. Whether this splitting also reflects a fundamental phenotypic difference and,
therefore, may direct future DNA studies, remains to be established.
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Abstract
Harding was the first to recognize a clinical syndrome characterized by progressive cerebellar ataxia, retained
tendon reflexes and an onset before the age of 25 years. The syndrome was called early-onset cerebellar ataxia
(EOCA) and was distinguished from Friedreich’s ataxia (FRDA) mainly by the preservation of tendon
reflexes, a slower disease course and a better prognosis. Nowadays, EOCA is considered a heterogeneous
syndrome that overlaps clinically with classic FRDA, atypical FRDA and a group of other slowly progressive
early-onset hereditary cerebellar syndromes that consists of well-known clinical entities as well as a group
of disorders for which a definite genetic or biochemical diagnosis cannot be established yet. To further cha-
racterize this last group, we re-evaluated the clinical features, progression, and neurophysiological findings
of 191 patients that visited our outpatient clinic with a slowly progressive cerebellar ataxia over a period of
nearly 10 years. In 51 patients no known metabolic or genetic disorder could be diagnosed. These patients
could then be subdivided in four groups, based on their clinical phenotypic features. 
Patients with an uncomplicated cerebellar syndrome (group I) or uncomplicated spinocerebellar syndrome
(group II) appeared to have a slow disease progression and a good clinical outcome. In contrast, most
patients with a spinocerebellar syndrome and neuropathy (group III) were wheelchair bound. The handicap
of the patients with a ‘complicated’ spinocerebellar syndrome with additional auditory, ophthalmologic or
mental impairment (group IV) was determined by both their ataxia and the other clinical features. We con-
clude that further differentiation within this group of EOCA patients is important for clinical counseling.
Introduction
The degenerative ataxias are a clinically and pathophysiologically heterogeneous group of neurological dis-
orders which share the clinical feature of slowly progressive ataxia due to degeneration of the cerebellum,
the spinal tracts, the peripheral nervous system and various other nervous system structures (Harding
1984; Klockgether et al. 1998). The most basic classification of this group of disorders distinguishes spo-
radic forms, such as multiple systems atrophy (MSA), from hereditary ataxias. 
The hereditary ataxias are further subdivided into autosomal dominant cerebellar ataxias (ADCAs) and
autosomal recessive forms. Since 1993, when the SCA1 CAG repeat expansion was first described (Orr et
al. 1993), molecular methods have identified a large number of ADCA genotypes that now include the spi-
nocerebellar ataxia loci SCA 1-8, and 10-26. Mutations have been identified for SCA1, 2, 3, 6, 7, 8, 10, 12, 14,
17 and fibroblast growth factor type 14 (FGF14) (http://www.gene.ucl.ac.uk/cgi-bin/nomenclature) (Schols
et al. 2004). Striking differences between genotype frequencies in different countries and populations have
been reported (vd Warrenburg et al. 2002; Brusco et al. 2004).
Much less is known about the genetic background of autosomal recessive ataxias. In western countries,
Friedreich’s ataxia (FRDA) seems to be the most common type with an estimated prevalence of about 2 per
100,000. Linkage to chromosome 9 was described in 1988 and the gene with a pathogenic GAA trinucleo-
tide repeat expansion in intron 1 was described in 1996 (Chamberlain et al. 1988; Campuzano et al. 1996).
Since then, the molecular basis has been elucidated for additional recessive Friedreich-like, as well as non-
Friedreich-like slowly progressive ataxias, such as ataxia with isolated Vitamin E deficiency (AVED), auto-
somal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), ataxia with oculomotor apraxia type 1 and
type 2 (AOA1 and 2), infantile-onset spinocerebellar ataxia (IOSCA), spinocerebellar ataxia with axonal
neuropathy (SCAN1) and ataxia teleangiectasia (See also Table 10.1) (Ouahchi et al. 1995; Richter et al.
1999; Engert et al. 2000; Moreira et al. 2001; Németh et al. 2000; Nikali et al. 1995). However, these muta-
tions probably explain only a minority of cases in large populations, and the range of genotypes that cause
recessive ataxias may be as broad as that for the dominant ataxias.
In clinical practice, many patients present with a very slowly progressive (spino) cerebellar ataxia that is not
a dominant disorder or FRDA. The ataxia usually starts at an early age, deteriorates over the years, and leads
to severe disability later in life. Before the frataxin gene was identified, many of these cases were classified
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according to Harding’s definition as EOCA (Harding 1981a). EOCA was distinguished from FRDA mainly
by the preservation of tendon reflexes and a better prognosis (Geoffroy et al. 1976; Harding 1981a).
However, the discovery of the frataxin gene revealed that the phenotype was broader than originally antici-
pated. In contrast to the original clinical criteria, mutation analysis made it possible to unambiguously dia-
gnose Friedreich’s ataxia in patients with a disease onset older than 25 years, with retained tendon reflexes,
a much slower disease course and even atypical neurological features, e.g. extrapyramidal signs (Durr et al.
1996). Moreover, it is now possible to exclude a diagnosis of Friedreich’s ataxia in patients presenting with
a clinical phenocopy of the disorder. 
Table 10.1 Current state: the autosomal recessive spinocerebellar ataxias with the gene(locus) and gene product
(see also chapter 3; table 3.1). 
Recessive ataxia Gene product Gene/locus
Ataxia teleangiectasia ATM protein kinase ATM
Ataxia teleangiectasia like disorder Human Mre11 protein MRE11
Ataxia with axonal neuropathy (SCAN 1) TDP1 TDP1
Ataxia with oculomotor apraxia type 1 Aprataxin APTX
Ataxia with oculomotor apraxia type 2 Senataxin SETX
Ataxia with vitamin E def. (AVED) TTP1 alpha-TTP
Charlevoix-Saquenay (ARSACS) Sacsin SACs
Early onset recessive ataxia with hearing Unknown 6p21-23
impairment and optic atrophy
Friedreich’s ataxia type 1 (FRDA) Frataxin Frataxin
Friedreich’s ataxia type 2 (FRDA 2) Unknown 9p23-p11
Infantile onset spinocerebellar ataxia Unknown 10q23.3-q24.1
and sensory neuropathy (IOSCA)
Non-progressive infantile ataxia Unknown 20q11-q13
X-linked sideroblastic anemia with ataxia ATP-binding cassette transporter ABC7
For abbreviations, see last page of this thesis.
The current clinical situation is that many slowly progressive, early-onset spinocerebellar ataxias cannot yet
be classified in detail. Patients with sporadic disease may or may not have recessive disease. Many reces-
sive genes have not yet been found, and even in the case of known genes, the complete genomic sequen-
ce that is required to identify mutations often exceeds the capacity of available DNA diagnostic services.
Phenotypic recognition and classification may help to elucidate the molecular genetics of the early onset
progressive cerebellar ataxias and generate adequate and targeted diagnostic strategies.
We undertook the clinical analysis and classification of clinical variability in a cohort of patients with early-
onset slowly progressive degenerative cerebellar ataxias, without a known metabolic or genetic defect. We
attempted to define certain subgroups that might share a common pathogenesis; a common prognosis;
and to obtain evidence that would support recessive inheritance in the various subgroups. To this end we
investigated a large cohort of patients with ataxia that had visited our clinic for hereditary brain disease from
1994 until 2003.
Patients and methods
We conducted a retrospective chart review of all patients with a slowly progressive cerebellar ataxia who had
visited our out patient clinic, a tertiary referral centre for the Netherlands, and in whom non-degenerative
causes such as multiple sclerosis, alcohol abuse or a slowly growing posterior fossa tumor had been exclu-
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ded. The sampling period was from 1 January 1994 to 31 December 2002. All patients were older than 16
years when they first visited our clinic. Cases were grouped according to clinical features as obtained from
clinical examination or ancillary (primarily neurophysiological) examination.
Patients
All patients with a slowly progressive cerebellar ataxia with onset after the age of 45 were excluded, as many
may ultimately be diagnosed with the cerebellar subtype of multiple system atrophy (MSA) (Wenning et al.
1994; Gilman et al. 1999), a dominant ataxia, e.g. SCA6, or with idiopathic late-onset cerebellar ataxia.
Whereas ‘early onset’ is usually ‘arbitrary’ defined as an age at onset before 25, we now know that autoso-
mal recessive inheritance can also present many years after the age of 25. For this, and as little is known
about the phenotype and pathogenesis of patients presenting with a slowly progressive ataxia starting after
25 and before 45 we decided not to exclude these patients. All patients were examined by one of the authors
(HPHK), and underwent a comprehensive neurological examination. Pedigrees were obtained from the
patients themselves and their accompanying family members, but no additional genealogical studies were
performed. Ancillary tests were performed to exclude other differential diagnoses. These tests were either
performed prior to referral or at our clinic, and included standard clinical chemical and hematological eva-
luation, creatine kinase, thyroid-stimulating hormone, total thyroxin or free thyroxin, lues serology, serum
vitamin E concentration, anti-gliadin IgM serology, serum very long-chain fatty acids, serum lactate, serum
albumin, alpha-fetoprotein, cholesterol and urine organic acid analysis. All patients were screened for muta-
tions in the SCA1, 2, 3, 6 and 7 and frataxin genes. If oculomotor apraxia or elevated levels of alpha-feto-
protein were present, patients were screened for the AOA1 mutation. Patients with spastic ataxia and neuro-
pathy were screened for mutations in the SACs gene, covering mutations 6594delT and 5254C→T, but the
entire gene was not sequenced. In all cases, except one, 1.0 or 1.5-T magnetic resonance imaging of the
brain (standard T1 and T2 sequences) was performed. Those patients with leuco-encephalopathy under-
went additional lysosomal enzyme analysis to investigate possible metabolic storage disorders. Needle
muscle biopsy was performed for histology and mitochondrial DNA analysis only in those patients sus-
pected to have mitochondrial disease. Ophthalmological, cardiological, and otological investigations were
performed as necessary. Nerve conduction studies and electromyography were performed in all but five
patients.
Chart review
Clinical details were extracted from the patient files. Onset age was defined as the age at which the first
motor signs became apparent, as revealed by either the patient’s own recollection or the history provided
by an accompanying family member. Patients were followed up for several years, at 1- or 2-year intervals.
A cerebellar syndrome was defined as the presence of cerebellar ataxia, dysarthria and eye movement dis-
orders such as nystagmus or saccadic pursuit eye movements. Peripheral nerve disease was considered
present if nerve conduction studies were abnormal, or if typical signs were found on clinical examination.
Pyramidal tract lesion was defined as the presence of a Babinski’s sign or, in case of a severe neuropathy
with paresis of the lower leg muscles, a delayed central motor conduction time.
Results
From 1 January 1994 to 31 December 2002 we examined 191 patients with a slowly progressive cerebellar
syndrome with an age at onset younger than 45 years. Of these, 129 were excluded after being diagnosed
with ADCA (n=105) or FRDA (n=24). Of the remaining 62 patients, 11 had other metabolic or characterized
genetic diseases: 2 Mohr-Tranebjaerg syndrome, 2 Niemann Pick type C, 1 episodic ataxia (with negative
family history), 1 mevalonate kinase-deficiency, 2 mitochondrial myopathy and ataxia, 1 mitochondrial com-
plex I deficiency, 1 Klinefelter Syndrome, and 1 multiple sclerosis (despite a referral after initial exclusion).
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Sample description
The remaining 51 patients (20 women, 31 men) formed our study population. The mean age at onset was
16.5 years (median 14.0; range 0-44); mean disease duration at time of the study was 21.4 years (range 4-
48). Females had an earlier disease onset (median 11.0 years, range 0-41 vs. median 16 years, range 0-44,
respectively). Tables 10.2.A and 10.2.B provide the clinical details of the study population.
The presenting symptom was gait impairment in 26 patients (50.9%), speech impairment in 4 patients
(7.8%), tremor in 5 patients (9.8%), dizziness in 3 patients (5.9%), hearing loss in 1 patient (2.0%) and visu-
al impairment in 1 patient (2.0%). Delayed motor milestones were present in 8 patients (15.7%), 7 of whom
had a disease onset before the age of 2 (range 9 months to 2 years). In 3 patients (5.9 %) the first signs could
not be retrospectively assessed. Fourteen patients were older than 25 years at disease onset and this group
presented with walking impediments (11 patients; 78.6%) or speech problems (3 patients; 21.4%). 
The 51 patients came from 45 families. Twenty patients (39.2%) from 14 different families had one or more
similarly affected siblings. In 5 of these 14 families we could investigate all affected family members: 4 fami-
lies consisted of two affected sibs, and 1 family consisted of three affected sibs. In the remaining 9 families
(and patients) only the affected index sibling was investigated; the other affected sibs with similar signs and
disease course were not available for examination. Parental consanguinity was reported in two families only.
At initial examination, 15 patients were wheelchair bound (mean duration after onset till wheelchair: 14.6
years; range: from ‘never been able to walk’ until 34 years), while 36 were still ambulant. The mean dura-
tion from onset till examination was in the wheelchair-bound group 23.6 years, in the wheelchair-indepen-
dent group 20.7 years. Only one patient died while under observation.
Table 10.2 Clinical characteristics study population/baseline details.
Study population %
Number 51
Men vs. women 31 vs 20
Mean age at onset (yr) 16.5
Range age at onset (yr) 0-44
Mean follow up (yr) 21.4
With affected family member 20 39.2
Wheelchair bound 15 29.0
Presenting symptoms:
Gait impediment 26 50.9
Tremor 5 9.8
Vision impairment 1 2.0
Dizziness 3 5.9
Motor milistone delay 8 15.7
Speech impairment 4 7.8
Hearing loss 1 2.0
Unknown 3 5.9
Clinical subtypes
The predominant features, apart from ataxia (the inclusion criterion), were peripheral nerve disease and
pyramidal tract lesion. The 51 patients were grouped according to these predominant signs, culminating
into four subtypes. The first group consisted of patients with an uncomplicated, pure cerebellar syndrome.
Group II consisted of patients with both cerebellar ataxia and pyramidal features (uncomplicated spinoce-
rebellar syndrome). Group III consisted of patients with both cerebellar ataxia and peripheral nerve disea-
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se. This group was further subdivided into those without pyramidal tract dysfunction (group IIIA) and those
with pyramidal tract dysfunction (group IIIB). Group IV consisted of patients with additional clinically
distinct features (other than cerebellar ataxia, pyramidal tract dysfunction or peripheral nerve disease).
Group I: Uncomplicated cerebellar syndrome (Table 10.3).
Seven patients from seven different families showed a pure cerebellar syndrome that consisted of dysar-
thria, ataxia, and ocular movement disturbances, without pyramidal tract lesions, neuropathy, or other
clinical signs. Gait ataxia or dysarthria were the presenting signs. Median age at onset was 19 years (range
14-41 years). None of the patients was wheelchair bound, even though the long mean disease duration of
15.1 years. None of these patients had an affected sib. No parental consanguinity was reported in any of the
families.
Table 10.3 Clinical characteristics of the patients with an uncomplicated cerebellar syndrome (group I).
Sex Age at onset Time from onset Affected Presenting Tendon Wheelchair
(Years) till study (Years) sibs signs reflexes bound
1 M 14 26 1/7 Dysarthria, ataxia Normal -
2 F 41 10 1/3 Dysarthria Absent -
3 F 36 5 1/1 Ataxia Vivid -
4 F 18 18 1/3 Ataxia Vivid -
5 F 38 6 1/2 Ataxia Vivid -
6 F 14 20 1/3 Ataxia Normal -
7 M 19 21 1/8 Ataxia Vivid -
Group II: Uncomplicated spinocerebellar ataxia (Table 10.4).
Eight patients had cerebellar ataxia and a pyramidal tract lesion without clinical or neurophysiological signs
of peripheral nerve disease. Median age at onset was 36.5 years (range 3-42 years). Mean disease duration
at the time of the study was 13.1 years. There was one outlier in this group (nr. 2 in Table 10.4). This patient
was wheelchair bound and had a very early disease onset but disease duration was not significantly diffe-
rent. Apart from this patient, clinical characteristics were similar. Age at onset was well over 25 years, all
patients were male, and none was wheelchair bound. One patient refused an EMG, but there were no cli-
nical signs of neuropathy (nr.1). One patient (nr. 3) had an affected family member that was not seen by us.
No parental consanguinity was reported.
Table 10.4 Clinical characteristics of the patients with an uncomplicated spinocerebellar (cerebellar ataxia and
pyramidal features) syndrome (group II).
Sex Age at onset Time from onset Affected Presenting Sensory Wheelchair
(Years) till study (Years) sibs signs disturbance bound
1 M 37 15 1/4 Ataxia - -
2 M 3 17 1/2 Hypertonia + +
3 M 41 8 2/12 Ataxia - -
4 M 36 4 1/3 Spasticity - -
5 M 40 15 1/3 Dysarthria - -
6 M 42 15 1/3 Ataxia + -
7 M 30 22 1/5 Spastic ataxia + -
8 M 29 9 1/2 Dysarthria, ataxia - -
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Group III (spino) cerebellar syndrome with neuropathy (Tables 10.5A and 10.5B).
Nineteen patients had additional peripheral nerve disease. Four patients (two males and two females) suf-
fered from cerebellar ataxia and neuropathy without pyramidal features (group IIIA). Mean age at onset was
21 years (range 17-28 years). Mean disease duration was 17.3 years. None of the patients had an affected
family member and consanguinity was not reported (Table 10.5A). Although the age at onset and progno-
sis (none was wheelchair bound) might initially suggest a homogenous group, nerve conduction studies
clearly distinguished between these patients. One patient showed a pure but severe sensory axonal neuro-
pathy, a second patient showed a pure motor axonal neuropathy, and two patients had a fairly mild, mixed
motor and sensory axonal neuropathy. 
Table 10.5A Clinical characteristics of patients with cerebellar ataxia and neuropathy, no pyramidal tract lesion
(subgroup IIIA).
Sex Age at onset Time from onset Affected Presenting Neuropathy Wheelchair
(Years) till study (Years) sibs signs bound
1 M 17 32 1/3 Ataxia Axonal, motor -
2 F 17 13 1/4 Ataxia Axonal, mixed* -
3 M 22 15 1/5 Ataxia Axonal, sensory -
4 F 28 9 1/2 Ataxia Axonal, mixed* -
* Mixed, sensory and motor neuropathy.
Fifteen patients suffered from a spinocerebellar syndrome (ataxia and pyramidal features) and neuropathy
(group IIIB; Table 10.5B). The group consisted of seven males and eight females. Median age at onset was
3 years (range 1-16 years). Mean disease duration was 29.3 years. Nine patients were wheelchair bound
(60%); mean disease duration from onset to being wheelchair bound was 17.4 years (range, 7 to 23 years)
(see Table 10.5B). Nerve conduction studies, performed in all patients in this group, revealed a highly uni-
form picture with absent sensory nerve action potentials (SNAPs) and compound muscle action potentials
(CMAPs) in the lower extremities and reduced SNAPs and CMAPs in the upper extremities. Conduction
velocities were slowed, but were still compatible with an axonal type of neuropathy. Only one patient dis-
played a pure sensory neuropathy. In one patient (nr. 13) asymptomatic mitral valve prolapse was discove-
red during cardiological evaluation. The fifteen patients came from 10 separate families and 10 of the
patients had an affected family member. In one case (nr. 13), the affected sibling was not seen by us. One
family had three affected members (nr. 1, 2 and 3); the other families had two affected members.
Consanguinity was present in 4 patients (nr. 8 and in the three affected siblings, nr. 1, 2, 3). Thus, recessive
inheritance was proven in 11 of these 15 patients.
Group IV: (Spino) cerebellar syndrome with complex features
The 17 patients who had other features besides (spino) cerebellar ataxia or neuropathy were clustered in a
clinically heterogeneous group, group IV. The additional features were both neurological and non-neurolo-
gical (see Table 10.6). Five male and one female patients suffered from a progressive cerebellar ataxia toge-
ther with myoclonus (‘Ramsay-Hunt syndrome’)(nr. 5, 12, 13, 14, 15 and 16). The 11 other patients in group
IV could not be placed into known clinical entities. Five patients were mentally retarded and one patient suf-
fered from hypogonadism. In 5 patients various forms of retinal degeneration were found, In 1 patient there
was hyperphoria and 3 patients suffered from cataract. 
Various patients showed extrapyramidal signs: blepharospasm, dystonia, torticollis (and myoclonus). Four
patients suffered from epilepsy. Hearing loss was noted in 5 patients. Most patients in this group showed
more than one other feature. One patient (nr. 10) died of renal failure during follow up; the renal problems
were not considered to be associated with the cerebellar syndrome. 
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Table 10.5B Clinical characteristics of patients with a spinocerebellar (cerebellar ataxia and pyramidal features)
syndrome and neuropathy (group IIIB). 
Sex Age at onset Time from onset Affected Presenting Neuropathy Wheelchair
(Years) till study (Years) sibs signs bound
1 F 1 21 3/3 Ataxia Axonal, mixed* +
2 M 1 21 3/3 Ataxia Axonal, mixed* +
3 F 2 24 3/3 Ataxia Axonal, mixed* +
4 F 3 23 2/2 Ataxia -
5 M 12 30 2/9 Ataxia Axonal, sensory +
6 F 3 25 1/2 Ataxia Axonal, mixed* +
7 M 6 33 2/9 Ataxia Axonal, mixed* -
8 F 3 35 1/2 Ataxia Axonal, mixed* -
9 M 12 37 2/3 Spastic ataxia Axonal, mixed* +
10 F 1 24 2/2 Spastic ataxia Axonal, mixed* -
11 F 1 33 1/3 Ataxia Axonal, mixed* +
12 M 1 45 2/3 Ataxia Axonal, mixed* -
13 F 10 30 2/2 Eye movement- Axonal, mixed* +
disorders
14 M 16 20 1/3 Ataxia Axonal, mixed* +
15 M 8 38 1/5 Ataxia Axonal with -
demyelinating
features, mixed*
* Mixed: sensory and motor neuropathy.
Discussion
An early onset, degenerative ataxia that is slowly progressive over many years presents a formidable challenge
to clinicians in terms of diagnoses to be considered. Most, if not all, patients may suffer from hereditary dise-
ase, but once Friedreich’s ataxia has been excluded (together with dominant forms) it becomes difficult to
make a correct diagnosis. A number of additional recessive genotypes have been established in the recent
years (Table 10.1) but the molecular diagnoses and work-up still present many practical problems. Complete
sequencing, including exon / intron boundaries, exceeds the capacity of individual routine DNA diagnostic labs.
We analyzed a sample of patients with early onset, over many years slowly progressive degenerative cere-
bellar ataxia, without or with associated neurological features. Whereas ‘early onset’ is usually arbitrarily
defined as an age at onset before 25 (Harding 1984), we now know from Friedreich’s ataxia that autosomal
recessive ataxia can also present many years after the age of 25. For this reason, and in order to be as com-
prehensive as possible in our clinical grouping, we decided to include patients with onset up to age 45. We
assumed that later onset would yield many patients with multiple systems atrophy, as well as cases with
possible dominant disease. 
It may be assumed that almost all patients with such early onset ataxia suffer from hereditary recessive dise-
ase, once dominant disease has been excluded. We grouped sporadic together with familial cases. Twenty
out of the 51 cases had at least one affected sib, while in 1 sporadic patient parental consanguinity made
recessive disease very likely. Thus, in our sample, 40 % of cases represented proven recessive cases. 
Contrary to FRDA, the clinical progression and outcome of our cases appears to be relatively mild. Only one
out of our 51 patients died (of a non-neurological cause), and 36 were still ambulant after many years of
disease. The presence of a severe sensory and motor axonal neuropathy that was found in 15 patients had
a clearly negative influence on mobility. This relatively benign course of the disease has been documented
previously (Harding, 1981; Klockgether et al 1998).
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Table 10.6 Clinical characteristics of the patients with cerebellar ataxia, and additional neurological and non-
neurological features (group IV).
Sex Age at Time from Affected Presenting Neuro- Babinski Additional Wheel
onset onset to sibs signs pathy sign features -chair
(Yrs) study (Yrs) bound
1 M 27 27 1/2 Ataxia - + Retinal -
degeneration
2 M 44 25 2/5 Ataxia Motor axonal - Blepharospasm -
3 M 25 22 2/7 Eye n.p. - Hypogonadism, -
movement cataract
disorder
4 M 18 17 1/2 Ataxia and - - Hearing loss, -
deafness hyperforie
5 M 14 4 1/3 Myoclonus Mixed - Mental retardation, +
mental axonal myoclonus, epilepsy,
retardation retinal degeneration
6 F 15 10 2/2 Visual loss, n.p. + Hearing loss, -
retardation visual loss,
mental retardation
7 F 3 29 2/2 Ataxia Mixed axonal + Cataract -
8 M 11 19 1/2 Visual loss n.p. - Retinal degeneration, +
Hearing loss, epilepsy
9 M 2 26 2/2 Spastic Mixed axonal Cataract, -
ataxia mixed + mental retardation
10 F 31 11 3/6 Ataxia Mixed axonal - Retinitis pigmentosa, -
epilepsy
11 M 7 44 2/11 Ataxia - - Retinal degeneration, + 
12 M 0 48 1/12 Mental - - Mental retardation, -
retardation myoclonus, opticopathy
13 M 15 27 1/2 Myoclonus - - Myoclonus, +
hearing loss, epilepsy,
dystonia
14 M 16 16 2/2 Myoclonus Mixed axonal + Myoclonus -
15 F 12 10 2/2 Myoclonus n.p. + Torticollis, myoclonus -
16 M 1 18 1/2 Ataxia - - Mental retardation, 
myoclonus
17 F 0 25 1/3 Hypertonia - + Hearing loss
* Mixed: sensory and motor neuropathy.
Table 10.7A tentative new classification for autosomal recessive ataxia.
I Uncomplicated cerebellar syndrome
II Uncomplicated spinocerebellar syndrome
III (Spino)cerebellar syndrome with neuropathy
IIIA Without pyramidal features
IIIB With pyramidal features
IV Complicated (spino) cerebellar syndrome, with or without neuropathy, and with prominent 
additional non-ataxic features
We grouped our patients into four subgroups, on the basis of relatively simple clinical features as well as
neurophysiological studies (Table 10.7): uncomplicated cerebellar ataxia, uncomplicated spinocerebellar
ataxia, (spino)cerebellar ataxia with neuropathy, and complicated forms of (spino)cerebellar ataxia. In
patients with an uncomplicated, or pure, cerebellar syndrome (group I) the age at onset was relatively late,
between 14 and 41 years. Progression was slow and clinical outcome remained good. None of these
patients died, and all were still ambulant at the time of the first clinical examination. No family members
were known to be affected. Thus, patients with an isolated and uncomplicated cerebellar ataxia and an age
at onset in the second, third, or fourth decade, may represent a non-hereditary disease, akin to what has
been termed Idiopathic Late Onset Cerebellar Ataxia (ILOCA; Harding 1981(c)). In patients with uncompli-
cated spinocerebellar syndrome (group II), the clinical characteristics were again quite distinct, apart from
one outlier. As in patients with an isolated cerebellar syndrome (group I), disease progression also seemed
to be slow and to lead to a relatively benign disease. Age at onset, again, was after 25 years, and none was
wheelchair bound. The fact that all patients were male may represent an X-linked inheritance, although the
total number of 8 patients is small and it can also be a statistical anomaly. X-linked ataxia with sideroblastic
anemia should be considered in the differential diagnosis (Pagon et al. 1985), but the age at onset and the
absence of anemia and mental retardation excludes this possibility.
In the patients with cerebellar ataxia and neuropathy (group III), a further differentiation was made between
those without (group IIIA) and those with (group IIIB) pyramidal features. Group IIIA consisted of only four
patients with highly variable nerve conduction findings. Age at disease onset ranged from 17 to 28 years.
None of the patients was wheelchair bound. Group IIIB was fairly large and strikingly homogenous. Age at
onset in this group was infancy to 16 years. The mean disease duration was 19 years while 60 percent of
patients were wheelchair bound. This suggests that progression to disability is faster than in the other
groups. Nine patients showed unambiguous recessive inheritance. Clinical features, including the severe
sensory axonal neuropathy, could be compatible with autosomal recessive spastic ataxia of the Charlevoix-
Saguenay type (ARSACS; Bouchard et al 1998). Unlike ARSACS, however, none of these patients showed a
clinically relevant spastic paraparesis and none showed prominent retinal myelinated fibers. Subclinical
mitral valve prolaps was showed in only one patient. None of the patients carried the ARSACS mutations
(6594delT and 5254C→T), had hypo-albuminemia or elevated alpha-fetoprotein, or AOA1 mutations. It was
not possible to sequence the entire sacs-gene, but the phenotype seemed different from the patients des-
cribed with other mutations in the sacs gene (no dementia or oculomotor symptoms). AOA2 mutations
were also not assessed, but none of the patients had the characteristic oculomotor disorder nor an eleva-
ted alpha-fetoprotein level. The absence of pyramidal features and the type of neuropathy clearly distin-
guished group IIIA from group IIIB, and this distinction may be important in the assessment of the prog-
nosis. 
The clinical features of group IV were highly diverse. The impairment of these patients was caused as much
by the additional features such as loss of vision, hearing loss or mental retardation, as by the ataxia.
We conclude that four clinically different phenotypes of slowly progressive cerebellar ataxia can be distin-
guished. Because phenotypic characteristics such as disease onset, progression and clinical characteristics
are fairly compatible at least for group I, IIB, and III it may be assumed that the patients in these subgroups
share a similar pathogenesis. We cannot exclude the possibility that at least some of the patients within
these groups represent cases of ARSACS, AOA1 or AOA2, but we strongly suspect that yet unknown geno-
types are represented as well. The clinical differentiation between these subgroups is important for patient
counseling regarding prognosis and might also be important for research. Those with an uncomplicated
cerebellar syndrome that starts in the second, third or fourth decade, as well as those with a spinocerebel-
lar ataxia without peripheral nerve disease fare definitely better than those with neuropathy or auditory, oph-
thalmological or mental impairment. 
Acknowledgements: AOA1 mutation analysis was performed by Dr. D. Dooijer, Dept. of Clinical Genetics,
Erasmus University Medical Center, Rotterdam.
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Summary
This thesis presents the results of clinical and genetic research into various autosomal dominant and auto-
somal recessive cerebellar syndromes. The thesis starts with the recognition that ‘inherited cerebellar
ataxia’ always has been (Section I; chapter 1) and still is a bewildering complex neurological syndrome. The
aim of the study was to unravel several aspects of this complex syndrome and defined as ‘expanding the
knowledge regarding the pheno and genotype of the autosomal dominant and autosomal recessive spino-
cerebellar syndromes’. Before being able to tackle the issue of expanding knowledge a review of the litera-
ture concerning the current state of the autosomal dominant (chapter 2) and autosomal recessive cerebel-
lar disorders (chapter 3) is necessary, and provided. Then different aspects, covering the genotype of the
dominant spinocerebellar syndromes (section II), the pathofysiology of the dominant spinocerebellar syn-
dromes (section III), and phenotype recognition of the recessive cerebellar syndromes (section III), are
covered in three sections.
In Section II, we focused on the issue that in about thirty percent of dominant spinocerebellar syndromes
a mutation cannot be found. These patients cannot be classified according to the SCA classification and
both their diagnosis and prognosis remain surrounded with uncertainty. We tried to tackle this issue by
searching for a new locus in a Dutch ADCA pedigree that could not be assigned to any of the known loci. 
In the first chapter of this section (chapter 4) the clinical, neuropsychological, MRI, and neurophysiologic
data of this family are described. The clinical features are dominated by a relatively mild cerebellar syndro-
me, frontal cognitive dysfunction and myoclonus. 
In chapter 5 we documented the linkage analysis for the above-mentioned Dutch ADCA family. No repeat
expansion could be detected in the SCA1, 2, 3, 6, 7, 8, 12, 14 and 17 genes. The remaining SCA loci, for which
mutations still have to be identified, were excluded by 2-point linkage analysis. By further linkage studies
evidence for a new locus was found on chromosome region 1p21-1q21. The new locus was assigned SCA19,
and current evidence suggests that it may be a new SCA with a worldwide distribution (Schelhaas et al.
2004).
In Section III, we addressed some pathophysiological aspects regarding the dominant spinocerebellar syn-
dromes. For this, we focused our attention on SCA3 and SCA6. SCA3 and SCA6 are the two SCAs with the hig-
hest prevalence in the Netherlands and current evidence suggests that their pathogenesis might be different.
Although the neuropathology of SCA3 shows considerable variation, some generalizations can be made
(chapter 6). For example, while the cerebral cortex is typically spared, the anterior horn is usually affected.
This pattern of neurodegeneration made it possible to determine whether the clinical feature of a ‘split
hand’ has localizing value. The ‘split hand’ refers to a type of atrophy by which the muscles of the lateral
aspect of the hand are affected more than those of the medial aspect. Initially, the phenomenon was con-
sidered to be specific for anterior horn disease but, as the thenar and hypothenar muscles have the same
segmental supply and a different cortical presentation, it could also be of cortical origin. We observed this
phenomenon, both clinically and electrophysiological, in five consecutive patients with SCA3. As we were
able to confirm our observation in patients with two other disorders that are characterized by a ‘compara-
ble pattern’ of neurodegeneration, we concluded that muscle atrophy in a split hand distribution points to
a spinal, instead of cortical, origin.
Whereas in chapter six the ‘general’ pathology of SCA3 was sufficient to explain an interesting clinical
aspect of the disorder, in chapter 7 the neuropathology is addressed in far more detail. The central issue in
this chapter is the relation between celdeath, the presence of neuronal intranuclear inclusions (NII) and the
expression of cytokines and transcription factors.
Like various other SCAs, SCA3 is caused by a translated unstable CAG trinucleotide repeat expansion. The
translation of the CAG repeat in an expanded polyglutamine stretch leads to conformational changes of the
protein (ataxin-3), with subsequent formation of NII. While initially, NII was considered a prerequisite for
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neurodegeneration in all CAG repeat disorders, recent data suggest a more complex picture. Additional fac-
tors, such as transcriptional dysregulation, appear to contribute to the pathogenesis of these disorders. To
clarify the functional significance of transcriptional dysregulation in relation to cell loss and the occurrence
of NII, we investigated the expression of these factors in several regions of normal, and SCA3, human brain
and spinal cord. In SCA3 brains, NII were found almost exclusively in brain regions that also showed neuro-
nal cell loss. In the pons, NII were less frequent in SCA3 brains with severe neuronal cell loss, suggesting
that NII-bearing neurons have a higher probability to die. Increased expression of IL-1ß and related proteins
was confined to the pons and dentate nucleus, two brain regions heavily involved in neurodegeneration.
Within the pons, increased IL-1ß expression occurred both in neurons with and without NII. There was no
generalized up regulation of cytokines or increased microglia in SCA3 brains, and in some brain regions
undergoing severe neurodegeneration such as the pallidum, cytokine expression was not increased. Taken
together, we concluded that the occurrence of NII and enhanced cytokine expression are cellular events
associated with neurodegeneration in specific affected brain regions of SCA3. Neither of the two however,
appeared to be a necessary or sufficient condition for neuronal cell death. 
In chapter 8, we focused on SCA6. SCA6 is caused by a small CAG expansion in the CACNA1A gene enco-
ding the α1A-subunit of the P/Q-VGCC. P/Q-VGCCs are widely expressed, not only in the CNS, but also at
the neuromuscular junction. The presence of P/Q-VGCCs at motor nerve terminals suggests that neuro-
muscular transmission might be compromised in SCA6. If so, this could have major clinical and scientific
consequences. For this, we investigated neuromuscular function in ten patients with SCA6. Abnormalities
in neuromuscular transmission were not detected and thus our study indicates that SCA6 results from
CNS-specific disease pathways. 
In Section IV, we studied the phenotype of the autosomal recessive spinocerebellar syndromes. 
The discovery of the frataxin gene and the suggestion of a worldwide occurrence of the genes for AOA1,
AOA2 and ARSACS suggest that a genetic classification for the autosomal recessive cerebellar syndromes
is only a matter of time. Until then some guidance for a realistic clinical work up (chapter 9), and a clinical
classification system seems essential for patient care (chapter 10).
In chapter 9 we performed nerve conduction and EMG studies in 15 patients with NF-EOCA. The clinical
and neurophysiological data clearly differentiated three phenotypes: group 1 with retained tendon reflexes
and normal conduction studies; group 2 with an onset in the second decade, absence of foot deformities,
and a mild motor axonal neuropathy; and group 3 with pyramidal and ataxic features and a severe sensory
and motor axonal neuropathy. The presence and type of neuropathy has differential diagnostic consequen-
ces and, therefore, might guide additional tests. Whether this distinction also reflects a fundamental phe-
notypic difference and thus can be used to guide future DNA studies remains to be established.
In order to develop a useful clinical classification system for EOCA patients we re-evaluated the clinical fea-
tures, progression, and neurophysiological findings of 51 EOCA patients that visited our outpatient clinic
over a period of nearly 10 years (chapter 10). Patients with an uncomplicated cerebellar syndrome appeared
to have a slow disease progression and a good clinical outcome. Most patients with cerebellar ataxia and
neuropathy are wheelchair-bound and only a few are still ambulant. We concluded that in those patients
with autosomal recessive ataxia, in whom extensive testing has excluded metabolic or genetic disorders, a
clinical classification system is important for counseling concerning the expected prognosis. 
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Discussion (clinical approach)
In the last phrase of the section ‘aims of the study’ we promised that we would try to provide a clinical
algorithm for both the autosomal dominant and autosomal recessive cerebellar disorders. Whereas the
algorithms that are described in this chapter are based on acquired experience and available literature, the
usefulness of the approach has not been confirmed by a prospective study. For this, the clinician should
realize that these algorithms can be used for the clinical work-up but should not be looked upon as a fixed
set of knowledge. 
Anatomy
The afferent and efferent connections of the cerebellar cortex are topographically organized, resulting in
functional specialization of different parts of the cerebellum. For example, dysfunction of the lower vermis
(vestibulocerebellum) leads to truncal ataxia; spinocerebellar lesions (upper vermis and anterior parts of
hemispheres) lead to unsteadiness of gait and stance; and neocerebellar damage (cerebellar hemispheres)
leads to ataxia of intended limb movements. A logical first step in the management of patients with a cere-
bellar ataxic syndrome would be to localize the lesion. However, while knowledge of the topographical orga-
nization of the cerebellum might be helpful in localizing the lesion in focal cerebellar disease, it is only of
limited value in the differential diagnosis of non-focal cerebellar disease, such as cerebellar degeneration. 
Therefore, and generally accepted, the first step in the work up of patients with a hereditary cerebellar syn-
drome is the determination of the age at onset. While the autosomal recessive cerebellar ataxias usually
start before the age of 25, the age at onset in patients with ADCAs is usually after the age of 35 (Klockgether
et al. 1998). In the following clinical approach we arbitrarily choose 30 years to be the cut-off between early-
and late-onset ataxia. 
Late-onset cerebellar ataxia
In those patients with a late onset of symptoms, the first step is to establish the family history (figure 11.1).
Is there evidence for an autosomal dominant disorder? In patients with a proven autosomal dominant
mode of inheritance, diagnostic tests can be restricted to a small number of molecular genetic tests. If tests
for SCA mutations are negative, dentatorubral-pallidoluysin atrophy (DRPLA) or Gerstmann-Straussler-
Scheinkler disease (GSS) should be considered. After the exclusion of these two disorders, on the basis of
clinical features, or DNA analysis (Table 11.2), available molecular tests will remain negative in up to 30%
of ADCA families. If this is the case, the family probably suffers from an as yet unidentified SCA mutation.
In these patients further classification will only be possible in a large pedigree that allows linkage studies. 
In the absence of a family history suggestive of an autosomal dominant disorder, de novo SCA mutations
are not excluded. They have been described for various SCAs but they are considered rare. Therefore, in
patients above 50, we would not propagate further DNA analysis. In these patients the most likely diagno-
sis is multiple system atrophy (MSA) or idiopathic late-onset cerebellar atrophy (ILOCA). These two disor-
ders can be differentiated by the absence (ILOCA) or presence (MSA) of autonomic failure. In those
patients with a tremor, fragile-X tremor ataxia syndrome (FXTAS) might also be considered. In patients with
an age at onset between 35 and 50 we would usually perform DNA analysis to exclude SCA1, 2, 3, 6, 7, 14
and 17. Certainly at this age, a diagnosis of MSA and ILOCA can only be made ‘per exclusionem’. 
Early-onset cerebellar ataxia
Most cases of early-onset sporadic ataxia are manifestations of an autosomal recessive disorder. Although
early-onset cerebellar ataxia may occur as an acquired disease, (Klockgether et al. 1993) or may be due to
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Figure 11.1 Tentative algorithm for the clinical approach to patients with late-onset (>30 years), non-focal, slowly
progressive, spinocerebellar syndromes. 
ILOCA. Consider unidentified
SCA mutation i.e. SCA-6,
FXTAS (in case of tremor)
maternal (mitochondrial disease), X-chromosomal (adrenoleukodystrophy) (Kurihara et al. 1993), or auto-
somal dominant inheritance, this is considered rare and will usually be evident from the patient’s history.
As a first step in the clinical approach of these patients, additional studies should be performed, the extent
of which is much debated (figure 11.2). As FRDA is the most common early-onset hereditary cerebellar syn-
drome, even if the phenotype is not classic, we would propagate DNA analysis to exclude a GAA repeat
expansion in the frataxin gene (Table 11.2). 
In our approach nerve conduction studies are recommended as the second step in the work up of these
patients. The reason for this is that the presence and type of neuropathy has important differential dia-
gnostic consequences. The differential diagnostic considerations that are brought up by the presence or
absence of neuropathy should guide the next set of additional diagnostic tests (third step). For example, in
case of a severe demyelinating neuropathy, lysosomale analysis to exclude Krabbe’s disease should be per-
formed. 
In the absence of a neuropathy the next step is to see whether the neurological and non-neurological fea-
tures are characteristic of a specific clinical syndrome. Although most of these syndromes are clinically and
genetically heterogeneous, the combination of features might provide information about the underlying
cause. Examples of some, more generally accepted, clinical syndromes, together with their differential dia-
gnoses, are given in Table 11.1.
Table 11.1 Differential diagnosis of clinical syndromes with early-onset cerebellar ataxia as a prominent feature. 
Syndrome Additional clinical Differential diagnostic considerations
symptom(s)
Behr Optic atrophy and 3-methylglutaconic aciduria
mental retardation (especially type I and type III)
Boucher Neuhauser Hypogonadotrophic
hypogonadism and Hypocalciuric hypercalcemia.
choroideo-retinal ‘Mitochondrial disorders’
degeneration 
Holmes Hypogonadism ‘Mitochondrial disorders’, infantile 
onset spinocerebellar ataxia
Marinesco-Sjogren Congenital cataract, CCFDN, ‘mitochondrial disorders’
mental retardation
and muscle weakness
Ramsay Hunt Myoclonus Lafora disease, progressive myoclonus epilepsy of
Unverricht-Lundborg (EPM1), MERRF, sialidosis type 1,
ceroid lipofuscinosis, DRPLA 
For abbreviations: see last page of this thesis. For diagnostic tests see table 11.2. For references: see also chapter 9.
this work-up does not provide a classifying diagnosis, again additional test have to be performed to exclude
some treatable disorders. Examples of these are vitamin E analysis (reduced in AVED and abetalipoprotei-
naemia), phytanic acid (Refsum disease), ceruloplasmin (Wilson disease) and anti-gliadin/anti-endomysium
antibodies (celiac disease).
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Figure 11.2 Tentative algorithm for the clinical approach to patients with an early-onset (< 30 years), non-focal,
slowly progressive spinocerebellar syndrome.
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Table 11.2 Differential diagnostic considerations of hereditary cerebellar syndromes. 
Syndrome Additional prominent Diagnostic tests
clinical symptom(s)
Abetalipoproteinemia Failure to thrive, Acanthocytes in blood smear, low total
malabsorbtion syndrome cholesterol, undetectable triglycerides, absent
low-density and very low-density lipoprotein 
AOA1 Oculomotor apraxia DNA analysis 
AOA2 Oculomotor apraxia Alpha fetoprotein in serum (always ↑)
ARSACS Spasticity, prominent Combination of clinical features,
myelinated fibers in DNA analysis (research)
the optic fundus
AT Oculomotor apraxia ↑ Alpha fetoprotein (90 percent of patients)
AVED Friedreich-like ↓ Vit E, normal levels of vit A,D,K, triglycerides, 
cholesterol, DNA analysis
CCFDN Congenital cataract, Combination of clinical features
mental retardation, and DNA analysis (Varon et al. 2003)
muscle weakness
CDG Extreme variable Transferin isofocussing
Ceroid lipofuscinose Psychiatric and Lysosomal analysis, skin or muscle biopsy
extrapyramidal features,
myoclonus
Celiac disease Extreme variable, Anti endomysisium-, anti gliadin antibodies,
gastrointestinal ↓ Vit E, intestinal biopsy
disturbances, neuropathy
CTX Cataract, chronic diarrhea, ↑ cholestanol in urine
tendon xanthomas, 
psychiatric and 
pyramidal features
DRPLA Autosomal dominant DNA analysis
inheritance, myoclonus
EA-1 Myokymia DNA analysis
EA-2 Interictal nystagmus DNA analysis
EPM1 Myoclonus Clinical features, regional distribution (Finland),
DNA analysis (Lalioti et al. 1997)
FRDA Sensory neuropathy DNA analysis
FXTAS Age>50, intention tremor, DNA analysis
cognitive decline 
(Hagerman et al. 2001a)
GSS Autosomal dominant CSF: ↑ Tau, ↑ 14-3-3 protein,
inheritance, dementia DNA analysis
Hexosaminidase Motor neuron disease, Lysosomal analysis
deficiency cognitive impairment, 
dystonia
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Syndrome Additional prominent Diagnostic tests
clinical symptom(s)
Hypocalciuric Hypogonadotrophic Elevation of serum calcium levels, low urinary 
hypercalcaemia hypogonadism and Ca excretion, DNA analysis
choroideo-retinal 
degeneration
IOSCA Sensory neuropathy, Diagnosis is based on the combination of 
hypogonadism clinical features and genetic background 
(only encountered in Finland)
Krabbe (globoid cell Pyramidal features Lysosomal analysis
leukodystrophy)
Lafora disease Myoclonus Skin biopsy (lafora bodies)
3-Methylglutaconic Optic atrophy and Elevated urinary levels of 3-methylglutaconic acid,
aciduria (especially mental retardation 3-methylglutaric acid and 3-hydroxyisovaleric acid
type I and type III)
‘Mitochondrial disorders’ Extreme pleiomorphic ↑ lactate, pyruvate and alanin in serum. 
Increased aminoaciduria, muscle biopsy
MERFF Myoclonus, hearing loss, See ‘mitochondrial disorders’, 
muscle weakness DNA analysis (serum)
Metachromatic Psychiatric features, Lysosomal analysis 
leukodystrophy cognitive impairment, (arylsulfatase A deficiency)
(adult onset) white matter lesions
Neuroacanthocytosis Chorea and cognitive Acanthocytes in fresh blood smear
changes
NF-EOCA Slow progression, Diagnosis per exclusionem
cerebellar atrophy on MRI
Niemann Pick type C Mental impairment, Lipid storage in macrophages
supranuclear vertical (bone marrow aspiration, liver biopsy)
gaze paralysis
Refsum disease Retinitis pigmentosa, ↑ Phytanic acid
anosmia, neuropathy
SCAN1 Severe axonal neuropathy ↑ Cholesterol, ↓ albumin. 
DNA test only available in research setting
Sialidose type 1 Myoclonus, retina: Lysosomal analysis
‘cherry-red spot’
‘Urea cycle defects’ Various and often related Hyperammonemia
to ↑ammonium
Vit E dependent ataxia Sensory neuropathy ↓ Vit E
(see also AVED, 
Abetalipoproteinemia)
Wilson Extrapyramidal features ↓ Ceruloplasmin in serum, ↑urine copper 
excretion, increased hepatic enzymes
For abbreviations see last page of this thesis. 
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Finally, if additional tests remain negative the ultimate step is to realize that a definite diagnosis cannot be
made in a considerable number of patients. These patients are usually diagnosed as early-onset cerebellar
ataxia (EOCA). To prevent confusion with the original description of EOCA, we prefer to use the term NF-
EOCA to describe this heterogeneous group of patients. The clinical syndrome of these patients is charac-
terized by an early onset (first-, second-, or, rarely, third-decade), slowly progressive cerebellar syndrome
(over decades), with or without pyramidal features and often, but not always, a relatively severe axonal,
neuropathy. (Chapter 9) Typically, cerebral MRI in these patients show prominent cerebellar atrophy. Follow
up of these patients is recommended as rapid progression excludes a ‘diagnosis’ of NF-EOCA.
Conclusions and future research
The degenerative ataxias are a clinically and pathophysiologically heterogeneous group of neurological dis-
orders. After decades of classificatory confusion, molecular analysis has identified some of the loci and
genes involved, providing the basis for a new classification. This is particularly true for the autosomal domi-
nant spinocerebellar ataxias as about 70 percent of these families can now be classified in terms of the
genetic mutation involved (SCA). For the remaining 30 percent of these families, the identification of addi-
tional loci and genes, such as the SCA19 locus, is important in order to improve diagnostic possibilities and
to provide adequate genetic counseling. The identification of new genes will undoubtedly also provide fur-
ther insight into the pathophysiology of the autosomal dominant spinocerebellar ataxias.
Now the basis of the genetic classification for autosomal dominant spinocerebellar ataxias is well establis-
hed, research has focused on the pathophysiological process that starts with the genetic mutation and
which results in the selective degeneration. A major breakthrough came with the discovery of the distin-
guishing pathological hallmark of these disorders, that is, neuronal intranuclear inclusions (NII). Although
an increased propensity to form aggregates is a common feature of nearly all polyglutamine disease pro-
teins, the role of NII is still far from clear. In this thesis, we showed that the presence of NII and enhanced
cytokine expression are cellular events that are associated with neurodegeneration in the specific brain
regions affected in SCA3. However, neither NII nor enhanced cytokine expression appeared to be necessa-
ry or sufficient to cause neuronal cell death. Indeed, although current evidence suggests that specific poly-
glutamine-dependent, NII-associated, protein-protein interactions contribute to disease pathogenesis, the
mechanisms underlying the neurodegeneration seen in the SCAs remain to be identified. 
Finally, the ultimate step of clinical research is to look for treatment options, in this case for the degenera-
tive ataxias. Although suggestions for treatment are often greeted with skepticism, the successful treatment
of extrapyramidal features in patients with SCA2 and SCA3 (Svetal et al. 2003), the transient improvement
seen in patients with SCA2 treated with zolpidem (Clauss et al. 2004), and the responsiveness of patients
with SCA 6 to acetazolamine (Jenn 1998) should be considered as a first step in the right direction.
It is anticipated that a similar development will occur for the autosomal recessive cerebellar ataxias, which
are suspected to show an even greater genetic heterogeneity than the autosomal dominant phenotype. At
the moment, emphasis is still on clinical recognition and the update of clinical classification systems; howe-
ver, the discovery of the genes for FRDA, ARSACS, AOA1, AOA2, and SCAN1 suggests that a genetic clas-
sification system will only be a matter of time. Ultimately, again in line with the ADCAs, such a genetic clas-
sification will lead to a better understanding of the underlying pathophysiology and to the development of
treatment options.
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Samenvatting
De patiëntengroep die lijdt aan een erfelijke aandoening van de kleine hersenen (cerebellum) is zeer hetero-
geen. De overeenkomst in deze groep is het verschijnsel ataxie (taxis: orde): het ontbreken van geordende
spraak, schrift (slordig en groot), oogbewegingen en bewegingen van romp en extremiteitspieren (“lopen
als een dronkeman”). De verschillen binnen deze groep van aandoeningen bestaan onder andere uit een
verschil in de beginleeftijd waarop de klachten zich presenteren (vroege beginleeftijd, versus late begin leef-
tijd), de manier van overerving (meestal autosomaal recessief bij een vroeg debuut en autosomaal domi-
nant bij een laat debuut) en bijkomende verschijnselen (bijvoorbeeld spasticiteit). 
Om kennis over deze groep van aandoeningen te vermeerderen zonder de rode draad te verliezen start het
proefschrift in sectie I met een literatuuroverzicht van de autosomaal dominante (hoofdstuk 2) en autosomaal
recessieve (hoofdstuk 3) cerebellaire aandoeningen. Daarna worden verschillende klinische, neurofysiolo-
gische, genetische en pathologische aspecten van deze groep van aandoeningen behandeld in drie secties.
In sectie II wordt ingegaan op het feit dat in ongeveer 30 procent van de autosomaal dominante cerebel-
laire ataxie (ADCA) families geen mutatie kan worden aangetoond. Deze families kunnen niet worden
geclassificeerd volgens de zogenaamde spinocerebellaire ataxie (SCA) classificatie. Door het verrichten van
klinisch en genetisch onderzoek in een grote Nederlandse ADCA familie waarin de bekende SCA mutaties
waren uitgesloten probeerden wij een nieuw gen te vinden dat wellicht een deel van deze 30 procent zou
kunnen verklaren.
Hiertoe beschrijven wij in hoofdstuk 4 de klinische, neuropsychologische, neurofysiologische en MRI gege-
vens van deze familie. De klinische verschijnselen worden gedomineerd door frontaal cognitieve disfunc-
tie, een relatief mild cerebellair syndroom en myoclonus.
In hoofdstuk 5 beschrijven we het genetisch onderzoek in de bovengenoemde Nederlandse familie. Zowel
bekende mutaties met een verlengde (geëxpandeerde) trinucleotide herhaalsequentie (‘repeat’), als overige
SCA loci waarbij het gen nog niet geïdentificeerd is, konden worden uitgesloten. Bij verder koppelings-
onderzoek werden er harde aanwijzigen gevonden voor een nieuw locus op chromosoom 1 (1p21-1q21). Het
nieuwe locus werd aangemeld bij de ‘HUGO Genome Nomenclature Committee’ en toegekend als SCA19.
Inmiddels werd dit locus ook gevonden in een Chinese SCA familie, hetgeen suggereert dat de aandoening
wellicht wereldwijd zou kunnen voorkomen.
In sectie III wordt de aandacht verlegd van genetische mutatie naar het fenotype en de pathofysiologie van
de twee meest voorkomende SCAs in Nederland; SCA3 en SCA6. 
Met betrekking tot het fenotype van SCA3 ontdekten wij dat veel patiënten met SCA3 het verschijnsel ver-
toonden van wat in de Angelsaksische literatuur ‘the split hand’ wordt genoemd (hoofdstuk 6).
De term ‘split hand’ verwijst naar een patroon van handspieratrofie waarbij het laterale deel van de hand
meer is aangedaan dan het mediale deel. Aanvankelijk werd dit fenomeen in de literatuur beschouwd als
zijnde specifiek voor een aandoening waarbij de motorische voorhoorn cel betrokken is. Later werd, op the-
oretische basis en ondersteund door onderzoek, gesuggereerd dat de ‘split hand’ een corticale origine zou
hebben. Bij overleden patiënten met SCA3 blijkt nagenoeg altijd dat de hersenschors gespaard blijft terwijl
het ruggenmerg, en dan met name de motorische voorhoorn cel, degenereert. De aanwezigheid van een
‘split hand’ bij patiënten met SCA3 suggereert daarom veeleer een spinale (motorische voorhoorn), dan
corticale origine van dit klinisch fenomeen. Deze suggestie werd later bevestigd bij tien patiënten met een
andere aandoening maar met een vergelijkbaar patroon van neurodegeneratie (cortex niet aangedaan,
motorische voorhoorn wel aangedaan). 
In hoofdstuk 7 gaan we in op een pathofysiologisch aspect van de SCAs. Net als in veel andere SCAs wordt
ook SCA3 veroorzaakt door een CAG trinucleotide repeatverlenging in het coderende deel van het gen. De
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translatie van de CAG repeat in een verlengde polyglutamine expansie leidt tot structuurveranderingen van
het eiwit (ataxine-3). Deze structuurverandering leidt uiteindelijk tot de formatie van bepaalde neuronale
intranucleaire insluitlichaampjes (NII) en celdood. Deze NII’s worden dan ook niet alleen aangetroffen in
het brein en ruggenmerg van overleden SCA3 patiënten maar ook bij patiënten met SCA1, 2, 7 en 17.
Aanvankelijk werd de aanwezigheid van NII beschouwd als een voorwaarde voor celdood in deze groep van
aandoeningen. Recente ontwikkelingen suggereren echter een meer complex beeld. Zo lijken additionele
factoren, zoals transcriptie disregulatie, eveneens bij te dragen aan de pathogenese. Om nu de relatie tus-
sen transcriptie disregulatie, NII en celdood te verhelderen onderzochten we zowel brein als ruggenmerg
van vijf overleden SCA3 patiënten. NII werden nagenoeg alleen gevonden in de hersenstam (pons) en de
nucleus dentatus van de kleine hersenen. Disregulatie van genen betrokken bij ontstekingsprocessen bleek
niet beperkt tot neuronen met NII en evenmin was er een verschil tussen degenererende neuronen met en
zonder NII. Deze resultaten suggereren dat noch de aanwezigheid van NII, noch de expressie van ontste-
kingsmediatoren, voldoende zijn om celdood te verklaren. 
In hoofdstuk 8 gaat we in op pathofysiologische aspecten van SCA6. SCA6 wordt veroorzaakt door een rela-
tief korte repeatverlenging van CAG in een gen dat codeert voor de α1A-subunit van het P/Q-spanningsaf-
hankelijke calcium kanaal (‘voltage-gated calcium channel (P/Q-VGCC)’. P/Q-VGCC komen niet alleen in
het centrale zenuwstelsel tot expressie, maar ook ter plaatse van de neuromusculaire overgang. De aanwe-
zigheid van P/Q VGCC ter plaatse van de neuromusculaire overgang suggereert dat neuromusculaire trans-
missie gecompromitteerd zou kunnen zijn in SCA6. Om deze hypothese te testen onderzochten we de
functie van de neuromusculaire overgang met behulp van single fiber EMG bij tien patiënten met SCA6.
Afwijkingen in de neuromusculaire overgang werden niet gevonden. Hiermee toont onze studie aan dat
SCA6 veroorzaakt wordt door ziekteprocessen die specifiek optreden in het centrale zenuwstelsel. 
In sectie IV concentreerden wij ons op het fenotype van de autosomaal recessieve cerebellaire syndromen.
De ontdekking van het frataxine gen in 1996 en de ontdekking dat andere relatief zeldzame ataxieën wereld-
wijd voorkomen suggereren dat een genetische classificatie voor de recessieve ataxieën slechts een kwestie
van tijd is. Vooralsnog moet de clinicus het echter doen met een vaak lastige klinische work-up en een ver-
ouderd klinisch classificatiesysteem. Het ontwikkelen van een acceptabel klinisch classificatiesysteem en
een realistisch ‘work-up’ schema zijn daarom essentieel voor een goede patiëntenzorg.
De aanwezigheid van neuropathie en het type neuropathie hebben differentieel diagnostische consequen-
ties en kunnen daarom een gids zijn voor het al dan niet aanvragen van aanvullend diagnostisch onder-
zoek. In hoofdstuk 9 worden hiertoe de resultaten beschreven van klinisch onderzoek en zenuwgeleidings-
onderzoek bij 15 patiënten met een ‘early onset cerebellar ataxia’ (EOCA). Drie groepen konden worden
onderscheiden: groep I met behouden reflexen en normale geleidingssnelheden, groep II met een begin-
leeftijd in het tweede decade, afwezigheid van voetafwijkingen en een milde motore axonale neuropathie en
groep III met piramidale en atactische verschijnselen en een ernstige sensorische en motorische axonale
neuropathie. In hoeverre dit onderscheid fundamentele fenotypische verschillen reflecteert en dus gebruikt
kan worden voor aanvullende DNA research moet verder worden onderzocht.
In hoofdstuk 10 evalueerden we de klinische verschijnselen, progressie en neurofysiologische bevindingen
van EOCA patiënten die onze polikliniek bezochten over een periode van ongeveer 10 jaar.
Patiënten met een ongecompliceerd cerebellair syndroom bleken een heel langzame progressie te vertonen
en een relatief goede prognose te hebben. De meeste patiënten met een cerebellaire ataxie en een neuro-
pathie waren rolstoelgebonden; nog slechts een paar waren ambulant. Geconcludeerd werd dat bij patiën-
ten met een autosomaal recessieve ataxie, waarbij middels uitgebreid aanvullende diagnostiek bekende
metabole en genetische aandoeningen zijn uitgesloten, een klinische classificatie van belang is voor coun-
seling met betrekking tot de prognose. 
122
Dankwoord
Mijn dank gaat uit naar eenieder die heeft bijgedragen aan de totstandkoming van dit proefschrift. 
Een aantal personen heeft dat gedaan op een indirecte manier. Zij kennen mijn passie voor onderzoek 
en gunnen mij het plezier. Zij zijn er voor de lol, de liefde en de vriendschap; de essentie:
Carina: vrolijkheid
Meike en Wouter: verwondering
Klaas: vriendschap
Ouders en schoonouders: onvoorwaardelijk 
Anderen waren direct betrokken. Een aantal van hen zou ik hier willen noemen:
Gerard Hageman, voor je humor, bescheidenheid, jarenlange steun en vertrouwen en 
voor je aanstekelijk enthousiasme bij de patiëntenzorg, het onderwijs en het onderzoek.
Berry Kremer, voor je liefde voor het vak, je buitengewone collegialiteit en je kritische commentaar en 
morele steun bij de totstandkoming van dit proefschrift.
Machiel Zwarts, voor je vertrouwen, je manier van werken en het feit dat de deur van je werkkamer 
altijd wagenwijd openstaat.
Baziel van Engelen, voor het evenwicht, de interactie en het feit dat je me naar Nijmegen hebt gehaald.
Martha Huvenaars, voor je kennis en betrokkenheid bij patiënten op de neuromusculaire 
en neurodegeneratieve polikliniek.
Raymond Menkenhorst en Arnoud Kappelle, de paranimfen. Voor cafébezoek, culinaire kennis en 
organisatietalent. 
Bas Bloem voor borrelhap, Gewürztraminer en tomeloos enthousiasme.
Rianne Esselink, voor je betrokkenheid en collegiale houding: eerst als arts-assistent toen ik 
co-assistent was, later als ‘oudste assistent’ toen ik pas begon en nu als collega alhier.
Anneke Ramdhani-Joosten en de andere arts-assistenten van het Medisch Spectrum Twente, Enschede 
voor solidariteit en tranentrekkende humor.
De afdeling KNF, mijn huiskamer in dit ziekenhuis. May Eikholt en Henny Janssen in het bijzonder,
maar ook Netty, Mirjam, Maarten, José, Yvonne en de anderen.
Leo en Norbert, daar waar alles vastliep.
Dorien Langenkamp en Marie-Louise Vennemans-Kropmans voor correctie van de Nederlandse 
samenvatting van dit proefschrift.
Secretaresses van de vijfde, Emilie Langstraat in het bijzonder, voor hard werken en vrolijk gelach. 
De assistenten Neurologie: ‘for those who keep the show on the road’ met kamer 5135 en 5141 
als vraagbaak en IT-ondersteuning. 
En tot slot de afdeling Neurologie Nijmegen met als hoofd George Padberg voor het creëren 
van een uitermate inspirerende, motiverende en vriendelijke werkomgeving.
123
Curriculum vitae
Helenius Jurgen Schelhaas was born on 15 October 1967 in Hoogeveen, the Netherlands. In 1985 he com-
pleted secondary school at the Menso Altinck College in Hoogeveen and started his medical training at the
State University of Groningen in 1988. He obtained his medical degree in 1994. In 1995 he moved to
England and later to Northern Ireland, where he worked for seven months as house officer internal medi-
cine and for six months as house officer psychiatry, respectively. During this year he not only enjoyed his
avocation walking and history but also wrote his first scientific manuscript. On his return to the
Netherlands in 1996, he became a resident at the Department of Neurology at the Medical Spectrum
Twente, Enschede (Dr. J.A.G. Geelen). While working here, he developed an interest in autosomal dominant
and autosomal recessive cerebellar disorders under the encouragement of Dr. G. Hageman. The last year
of his residency was spent at Radboud University Nijmegen Medical Center, where he learned more about
neuromuscular disorders and neurophysiological techniques, in particular nerve conduction studies and
EMG (Prof. G.W.A.M. Padberg and Prof. M.J. Zwarts) On completion of his residency in February 2002 he
was appointed member of staff at the Department of Neurology, Radboud University Nijmegen Medical
Center, but continued to work one day a week at the Neurophysiology Laboratory. He is an active member
of the Dutch Neuromuscular Research Support Center Website Committee since 2003 and was part of the
editorial staff of the ‘amyotrophic lateral sclerosis manual for patients and relatives’ in 2004.
124
List of publications
Schelhaas HJ, Van de Warrenburg BP. Clinical, psychological, and genetic characteristics of spinocerebellar
ataxia type 19 (SCA19). Cerebellum (in press).
Voermans NC, Vaneker M, Hengstman, GJD, ter Laak H, Zimmerman C, Schelhaas HJ, Zwarts MJ. Primary
respiratory failure in inclusion body myositis. Neurology 63:2191-2192, 2004.
Hengstman GJ, Schelhaas HJ, Zwarts MJ. Auditory dysfunction in chronic inflammatory demyelinating poly-
radiculoneuropathy. Neurology 62: 1446-1448, 2004.
Schelhaas HJ, Van de Warrenburg BP, Kremer HP, Zwarts MJ. Neuromuscular transmission in SCA6. Ann
Neurol 55: 451-452, 2004.
Van de Warrenburg BP, Notermans NC, Schelhaas HJ, van Alfen N, Sinke RJ, Knoers NV et al. Peripheral
nerve involvement in spinocerebellar ataxias. Arch Neurol 61: 257-261, 2004.
Van de Warrenburg BP, Schelhaas HJ. Zwarts MJ, Kremer HPH. Spinocerebellar Ataxia and Peripheral
Neuropathy. Author reply Arch Neurol 61: 1626, 2004.
Schelhaas HJ, Verbeek DS, van de Warrenburg BP, Sinke RJ. SCA19 and SCA22: evidence for one locus with
a worldwide distribution. Brain (electronic version) 127(Pt 1): E6, 2004.
Kappelle AC, Schelhaas HJ, Pasman JW, Bloem BR. Rotatie van het hoofd: een ongebruikelijke compensatie
voor een abductie beperking van een oog. Nederlands Tijdschrift voor Geneeskunde 148: 2084-2085, 2004. 
Schelhaas HJ, van de Warrenburg BP, Kremer HP, Zwarts MJ. The “split hand” phenomenon: evidence of a
spinal origin. Neurology 61: 1619-1620, 2004.
Schelhaas HJ, van de Warrenburg BP, Hageman G, Ippel EE, van Hout M, Kremer B. Cognitive impairment
in SCA-19. Acta Neurol Belg 103: 199-205, 2003.
Schelhaas HJ, Van Engelen BG, Gabreels-Festen AA, Hageman G, Vliegen JH, Van der Knaap MS, Zwarts
MJ. Transient cerebral white matter lesions in a patient with connexin 32 missense mutation. Neurology 59:
2007-2008, 2004.
Verbeek DS, Schelhaas JH, Ippel EF, Beemer FA, Pearson PL, Sinke RJ. Identification of a novel SCA locus
(SCA19) in a Dutch autosomal dominant cerebellar ataxia family on chromosome region 1p21-q21. Hum
Genet 111: 388-393, 2002. 
Schelhaas HJ, Ippel PF, Hageman G, Sinke RJ, van der Laan EN, Beemer FA. Clinical and genetic analysis
of a four-generation family with a distinct autosomal dominant cerebellar ataxia. Journal of Neurology
248:113-120, 2001.
Schelhaas HJ, Ippel PF, Beemer FA, Hageman G. Similarities and differences in the phenotype, genotype
and pathogenesis of different spinocerebellar ataxias. European Journal of Neurology 7: 309-314, 2000.
Schelhaas HJ, Hulst MV, Ippel PF, Prevo RL, Hageman G. Early onset cerebellar ataxia with retained tendon
reflexes: foot deformity in a first degree family member. Clinical J Neurol Neurosurg 101: 253-255, 1999. 
125
Schelhaas HJ, Brouwers PJ, van der Aa HE, Prevo RL. MRI locates a posterior fossa aneurysm in the fourth
ventricle. Clinical J Neurol Neurosurg 100: 216-218, 1998. 
Vloedbeld MG, Schelhaas HJ, Hageman G, Vreuls RC, Rozeboom AR. Het syndroom van Joubert: kliniek en
differentiaaldiagnostische overwegingen. Nederlands tijdschrift voor kindergeneeskunde 66: 202-205, 1998.
Schelhaas HJ, Hageman G, Post JG. Cerebellar ataxia, dementia, pyramidal signs, cortical cataract of the
posterior pole and a raised IgG index in a patient with a sporadic form of olivopontocerebellar ataxia.
Clinical J Neurol Neurosurg 99: 99-101, 1997.
126
Abbreviations
ABC7 ATP-binding cassette transporter gene (gene involved in X-linked sideroblastic
anemia with ataxia)
ADCA Autosomal dominant cerebellar ataxia
ADM Abductor digiti minimi muscle
Alpha-TTP Alpha-tocopherol transfer protein gene 
AOA1 Ataxia with oculomotor apraxia type 1
AOA2 Ataxia with oculomotor apraxia type 2
APTX Aprataxin (gene involved in AOA1).
ARSACS Autosomal recessive spastic ataxia of Charlevoix-Saguenay
AT Ataxia teleangiectasia
ATLD Aaxia teleangiectasia like disorder 
ATM The gene responsible for AT (AT mutated)
AVED Ataxia with isolated vitamin E deficiency 
BDI Beck Depression Inventory
CACNA1A P/Q- voltage-dependent calcium channel (α1A-subunit) 
CCFDN Congenital cataract, facial dysmorphism and peripheral neuropathy
CDG Congenital disorders of glycosylation
C/EBP CCAAT enhancer-binding protein 
CMCT Central motor conduction time
CNS Central nervous system
CSF Cerebro spinal fluid
DRPLA Dentatorubropallidoluysian atrophy 
DSMA Dominant distal spinal muscular atrophy 
EA-1 Episodic ataxia type 1
EA-2 Episodic ataxia type 2
EEG Electroencephalography
EMG Electromyography 
EOCA Early onset cerebellar ataxia 
EPM1 Progressive myoclonus epilepsy of Unverricht-Lundborg
FGF14 Fibroblast growth factor 14 gene
FHM Familial hemiplegic migraine 
FMR-1 Fragile X mental retardation gene type 1
FRAXA Fragile X syndrome (caused by FMR-1 mutation)
FRAXE Fragile X syndrome (caused by FMR-2 mutation)
FRDA Friedreich’s ataxia 
FXTAS Fragile-X tremor ataxia syndrome (caused by a FMR-1 premutation)
GSS Gerstmann Strausler Schlenker disease (prion disorder)
HD Huntington disease
HDL2 Huntington disease like-phenotype-2
HIT Histidine triad superfamily (involved in AOA1) 
ICARS International ataxia co-operative rating scale
ILOCA Idiopathic late onset cerebellar ataxia
IL-1ra Interleukin 1 receptor antagonist
IOSCA Infantile onset spinocerebellar ataxia 
IRF-1 Interferon-regulatory factor-1
JPH3 Junctophilin-3 gene (mutated in Huntington disease like-phenotype-2)
JMA Juvenile muscular atrophy
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LOD Logaritm of the odds
MCD Mean consecutive difference
MCV Motor nerve conduction velocities 
MEP Motor evoked potentials
MERRF Myoclonus epilepsy with ragged red fibers (mitochondrial disorder)
MJD Machado Joseph disease (SCA3)
MMSE Mini Mental State Examination
MRC Medical Research Counsel examination
MRI Magnetic resonance imaging
MRE11 Gene involved in Ataxia teleangiectasia like disorder (Meiotic Recombination)
MSA-C Multiple system atrophy cerebellar type
NF-EOCA Non-Friedreich early onset cerebellar ataxia
NII Neuronal intranuclear inclusions
NMJ Neuromuscular junction
OPCA Olivopontocerebellar atrophy
OPMD Oculopharyngeal muscle dystrophy 
PI3K Phosphatidyl-inositol 3-kinase
PIKKs Phosphatidyl-inositol 3-kinase-like protein kinases
P/Q-VGCC P/Q voltage gated calcium channel 
Raven CPM Raven colored progressive matrices
RMT-F Recognition Memory Test for Faces
Raven SPM Raven standard progressive matrices
SACS Gene involved in ARSACS
SAN ‘Stichting afasie Nederland’ (cortical language test)
SBMA Spinal and bulbar muscular atrophy 
SCA Spinocerebellar ataxia
SCAN1 Spinocerebellar ataxia with axonal neuropathy type 1
SETX Gene involved in ataxia with oculomotor apraxia type 2 (Senataxin)
SFEMG Single fiber electromyography 
SNAP Sensory nerve action potential 
TBP TATA binding protein
TFTC TATA-binding protein-free TAF-containing complex 
TDP1 Tyrosyl-DNA phosphodiesterase 1 gene
TTP Tocopherol transfer protein (involved in AVED)
5’ UTR 5’ untranslated region (that part of DNA that is located before the start codon)
VLDL Very low-density lipoprotein
WAIS-R Wechsler Adult Intelligence Scale-Revised
WCST Wisconsin Card Sorting Test
WMS Wechsler Memory Scale
XRCC1 X-ray repair cross-complementing group 1
YFH Yeast frataxin homologue 
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